Details of Disease

General Information of Disease (ID: DISZJHAP)

• Disease Name: Ovarian cancer
• Synonyms: ovarian cancer, epithelial; primary ovarian cancer; ovarian neoplasm; tumour of the ovary; ovary neoplasm; tumor of the ovary; ovarian cancer; ovarian malignant tumour; malignant ovarian tumour; malignant neoplasm of the ovary; cancer of ovary; malignant neoplasm of ovary; ovary cancer; malignant ovarian tumor; malignant tumor of ovary; malignant ovarian neoplasm; malignant tumor of the ovary; malignant tumour of ovary; ovarian cancer, somatic; cancer of the ovary; ovarian malignant tumor; malignant tumour of the ovary; malignant ovary neoplasm
• Disease Class: 2C73: Ovarian cancer
• Definition: A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.
• Disease Hierarchy:
  DISEAFTY: Ovarian neoplasm
  DIST2NIJ: Gynecologic cancer
  DISAT1Z9: Advanced cancer
  DISZJHAP: Ovarian cancer
• ICD Code:
  ICD-11: ICD-11: 2C73
  ICD-10: ICD-10: C56
  ICD-9: ICD-9: 183
  Expand ICD-9: 183
• Disease Identifiers:
  MONDO ID: MONDO_0008170
  MESH ID: D010051
  UMLS CUI: C1140680
  OMIM ID: 167000
  MedGen ID: 216027
  Orphanet ID: 213500
  SNOMED CT ID: 363443007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 25 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Altretamine	DMKLAYG	Approved	Small molecular drug	[1]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[2]
Avelumab	DMSZLJR	Approved	Monoclonal antibody	[2]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[2]
Cabozantinib	DMIYDT4	Approved	Small molecular drug	[3]
Carboplatin	DMG281S	Approved	Small molecular drug	[4]
Catumaxomab	DMXA9KU	Approved	Monoclonal antibody	[5]
Fluzone QIV	DML6IDH	Approved	NA	[6]
Intedanib	DMSTA36	Approved	Small molecular drug	[7]
KU-0058948	DMSA4HZ	Approved	Small molecular drug	[8]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[9]
Lurbinectedin	DMEFRTZ	Approved	Small molecular drug	[10]
Melphalan	DMOLNHF	Approved	Small molecular drug	[11]
Melphalan flufenamide	DMWF5R4	Approved	Small molecular drug	[12]
Mirvetuximab soravtansine	DM5S4LX	Approved	NA	[13]
MVax	DM853R7	Approved	NA	[6]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[2]
Olaparib	DM8QB1D	Approved	Small molecular drug	[14]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[2]
Plicamycin	DM7C8YV	Approved	Small molecular drug	[15]
Rucaparib	DM9PVX8	Approved	Small molecular drug	[16]
Taxol	DMUOT9V	Approved	Small molecular drug	[17]
Tisotumab vedotin	DMF8FK3	Approved	NA	[18]
Topotecan	DMP6G8T	Approved	Small molecular drug	[19]
Trabectedin	DMG3Y89	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 142 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-888	DM4HYMS	Phase 3	Small molecular drug	[2]
acelarin	DMY96O3	Phase 3	Small molecular drug	[2]
AL3818	DM3WP0N	Phase 3	NA	[2]
Amonafide	DMAH59S	Phase 3	Small molecular drug	[20]
Batiraxcept	DM98NOU	Phase 3	NA	[21]
DCVax-Ovarian	DMBLASN	Phase 3	NA	[2]
EC20	DMLA1ER	Phase 3	Small molecular drug	[22]
Epothilon	DMITJRU	Phase 3	NA	[9]
Etirinotecan pegol	DMQHX1Y	Phase 3	Small molecular drug	[17]
Farletuzumab	DMFLWX1	Phase 3	Monoclonal antibody	[23]
Galinpepimut-S	DMTEQEQ	Phase 3	NA	[24]
Glufosfamide	DMEFCTP	Phase 3	Small molecular drug	[9]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[2]
Karenitecin	DMCRGY4	Phase 3	Small molecular drug	[25]
Masitinib	DMRSNEU	Phase 3	Small molecular drug	[2]
MK-4827	DMLYGH4	Phase 3	Small molecular drug	[26]
MK-8109	DM84LO5	Phase 3	NA	[27]
Nemvaleukin alfa	DMOAZHY	Phase 3	Fusion protein	[28]
Ofranergene obadenovec	DMBLHIS	Phase 3	Gene therapy	[29]
Oregovomab	DM06KRC	Phase 3	Monoclonal antibody	[30]
Pelareorep	DM4WCF9	Phase 3	NA	[17]
Picoplatin	DM0PIY6	Phase 3	Small molecular drug	[31]
PM1183	DMZZGWP	Phase 3	NA	[17]
Rubraca rucaparib	DM25TMP	Phase 3	NA	[2]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[2]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[2]
SNS-595	DMZE2JO	Phase 3	Small molecular drug	[9]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[32]
Trebananib	DMOG2X1	Phase 3	Recombinant protein	[33]
Upifitamab rilsodotin	DMCWLHD	Phase 3	Antibody drug conjugate	[34]
VB-111	DMX04CA	Phase 3	NA	[2]
Abagovomab	DMZ0T24	Phase 2/3	Monoclonal antibody	[35]
Anetumab ravtansine	DMKFRWU	Phase 2	Antibody drug conjugate	[2]
APR-246	DMNFADH	Phase 2	Small molecular drug	[2]
BBI503	DMDSNIR	Phase 2	NA	[36]
BGB-290	DMRO6XT	Phase 2	NA	[37]
BNT141	DM9XRBT	Phase 2	Antibody	[38]
CA4P	DM9R0ZL	Phase 2	NA	[17]
CDX-1401	DMCGNJ6	Phase 2	NA	[2]
CP-547632	DMX054A	Phase 2	Small molecular drug	[39]
CRLX101	DMQUWXY	Phase 2	NA	[2]
CRS-207	DMXU5LZ	Phase 2	Vaccine	[24]
Dendritic cell vaccine	DML4PMG	Phase 2	Vaccine	[40]
DKN-01	DMOHT5V	Phase 2	Antibody	[2]
EGEN-001	DM6L5TR	Phase 2	NA	[41]
EP-100	DMY1JJV	Phase 2	Peptide	[2]
EP-201	DMRVC07	Phase 2	NA	[24]
EP0057	DMVROVE	Phase 2	Nanoparticle-drug conjugate	[42]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[24]
Folate binding protein vaccine	DMW2SNN	Phase 2	NA	[43]
GEN-1	DMJN09S	Phase 2	Gene therapy	[2]
GSK3377794	DMQ4RWW	Phase 2	NA	[2]
Ispinesib	DMP2BWX	Phase 2	Small molecular drug	[44]
Kevetrin	DMFO6MH	Phase 2	Small molecular drug	[2]
LY2606368	DM4XMF7	Phase 2	NA	[2]
Maveropepimut-S	DM361AO	Phase 2	Vaccine	[45]
Mecbotamab vedotin	DMU5KH4	Phase 2	Antibody drug conjugate	[46]
MEDI-546	DMPKWR3	Phase 2	NA	[47]
Mirvetuximab soratansine	DM0YL3Y	Phase 2	NA	[17]
MK-1775	DM3WDZ5	Phase 2	Small molecular drug	[48]
Motolimid	DMG03XW	Phase 2	NA	[17]
MUC-1 cancer vaccine	DMQHRAI	Phase 2	NA	[49]
NanoPac	DM0TD4G	Phase 2	NA	[2]
OGX-427	DMJTU8D	Phase 2	Antisense drug	[50]
OTL38	DMS0I49	Phase 2	NA	[17]
Ovapuldencel-T	DM9JKSD	Phase 2	NA	[2]
PF-07901801	DMEVYHR	Phase 2	Fusion protein	[51]
PMID27841036-Compound-37	DM0OVZ2	Phase 2	Small molecular drug	[52]
PTX-200	DM0ZIT2	Phase 2	NA	[2]
RG-7599	DM6R1PM	Phase 2	NA	[53]
RO-5126766	DM3U9BY	Phase 2	Small molecular drug	[54]
Sagopilone	DM6JXWL	Phase 2	Small molecular drug	[55]
SPL-108	DMRXCUQ	Phase 2	Peptide	[56]
Stenoparib	DMKVBL8	Phase 2	Small molecular drug	[57]
Tigatuzumab	DMKYJJC	Phase 2	Monoclonal antibody	[58]
TJ004309	DMFB54Y	Phase 2	Antibody	[59]
TLPLDC	DMYENTG	Phase 2	NA	[24]
TPIV200	DM4UZRE	Phase 2	NA	[24]
Varlilumab	DMQSC5O	Phase 2	NA	[2]
VS-6063	DMGBLI3	Phase 2	Small molecular drug	[2]
ZW25	DMRLZA1	Phase 2	Antibody	[2]
Anti-C-met CAR-T cells	DMV5H0S	Phase 1/2	CAR T Cell Therapy	[60]
Anti-HER2 CAR-T	DMQD6B9	Phase 1/2	CAR T Cell Therapy	[61]
Anti-mesothelin CAR transduced PBL	DMXI03L	Phase 1/2	CAR T Cell Therapy	[62]
CDX-014	DMBRQ99	Phase 1/2	NA	[2]
DPX-survivac cancer vaccine	DMOVQS4	Phase 1/2	NA	[63]
GALE-301	DMNEM46	Phase 1/2	NA	[24]
GALE-302	DM4WTRZ	Phase 1/2	NA	[2]
GL-ONC1	DMEXNZN	Phase 1/2	Oncolytic virus therapy	[64]
Her-2/neu vaccine	DMYPLCH	Phase 1/2	NA	[65]
IL-2/gene-modified lymphocytes	DMJ9CY4	Phase 1/2	NA	[66]
LY2940680	DMTJWIQ	Phase 1/2	Small molecular drug	[2]
NT-501 CNTF	DMBQRGV	Phase 1/2	NA	[67]
NY-ESO-TCR	DMS0L6J	Phase 1/2	NA	[68]
O-Vax	DM0VS8V	Phase 1/2	NA	[69]
ONCOS-102	DMACFVN	Phase 1/2	Oncolytic virus therapy	[2]
Ovarian dendritic cell-based vaccine	DMPYS2L	Phase 1/2	NA	[70]
Phenoxodiol	DMBUJVX	Phase 1/2	Small molecular drug	[71]
REGN4018	DM7LOSK	Phase 1/2	Antibody	[72]
REGN5668	DMH1UV5	Phase 1/2	Bispecific antibody	[73]
TC-210	DM9S5I1	Phase 1/2	TCR-T cell therapy	[74]
TC-510	DMSPG60	Phase 1/2	Cell therapy	[75]
XMT-1592	DMU6TG7	Phase 1/2	Antibody drug conjugate	[76]
AE-O	DM200F5	Phase 1	NA	[77]
Alvespimycin hydrochloride	DM6KU93	Phase 1	Small molecular drug	[78]
Anti-CD133-CAR vector-transduced T cells	DMGUM90	Phase 1	CAR T Cell Therapy	[79]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Phase 1	CAR T Cell Therapy	[80]
Anti-meso-CAR vector transduced T cells	DM5UQA9	Phase 1	CAR T Cell Therapy	[81]
BNT115	DMLIEN8	Phase 1	mRNA (uRNA)	[82]
Cantrixil	DM2211R	Phase 1	NA	[2]
COTI-2	DM6K3JQ	Phase 1	NA	[2]
DeTIL-0255	DMK8EZD	Phase 1	Cell therapy	[83]
DMUC-5754A	DMCT4BA	Phase 1	Antibody	[84]
DS-6000	DMB2RPG	Phase 1	Antibody drug conjugate	[85]
E 7974	DM3LOF1	Phase 1	Small molecular drug	[9]
FATE-NK100	DMT8WXM	Phase 1	NA	[2]
GRN-300	DMISPYI	Phase 1	Small molecule	[86]
Hu-CART meso cells	DM9VB4I	Phase 1	CAR T Cell Therapy	[87]
Iboctadekin	DMHS29U	Phase 1	NA	[88]
IMT-1012 immunotherapeutic vaccine	DM3JYBZ	Phase 1	NA	[89]
IMT1012	DMG5PF0	Phase 1	Vaccine	[90]
INKmune	DMZNGI9	Phase 1	Cell therapy	[91]
Ipafricept	DMGN96R	Phase 1	NA	[92]
ITIL-306	DMYN4P9	Phase 1	Cell therapy	[93]
JCAR020	DM1T8KN	Phase 1	NA	[68]
KHK-2866	DMR7EF6	Phase 1	Antibody	[94]
MCY-M11	DMAESQI	Phase 1	CAR-PBMC Cell therapy	[95]
MEDI3617	DM0H5JD	Phase 1	Antibody	[96]
Mibefradil	DMU9VDS	Phase 1	Small molecular drug	[97]
MOv19-BBz CAR T cells	DMYH98H	Phase 1	CAR T Cell Therapy	[98]
mRNA-2416	DMFTAWU	Phase 1	mRNA therapy	[99]
Navicixizumab	DMZ2G69	Phase 1	NA	[68]
Prolanta	DMLKF3H	Phase 1	NA	[2]
PTC596	DMI24V7	Phase 1	NA	[2]
PUMVC3-hIGFBP-2	DMZMPIK	Phase 1	NA	[100]
RG7882	DM2E5Z7	Phase 1	Antibody	[101]
SC-003	DMD5EFV	Phase 1	NA	[2]
SL-172154	DMN3D72	Phase 1	Recombinant protein	[102]
SOR-C13	DMBKL6O	Phase 1	NA	[103]
STM 434	DMDF29A	Phase 1	NA	[17]
STRO-002	DMC5HXI	Phase 1	Antibody drug conjugate	[104]
TG4050	DMSN21C	Phase 1	Vaccine	[105]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AR-A014418	DMUPN01	Patented	Small molecular drug	[106]

This Disease is Treated as An Indication in 10 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IDM-1	DMHRYWW	Discontinued in Phase 3	NA	[107]
R1549	DMH5JVV	Discontinued in Phase 3	Monoclonal antibody	[108]
Tanomastat	DMVB9XC	Discontinued in Phase 3	Small molecular drug	[109]
AGS-8M4	DMK1S59	Discontinued in Phase 2	NA	[110]
Biricodar	DM65JCM	Discontinued in Phase 2	Small molecular drug	[111]
Lurtotecan	DMF1RTW	Discontinued in Phase 2	Small molecular drug	[112]
Onyvax-O	DMMXHIX	Discontinued in Phase 1	NA	[113]
RG7458	DMW87YE	Discontinued in Phase 1	Antibody	[114]
RG7600	DMVVBET	Discontinued in Phase 1	NA	[115]
111In-OC-125 F(ab1/2)-DTPA	DMJ1LAM	Terminated	NA	[117]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
S-8184	DMCK6AV	Preclinical	NA	[116]

This Disease is Treated as An Indication in 14 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DMEJ83H	Investigative	Small molecular drug	[118]
AB-3D3	DMFBMT1	Investigative	NA	[119]
ALVAC-CEA/hB7.1	DMQ4UFK	Investigative	NA	[119]
Anti-CGEN-153 mab	DMW48PY	Investigative	Monoclonal antibody	[119]
Anti-folate receptor 1 humanized mab	DM3FQHS	Investigative	Monoclonal antibody	[119]
CGEN-991	DMGSOEF	Investigative	NA	[119]
Disorazol Z-LHRH conjugates	DMWQTA2	Investigative	NA	[119]
ET-006	DMR9OVS	Investigative	NA	[119]
FabOvar	DMSMUPY	Investigative	NA	[119]
FOLIGO 002	DMRVXT0	Investigative	NA	[119]
HS-210	DMED8XB	Investigative	NA	[119]
HumaRAD-OV	DMCN995	Investigative	NA	[119]
MX-35	DMGZH6G	Investigative	NA	[119]
RAP-701	DM4LEMQ	Investigative	NA	[119]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 610 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADM	TTV14YH	Limited	Altered Expression	[122]
ALOX12	TT12ABZ	Limited	Altered Expression	[123]
ALOX12B	TTQ4QQH	Limited	Biomarker	[124]
AMHR2	TTZDCPK	Limited	Biomarker	[125]
AREG	TT76B3W	Limited	Biomarker	[126]
BIRC2	TTQ5LRD	Limited	Altered Expression	[127]
BRS3	TTKYEPM	Limited	Biomarker	[128]
BUB1	TT78309	Limited	Biomarker	[129]
CD55	TT5Z9WY	Limited	Altered Expression	[130]
CDH1	TTLAWO6	Limited	Altered Expression	[131]
CDK5R1	TTBYM6V	Limited	Altered Expression	[132]
CLDN6	TTKSV48	Limited	Biomarker	[133]
CSE1L	TTTRULD	Limited	Altered Expression	[134]
CYP3A5	TTHS0OK	Limited	Biomarker	[135]
DCK	TTJOCE4	Limited	Biomarker	[136]
EDNRA	TTKRD0G	Limited	Biomarker	[137]
FGF18	TT6ICRA	Limited	Biomarker	[138]
FOXC2	TTLBAP1	Limited	Biomarker	[139]
FOXM1	TTD3KOX	Limited	Biomarker	[140]
GRIK2	TT0K5RG	Limited	Biomarker	[141]
GSTA2	TTNLFBE	Limited	Genetic Variation	[142]
GSTO1	TTWO3SH	Limited	Genetic Variation	[142]
HSPA9	TTMTPG3	Limited	Altered Expression	[143]
IGF2	TTE8WGO	Limited	Altered Expression	[144]
IKBKB	TTJ3E9X	Limited	Biomarker	[145]
IL12A	TTRTK6Y	Limited	Altered Expression	[132]
IL16	TTW4R0B	Limited	Altered Expression	[146]
IRAK1	TTXAJWN	Limited	Biomarker	[129]
ITGA8	TT1FW8B	Limited	Biomarker	[147]
KLK6	TTLPF4X	Limited	Biomarker	[148]
LNPEP	TTY2KP7	Limited	Biomarker	[149]
LTF	TTSZDQU	Limited	Genetic Variation	[150]
MKI67	TTB4UNG	Limited	Altered Expression	[151]
MMP15	TTNSTO3	Limited	Altered Expression	[152]
MRC1	TTKV8W5	Limited	Biomarker	[153]
NEDD8	TTNDC4K	Limited	Biomarker	[154]
NRP1	TTIPJCB	Limited	Altered Expression	[155]
NUAK2	TTHVOTQ	Limited	Altered Expression	[156]
PAK2	TT279WO	Limited	Altered Expression	[157]
PAK4	TT7Y3BZ	Limited	Biomarker	[158]
PRMT5	TTR1D7X	Limited	Biomarker	[159]
PROM1	TTXMZ81	Limited	Biomarker	[160]
PSMB8	TTEAD9J	Limited	Genetic Variation	[161]
PSMB9	TTOUSTQ	Limited	Genetic Variation	[161]
PTGDR2	TTQDMX5	Limited	Biomarker	[162]
PTP4A3	TT7YM8D	Limited	Biomarker	[163]
RENBP	TTZCG0Q	Limited	Genetic Variation	[164]
ROBO1	TTND1YP	Limited	Altered Expression	[165]
SERPINB3	TT6QLPX	Limited	Biomarker	[166]
SKP2	TT5B2EO	Limited	Altered Expression	[167]
SLC22A3	TTG2UMS	Limited	Biomarker	[168]
SLC5A6	TT61XTV	Limited	Biomarker	[169]
SOD1	TTP9K3Q	Limited	Altered Expression	[170]
SOD2	TT9O4C5	Limited	Genetic Variation	[171]
TLR4	TTISGCA	Limited	Biomarker	[172]
ZEB2	TTT2WK4	Limited	Altered Expression	[173]
BRD7	TT07ZS1	Disputed	Biomarker	[174]
CS	TTZA6B3	Disputed	Biomarker	[175]
CUL3	TTPCU0Q	Disputed	Biomarker	[176]
EGF	TTED8JB	Disputed	Biomarker	[177]
FAP	TTGPQ0F	Disputed	Biomarker	[178]
MAP2K7	TT6QY3J	Disputed	Biomarker	[179]
PPM1D	TTENJAB	Disputed	Genetic Variation	[180]
PTK7	TTXH2ZN	Disputed	Altered Expression	[181]
SPRY1	TT0PSN6	Disputed	Altered Expression	[181]
TERT	TTQY2EJ	Disputed	Biomarker	[182]
TNFRSF21	TT8UA0T	Disputed	Genetic Variation	[183]
BAP1	TT47RXJ	moderate	Genetic Variation	[184]
BSG	TT5UJWD	moderate	Biomarker	[185]
CDC7	TTSMTDI	moderate	Altered Expression	[186]
CGB3	TTUH273	moderate	Altered Expression	[187]
CNTN2	TT2Z1WB	moderate	Biomarker	[188]
CRYZ	TTP6UO8	moderate	Altered Expression	[189]
DKK3	TTY2ZV6	moderate	Altered Expression	[190]
DPP4	TTDIGC1	moderate	Altered Expression	[191]
EML4	TT92GY4	moderate	Biomarker	[153]
ESRRA	TTPNQAC	moderate	Altered Expression	[192]
EYA2	TTUY9C6	moderate	Biomarker	[193]
GLB1	TTNGJPH	moderate	Altered Expression	[194]
HGFAC	TTD96RW	moderate	Altered Expression	[195]
HOXA11	TTEX4ZA	moderate	Biomarker	[196]
HSPE1	TTWYMFE	moderate	Genetic Variation	[197]
ID2	TTW8A5N	moderate	Genetic Variation	[198]
IGF2R	TTPNE41	moderate	Posttranslational Modification	[199]
IL13RA2	TTMPZ7V	moderate	Biomarker	[200]
MASP2	TTR01E9	moderate	Altered Expression	[201]
NQO2	TTJLP0R	moderate	Genetic Variation	[189]
PGRMC1	TTY3LAZ	moderate	Altered Expression	[202]
RUNX3	TTKCVO7	moderate	Biomarker	[203]
SLC22A16	TTITAVR	moderate	Altered Expression	[204]
SLC2A4	TTP6MT5	moderate	Biomarker	[149]
SLIT2	TTDWK85	moderate	Biomarker	[165]
SRD5A2	TTT02K8	moderate	Biomarker	[205]
STEAP1	TT9E64S	moderate	Altered Expression	[206]
SYK	TT2HUPM	moderate	Altered Expression	[207]
TMEM97	TT9NXW4	moderate	Altered Expression	[208]
TNK2	TTIET93	moderate	Genetic Variation	[209]
VEGFD	TTOM5H4	moderate	Altered Expression	[210]
ABCA4	TTLB52K	Strong	Altered Expression	[211]
ABCC2	TTFLHJV	Strong	Altered Expression	[212]
ABCG2	TTIMJ02	Strong	Altered Expression	[213]
ACR	TTAHE2N	Strong	Biomarker	[214]
ACTG1	TTGAZF9	Strong	Genetic Variation	[215]
ADAM10	TTVXEGU	Strong	Biomarker	[216]
ADAM17	TT6AZXG	Strong	Biomarker	[217]
AGR2	TT9K86S	Strong	Altered Expression	[218]
AGTR1	TT8DBY3	Strong	Biomarker	[219]
AHSG	TTKF4WV	Strong	Biomarker	[220]
AKT2	TTH24WI	Strong	Biomarker	[221]
ALDH5A1	TTJUWVB	Strong	Altered Expression	[222]
ALOX5	TTSJ6Q4	Strong	Biomarker	[124]
ANGPTL3	TT59GO7	Strong	Biomarker	[223]
ANO1	TTOJI4S	Strong	Biomarker	[224]
ANXA2	TT4YANI	Strong	Biomarker	[225]
ANXA8	TTSW16P	Strong	Biomarker	[226]
APC2	TTSMK36	Strong	Biomarker	[227]
APEX1	TTHGL48	Strong	Biomarker	[228]
APLNR	TTJ8E43	Strong	Biomarker	[229]
APOBEC3G	TTP96KH	Strong	Biomarker	[230]
AQP3	TTLDNMQ	Strong	Biomarker	[231]
ARRB1	TTMVD4A	Strong	Biomarker	[232]
ASRGL1	TT4WT91	Strong	Biomarker	[233]
ATAD2	TT9A0HI	Strong	Biomarker	[234]
ATF3	TTCE793	Strong	Therapeutic	[235]
ATG7	TTLVB9Z	Strong	Biomarker	[236]
ATP7B	TTOPO51	Strong	Genetic Variation	[237]
AURKA	TTPS3C0	Strong	Biomarker	[238]
AURKB	TT9RTBL	Strong	Biomarker	[239]
AXL	TTZPY6J	Strong	Biomarker	[240]
BACH1	TT2ME4S	Strong	Biomarker	[241]
BAGE	TTS5GLJ	Strong	Altered Expression	[242]
BBC3	TT7JUKC	Strong	Biomarker	[243]
BCAT1	TTES57P	Strong	Altered Expression	[244]
BIRC3	TTAIWZN	Strong	Biomarker	[245]
BIRC5	TTTPU1G	Strong	Biomarker	[246]
BMI1	TTIPNSR	Strong	Biomarker	[247]
BMP10	TTTG6H1	Strong	Altered Expression	[248]
BMP7	TTKOBRA	Strong	Altered Expression	[249]
BPHL	TTTZ3EU	Strong	Biomarker	[250]
BRD1	TTT09OB	Strong	Biomarker	[251]
BRD2	TTDP48B	Strong	Biomarker	[252]
BRD4	TTSRAOU	Strong	Biomarker	[253]
BTG1	TTL7N2W	Strong	Biomarker	[254]
CALCR	TTLWS2O	Strong	Biomarker	[255]
CAMKK2	TTV298Y	Strong	Biomarker	[256]
CAMP	TTULOB6	Strong	Biomarker	[257]
CARM1	TTIZQFJ	Strong	Biomarker	[258]
CASP2	TT12VNG	Strong	Altered Expression	[259]
CASP9	TTB6T7O	Strong	Biomarker	[260]
CASR	TTBUYHA	Strong	Biomarker	[261]
CAV1	TTXUBN2	Strong	Altered Expression	[262]
CBR1	TTVG0SN	Strong	Biomarker	[263]
CBS	TTVZJ7G	Strong	Biomarker	[264]
CCL20	TT2XAZY	Strong	Biomarker	[265]
CCL21	TTLZK1U	Strong	Biomarker	[266]
CCL22	TTBTWI1	Strong	Biomarker	[267]
CCN1	TTPK79J	Strong	Biomarker	[268]
CCNE1	TTCEJ4F	Strong	Biomarker	[269]
CCR7	TT2GIDQ	Strong	Altered Expression	[270]
CCR9	TTIPS8B	Strong	Biomarker	[271]
CD163	TTTZ9DE	Strong	Biomarker	[272]
CD1A	TTBGTFN	Strong	Altered Expression	[273]
CD24	TTCTYNP	Strong	Altered Expression	[274]
CD276	TT6CQUM	Strong	Biomarker	[275]
CD3E	TTZAT79	Strong	Altered Expression	[276]
CD44	TTWFBT7	Strong	Biomarker	[277]
CD46	TTMS7DF	Strong	Altered Expression	[130]
CD47	TT28S46	Strong	Biomarker	[278]
CD58	TT5KSBY	Strong	Altered Expression	[279]
CD59	TTBGTEJ	Strong	Altered Expression	[130]
CDC123	TT3PRUG	Strong	Altered Expression	[280]
CDC25A	TTLZS4Q	Strong	Biomarker	[281]
CDC25B	TTR0SWN	Strong	Altered Expression	[282]
CDH11	TTRGWZC	Strong	Biomarker	[283]
CDH6	TT9QHUK	Strong	Altered Expression	[284]
CDK1	TTH6V3D	Strong	Altered Expression	[285]
CDK12	TTJ21A9	Strong	Genetic Variation	[286]
CDK19	TTNABU9	Strong	Biomarker	[287]
CDK2	TT7HF4W	Strong	Altered Expression	[288]
CDK4	TT0PG8F	Strong	Genetic Variation	[289]
CDK7	TTQYF7G	Strong	Biomarker	[290]
CDKN1B	TTLGFVW	Strong	Altered Expression	[291]
CEACAM1	TTA9CK4	Strong	Altered Expression	[292]
CEACAM5	TTY6DTE	Strong	Biomarker	[293]
CGA	TTFC29G	Strong	Biomarker	[294]
CHEK1	TTTU902	Strong	Biomarker	[295]
CHST15	TTFK7E1	Strong	Biomarker	[296]
CIT	TT3BKTU	Strong	Biomarker	[259]
CLCA1	TT3AF4R	Strong	Biomarker	[297]
CLDN4	TTMTS9H	Strong	Altered Expression	[298]
CLIC1	TT8KZG6	Strong	Biomarker	[299]
CLN3	TTORF9W	Strong	Biomarker	[300]
CLU	TTRL76H	Strong	Biomarker	[301]
CMA1	TT8VUE0	Strong	Altered Expression	[302]
COL18A1	TT63DI9	Strong	Biomarker	[303]
CREB1	TTH4AN3	Strong	Biomarker	[304]
CSF1	TT0IQER	Strong	Biomarker	[305]
CSK	TTX6F0Q	Strong	Altered Expression	[306]
CTAG1A	TTE5ITK	Strong	Biomarker	[307]
CTCFL	TTY0RZT	Strong	Biomarker	[308]
CTSK	TTDZN01	Strong	Biomarker	[309]
CTSL	TT36ETB	Strong	Altered Expression	[310]
CXCL11	TTWG0RE	Strong	Biomarker	[311]
CXCL12	TT4UGTF	Strong	Biomarker	[312]
CXCL8	TTCTE1G	Strong	Biomarker	[313]
CXCR2	TT30C9G	Strong	Biomarker	[314]
CXCR3	TT1UCIJ	Strong	Biomarker	[315]
CXCR6	TT2BVUA	Strong	Biomarker	[216]
CYP19A1	TTSZLWK	Strong	Biomarker	[316]
CYP1A2	TTS1DTU	Strong	Genetic Variation	[317]
CYP1B1	TTI84H7	Strong	Altered Expression	[318]
DDR2	TTU98HG	Strong	Biomarker	[319]
DDX58	TTVB0O3	Strong	Altered Expression	[320]
DEPTOR	TTLYP6D	Strong	Altered Expression	[321]
DIABLO	TTN74LE	Strong	Biomarker	[322]
DICER1	TTTEOPU	Strong	Altered Expression	[323]
DLK1	TTF4AVB	Strong	Altered Expression	[324]
DLL4	TTV23LH	Strong	Biomarker	[325]
DNMT3A	TTJUALD	Strong	Altered Expression	[326]
DOT1L	TTSZ8T1	Strong	Altered Expression	[327]
DPP8	TTJGLZF	Strong	Altered Expression	[328]
DPP9	TTNDUL7	Strong	Biomarker	[328]
DUSP3	TTIFAYS	Strong	Genetic Variation	[329]
DYRK1B	TTYGQ8A	Strong	Biomarker	[330]
E2F1	TTASI04	Strong	Altered Expression	[331]
E2F2	TT5FYX0	Strong	Biomarker	[331]
EIF4E	TTZGCP6	Strong	Biomarker	[332]
EIF5A	TTIVCNR	Strong	Biomarker	[333]
EIF5A2	TTH53G9	Strong	Biomarker	[334]
ENG	TTB30LE	Strong	Biomarker	[335]
ENTPD1	TTYM8DJ	Strong	Biomarker	[336]
EPHA1	TTLFZVU	Strong	Altered Expression	[337]
EPHA2	TTRJB2G	Strong	Biomarker	[338]
EPHA3	TTHS2LR	Strong	Biomarker	[280]
EPHA7	TTAHTVG	Strong	Biomarker	[339]
EREG	TTYSB89	Strong	Altered Expression	[340]
ERN1	TTKIAT3	Strong	Biomarker	[341]
ETS1	TTTGPSD	Strong	Biomarker	[342]
ETS2	TT9AH0M	Strong	Altered Expression	[343]
EZR	TTE47YC	Strong	Biomarker	[344]
F2RL2	TTVSEBF	Strong	Altered Expression	[345]
F2RL3	TTD0652	Strong	Biomarker	[346]
FABP4	TTHWMFZ	Strong	Altered Expression	[347]
FAM83D	TTFIW7J	Strong	Altered Expression	[348]
FASN	TT7AOUD	Strong	Biomarker	[349]
FBXW7	TT29KY7	Strong	Genetic Variation	[350]
FGF1	TTMY81X	Strong	Biomarker	[351]
FGF7	TTFY134	Strong	Biomarker	[352]
FLT4	TTDCBX5	Strong	Biomarker	[353]
FOLR3	TTSM9YR	Strong	Altered Expression	[354]
FOSL1	TTY8LZG	Strong	Altered Expression	[355]
FOSL2	TT689IR	Strong	Biomarker	[356]
FOXP1	TT0MUCI	Strong	Altered Expression	[357]
FOXQ1	TTEJZOL	Strong	Altered Expression	[358]
FSCN1	TTTRS9B	Strong	Altered Expression	[359]
FSHR	TTZFDBT	Strong	Biomarker	[360]
FST	TTDNM9W	Strong	Biomarker	[361]
FZD7	TTUQMO5	Strong	Altered Expression	[362]
GAL	TTXZAJ5	Strong	Altered Expression	[363]
GAS6	TT69QD2	Strong	Biomarker	[364]
GCLM	TTNFESW	Strong	Altered Expression	[365]
GDF2	TTAP4T1	Strong	Biomarker	[366]
GJB1	TTSJIRP	Strong	Altered Expression	[367]
GLI1	TTJOMH6	Strong	Genetic Variation	[368]
GNRH1	TT0ID4A	Strong	Altered Expression	[369]
GNRHR	TT8R70G	Strong	Biomarker	[370]
GPC3	TTJTSX4	Strong	Biomarker	[371]
GPER1	TTDSB34	Strong	Biomarker	[372]
GPR137	TTATO6X	Strong	Biomarker	[373]
GRB2	TTEYRJ9	Strong	Biomarker	[374]
GRN	TT0LWE3	Strong	Biomarker	[375]
GSN	TTUH7OM	Strong	Altered Expression	[376]
GUSB	TTHS7CM	Strong	Biomarker	[377]
GZMB	TTKEPHX	Strong	Biomarker	[378]
HBEGF	TT15SL0	Strong	Biomarker	[379]
HDAC1	TT6R7JZ	Strong	Biomarker	[380]
HDAC10	TTYHPU6	Strong	Biomarker	[381]
HDAC4	TTTQGH8	Strong	Biomarker	[382]
HDAC6	TT5ZKDI	Strong	Biomarker	[383]
HDAC7	TTMUEK1	Strong	Biomarker	[384]
HIPK2	TTOB49C	Strong	Biomarker	[385]
HK2	TTK02H8	Strong	Biomarker	[326]
HMGA1	TTBA219	Strong	Biomarker	[386]
HOXA5	TTXSVQP	Strong	Altered Expression	[387]
HOXA7	TTMRE4Q	Strong	Altered Expression	[388]
HOXB13	TTZ6I58	Strong	Biomarker	[389]
HPGDS	TTCYE56	Strong	Biomarker	[390]
HPN	TT25MVL	Strong	Altered Expression	[195]
HPSE	TTR7GJO	Strong	Altered Expression	[391]
HRC	TTR4FKD	Strong	Genetic Variation	[392]
HSD17B1	TTIWB6L	Strong	Genetic Variation	[393]
HSD17B2	TT0PT1R	Strong	Genetic Variation	[394]
HSF1	TTN6STZ	Strong	Biomarker	[395]
HTRA1	TT8POQR	Strong	Altered Expression	[396]
ID1	TTBXVDE	Strong	Altered Expression	[397]
IGFBP1	TTCJTWF	Strong	Biomarker	[398]
IGFBP5	TTDWEA8	Strong	Altered Expression	[399]
IL11RA	TTZPLJS	Strong	Biomarker	[400]
IL15	TTJFA35	Strong	Biomarker	[401]
IL15RA	TTGN89I	Strong	Biomarker	[402]
IL17D	TTC5LTG	Strong	Genetic Variation	[403]
IL21	TT9QEJ6	Strong	Biomarker	[404]
IL24	TT1EPXZ	Strong	Biomarker	[405]
IL7	TT8FRMO	Strong	Biomarker	[406]
ILK	TT7ALZG	Strong	Biomarker	[407]
INHBA	TTVB30D	Strong	Biomarker	[408]
ITGA2	TTSJ542	Strong	Biomarker	[319]
ITGA5	TTHIZP9	Strong	Biomarker	[409]
ITGA6	TT165T3	Strong	Biomarker	[410]
ITGB1	TTBVIQC	Strong	Biomarker	[411]
ITGB8	TTIF29E	Strong	Altered Expression	[412]
ITK	TT3C80U	Strong	Biomarker	[168]
KAT2B	TTVK7SB	Strong	Biomarker	[413]
KCNMA1	TTE87WJ	Strong	Biomarker	[414]
KCNN3	TT9JH25	Strong	Biomarker	[415]
KDM2A	TT8XTY2	Strong	Biomarker	[416]
KDM3A	TTKXS4A	Strong	Biomarker	[417]
KDM5A	TTIG67W	Strong	Biomarker	[418]
KDM6B	TTDIJUQ	Strong	Altered Expression	[419]
KDR	TTUTJGQ	Strong	Altered Expression	[420]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[421]
KIF26B	TTQWICZ	Strong	Altered Expression	[422]
KLK14	TTDA81R	Strong	Altered Expression	[423]
KLK3	TTS78AZ	Strong	Genetic Variation	[424]
KLK4	TT4319X	Strong	Altered Expression	[425]
KLK5	TTULSEW	Strong	Altered Expression	[426]
KLK7	TTE6GTB	Strong	Biomarker	[427]
KRT17	TTKV0EC	Strong	Biomarker	[428]
KRT19	TT3JF9E	Strong	Biomarker	[429]
L1CAM	TTC9D3K	Strong	Altered Expression	[430]
L3MBTL3	TTQDMJN	Strong	Genetic Variation	[431]
LAG3	TTNVXAW	Strong	Altered Expression	[432]
LAPTM4B	TTEJQT0	Strong	Altered Expression	[433]
LARP1	TTSN1YP	Strong	Biomarker	[434]
LATS2	TTML7FG	Strong	Altered Expression	[435]
LCAT	TTGZ91P	Strong	Biomarker	[436]
LCK	TT860QF	Strong	Biomarker	[437]
LGALS1	TTO3NYT	Strong	Biomarker	[438]
LGMN	TTPTWV5	Strong	Biomarker	[439]
LGR5	TTTSGRH	Strong	Biomarker	[440]
LIF	TTGZ5WN	Strong	Biomarker	[441]
LIMK1	TTWL9TY	Strong	Biomarker	[442]
LIN28A	TTO50LN	Strong	Altered Expression	[443]
LOX	TTQHNAM	Strong	Altered Expression	[444]
LPAR3	TTE2YJR	Strong	Biomarker	[445]
LRP1	TTF2V7I	Strong	Biomarker	[446]
LTB4R2	TTVJX54	Strong	Biomarker	[447]
LY75	TTG180Q	Strong	Biomarker	[448]
LYVE1	TTG8DNU	Strong	Genetic Variation	[449]
MAGEA1	TT63M7Q	Strong	Altered Expression	[242]
MAGEA3	TTWSKHD	Strong	Altered Expression	[242]
MAP2K1	TTIDAPM	Strong	Biomarker	[450]
MAP3K3	TTJZNIG	Strong	Biomarker	[451]
MAP3K5	TTOQCD8	Strong	Biomarker	[452]
MAP4	TT0VFPN	Strong	Altered Expression	[453]
MAPK1	TT4TQBX	Strong	Biomarker	[454]
MARCKS	TTHRM39	Strong	Altered Expression	[455]
MBTPS1	TTNSM2I	Strong	Biomarker	[456]
MCAM	TTHRE05	Strong	Biomarker	[457]
MCL1	TTL53M6	Strong	Biomarker	[269]
MDK	TTV8UE7	Strong	Posttranslational Modification	[458]
MDM4	TT9OUDQ	Strong	Altered Expression	[390]
MELK	TTBZOTY	Strong	Altered Expression	[459]
MET	TTNDSF4	Strong	Altered Expression	[460]
MIA	TT5HNVS	Strong	Biomarker	[461]
MKNK1	TTEZAUX	Strong	Altered Expression	[462]
MLH1	TTISG27	Strong	Autosomal dominant	[463]
MMP1	TTMX39J	Strong	Altered Expression	[464]
MMP7	TTMTWOS	Strong	Biomarker	[465]
MSH2	TTCAWRT	Strong	Autosomal dominant	[463]
MSH2	TTCAWRT	Strong	Genetic Variation	[350]
MSI1	TTSM4BA	Strong	Biomarker	[466]
MSI2	TTTXQF6	Strong	Biomarker	[467]
MSMB	TTYH1ZK	Strong	Biomarker	[468]
MST1R	TTBQ3OC	Strong	Altered Expression	[469]
MTDH	TTH6SA5	Strong	Biomarker	[312]
MTOR	TTCJG29	Strong	Biomarker	[141]
MUC17	TTVO0JU	Strong	Biomarker	[470]
MYC	TTNQ5ZP	Strong	Biomarker	[471]
MYD88	TTB6Q2O	Strong	Biomarker	[472]
NACC1	TT4AQ5F	Strong	Biomarker	[473]
NAPRT	TTVR1FW	Strong	Genetic Variation	[474]
NCAM1	TTVXPHT	Strong	Biomarker	[401]
NCK1	TTMA3VF	Strong	Altered Expression	[475]
NCOA3	TT124R0	Strong	Biomarker	[476]
NECTIN4	TTPO9EG	Strong	Altered Expression	[477]
NEDD9	TT1UREA	Strong	Altered Expression	[478]
NEK2	TT3VZ24	Strong	Altered Expression	[479]
NFKB1	TTUIZKC	Strong	Biomarker	[480]
NISCH	TT789FN	Strong	Biomarker	[481]
NOTCH3	TTVX7IA	Strong	Biomarker	[482]
NPEPPS	TT371QC	Strong	Genetic Variation	[424]
NPR1	TTM9IYA	Strong	Altered Expression	[483]
NR1D1	TTAD1O8	Strong	Biomarker	[484]
NR1H2	TTXA6PH	Strong	Altered Expression	[485]
NR1I3	TTRANFM	Strong	Biomarker	[261]
NTN1	TT0AH4L	Strong	Biomarker	[486]
NTRK3	TTXABCW	Strong	Biomarker	[487]
NTSR1	TTTUMEP	Strong	Biomarker	[488]
OGFR	TT6IEYX	Strong	Biomarker	[489]
OGG1	TTRU01G	Strong	Genetic Variation	[490]
OLFM4	TTK1CX7	Strong	Altered Expression	[491]
OSCAR	TT71Q5Y	Strong	Biomarker	[492]
PADI4	TTQHAXM	Strong	Altered Expression	[493]
PAK1	TTFN95D	Strong	Biomarker	[494]
PARG	TT39J16	Strong	Biomarker	[250]
PAWR	TT3I4WV	Strong	Biomarker	[346]
PBK	TTMY6BZ	Strong	Biomarker	[495]
PCSK6	TT75LN9	Strong	Altered Expression	[496]
PDCD1	TTNBFWK	Strong	Biomarker	[497]
PDGFA	TTSM78N	Strong	Altered Expression	[498]
PDGFD	TTSN0GA	Strong	Biomarker	[499]
PDK1	TTCZOF2	Strong	Biomarker	[500]
PF4	TTSG7Q5	Strong	Biomarker	[501]
PGF	TT48I1Y	Strong	Altered Expression	[502]
PIN1	TTJNTSI	Strong	Altered Expression	[503]
PKM	TT4LOT8	Strong	Altered Expression	[504]
PLAC1	TTM18HX	Strong	Altered Expression	[505]
PLCG1	TT6T4JI	Strong	Biomarker	[506]
PLG	TTP86E2	Strong	Genetic Variation	[507]
PLK2	TT976FS	Strong	Biomarker	[508]
PML	TTLH9NY	Strong	Biomarker	[509]
POLB	TTA0XPV	Strong	Genetic Variation	[510]
POSTN	TT8ALTZ	Strong	Altered Expression	[511]
PRKCI	TTWJTHX	Strong	Biomarker	[512]
PRKDC	TTK3PY9	Strong	Biomarker	[295]
PRLR	TTBPXMA	Strong	Biomarker	[513]
PRSS8	TTT4N0Q	Strong	Altered Expression	[514]
PSEN2	TTWN3F4	Strong	Altered Expression	[515]
PSIP1	TTH9LDP	Strong	Altered Expression	[516]
PTAFR	TTQL5VC	Strong	Altered Expression	[517]
PTBP1	TTWMX0U	Strong	Altered Expression	[506]
PTEN	TTXJ3W7	Strong	Biomarker	[518]
PTGS1	TT8NGED	Strong	Biomarker	[519]
PTK2	TTON5IT	Strong	Posttranslational Modification	[520]
PTPN13	TT405FP	Strong	Altered Expression	[521]
PTPN6	TT369M5	Strong	Genetic Variation	[392]
PTPRC	TTUS45N	Strong	Biomarker	[522]
PTPRZ1	TT4SEA8	Strong	Biomarker	[523]
RAB22A	TTAJ746	Strong	Altered Expression	[524]
RALBP1	TTVSRUA	Strong	Altered Expression	[525]
RBP4	TT0C8BY	Strong	Biomarker	[526]
RHBDF2	TTH1ZOP	Strong	Biomarker	[527]
RHOB	TT6LPFO	Strong	Biomarker	[528]
ROCK1	TTZN7RP	Strong	Altered Expression	[529]
ROCK2	TTGWKQJ	Strong	Altered Expression	[443]
ROR1	TTDEJAU	Strong	Biomarker	[530]
ROR2	TTUDPCI	Strong	Altered Expression	[531]
RPS6KA1	TTIXKA4	Strong	Biomarker	[532]
RPS6KA6	TT3KYWB	Strong	Altered Expression	[533]
RPS6KB1	TTG0U4H	Strong	Altered Expression	[534]
RRM2	TT1S4LJ	Strong	Biomarker	[535]
RSF1	TTMP86V	Strong	Altered Expression	[536]
RSPO1	TTI9HL4	Strong	Biomarker	[537]
SAA1	TTY0DN9	Strong	Altered Expression	[538]
SCGB1A1	TTONPVW	Strong	Altered Expression	[539]
SCN1A	TTANOZH	Strong	Biomarker	[473]
SEMA3A	TTVKD3S	Strong	Altered Expression	[540]
SEMA4D	TT5UT28	Strong	Biomarker	[541]
SERPINA6	TTJL8VG	Strong	Altered Expression	[542]
SERPINC1	TT4QPUL	Strong	Biomarker	[543]
SERPIND1	TT8XSKJ	Strong	Biomarker	[544]
SERPINF1	TTR59S1	Strong	Biomarker	[545]
SERPING1	TTVQ6R9	Strong	Biomarker	[546]
SFRP4	TTX8I1Y	Strong	Altered Expression	[547]
SFTPD	TTGLMU7	Strong	Altered Expression	[548]
SIK2	TTCUGZR	Strong	Biomarker	[549]
SIK3	TTW6L4V	Strong	Altered Expression	[550]
SIRT2	TTLKF5M	Strong	Altered Expression	[551]
SIRT3	TTVZLIJ	Strong	Biomarker	[552]
SIRT5	TTH0IOD	Strong	Altered Expression	[553]
SIRT6	TTUXYWF	Strong	Altered Expression	[553]
SLC11A2	TT2IS7P	Strong	Biomarker	[554]
SLC12A5	TTH6UZY	Strong	Biomarker	[555]
SLC13A5	TTFIMH7	Strong	Biomarker	[556]
SLC16A1	TTN1J82	Strong	Altered Expression	[302]
SLC16A3	TTG6VD5	Strong	Altered Expression	[557]
SLC2A1	TT79TKF	Strong	Altered Expression	[558]
SLC52A2	TT6TKEN	Strong	Biomarker	[559]
SLC6A1	TTPRKM0	Strong	Biomarker	[560]
SLC6A12	TTQBMPI	Strong	Posttranslational Modification	[561]
SLCO1B1	TTFGXEB	Strong	Altered Expression	[562]
SLCO1B3	TTU86P0	Strong	Altered Expression	[562]
SMAD6	TTON5JB	Strong	Genetic Variation	[563]
SMAD7	TT0J32Z	Strong	Biomarker	[564]
SMARCA4	TTVQEZS	Strong	Biomarker	[289]
SMC2	TTS8D17	Strong	Genetic Variation	[431]
SMYD3	TTKLJYX	Strong	Biomarker	[565]
SOCS1	TT8COJM	Strong	Biomarker	[566]
SPARC	TTBQFM7	Strong	Biomarker	[567]
SPDEF	TT2ZUPY	Strong	Biomarker	[568]
SPHK1	TTOHFIY	Strong	Altered Expression	[569]
SQSTM1	TTOT2RY	Strong	Genetic Variation	[570]
SRR	TTZFUY6	Strong	Biomarker	[571]
SSTR4	TTAE1BR	Strong	Biomarker	[128]
ST14	TTPRO7W	Strong	Biomarker	[572]
STAT3	TTHJT3X	Strong	Biomarker	[441]
STC1	TTDLUER	Strong	Biomarker	[573]
STC2	TT4EFTR	Strong	Biomarker	[574]
STMN1	TT7W5OT	Strong	Altered Expression	[575]
STOML2	TTOI329	Strong	Biomarker	[576]
STS	TTHM0R1	Strong	Biomarker	[577]
TACSTD2	TTP2HE5	Strong	Biomarker	[578]
TEK	TT9VGXW	Strong	Biomarker	[579]
TEP1	TTQGAVX	Strong	Genetic Variation	[580]
TFAP2A	TTDY4BS	Strong	Biomarker	[581]
TFF1	TTNOJIZ	Strong	Altered Expression	[515]
TGFA	TTTLQFR	Strong	Altered Expression	[582]
TGFB3	TTWOMY8	Strong	Biomarker	[583]
TGM2	TT2F4OL	Strong	Biomarker	[584]
THRA	TTTSEPU	Strong	Genetic Variation	[484]
TIE1	TTT4236	Strong	Biomarker	[585]
TIPARP	TT2FRAN	Strong	Genetic Variation	[586]
TK1	TTP3QRF	Strong	Biomarker	[587]
TKT	TT04R7I	Strong	Altered Expression	[588]
TLR8	TT8CWFK	Strong	Biomarker	[589]
TMSB4X	TTMVAIU	Strong	Altered Expression	[590]
TNFRSF10A	TT5WLRX	Strong	Genetic Variation	[591]
TNFRSF12A	TTKPS7V	Strong	Genetic Variation	[592]
TNFRSF13C	TT7NJSE	Strong	Genetic Variation	[593]
TNFRSF14	TTWGTC1	Strong	Biomarker	[594]
TNFRSF4	TTL31H0	Strong	Biomarker	[595]
TNFSF10	TTA5MS9	Strong	Biomarker	[596]
TNFSF15	TTEST6I	Strong	Altered Expression	[597]
TNKS	TTVUSO7	Strong	Biomarker	[598]
TOP1	TTGTQHC	Strong	Biomarker	[599]
TP53BP1	TTX4UE9	Strong	Biomarker	[141]
TPX2	TT0PHL4	Strong	Biomarker	[600]
TRIM27	TTTO3QN	Strong	Biomarker	[601]
TRIM28	TTQ2BKV	Strong	Biomarker	[602]
TRIM59	TT613U4	Strong	Biomarker	[603]
TRPC1	TTA76X0	Strong	Biomarker	[604]
TRPC3	TTNVC34	Strong	Altered Expression	[605]
TRPM7	TTFPVZO	Strong	Biomarker	[606]
TRPV6	TTBK14N	Strong	Altered Expression	[607]
TSG101	TTHU7JA	Strong	Altered Expression	[608]
TUSC2	TTJ8O14	Strong	Biomarker	[609]
TWIST1	TTX1MY7	Strong	Biomarker	[610]
TYMP	TTO0IB8	Strong	Altered Expression	[611]
TYMS	TTP1UKZ	Strong	Biomarker	[612]
UBC	TTBP3XA	Strong	Biomarker	[613]
UCHL3	TT23UD6	Strong	Biomarker	[614]
UCHL5	TTSX29Z	Strong	Biomarker	[615]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[616]
ULK1	TT4D7MJ	Strong	Biomarker	[617]
USP1	TTG9MT5	Strong	Biomarker	[618]
USP13	TTVJIO2	Strong	Biomarker	[619]
USP14	TTVSYP9	Strong	Biomarker	[620]
USP7	TTXU3EQ	Strong	Altered Expression	[621]
UTRN	TTNO1VA	Strong	Biomarker	[549]
VCAM1	TTHCEF6	Strong	Biomarker	[335]
VEGFB	TTPJQHE	Strong	Biomarker	[622]
VEGFC	TT0QUFV	Strong	Altered Expression	[210]
VSIR	TT51SK8	Strong	Altered Expression	[623]
VTCN1	TTCK85E	Strong	Altered Expression	[624]
WEE1	TTJFOAL	Strong	Biomarker	[625]
WNT7A	TT8NARC	Strong	Biomarker	[626]
XPA	TTGT87E	Strong	Altered Expression	[627]
XPO1	TTCJUR4	Strong	Biomarker	[628]
YAP1	TT8UN2D	Strong	Biomarker	[629]
ZNF217	TTY3BRA	Strong	Biomarker	[630]
ABCB1	TT3OT40	Definitive	Biomarker	[265]
AKT3	TTO6SGY	Definitive	Biomarker	[631]
BCL2L1	TTRE6AX	Definitive	Biomarker	[632]
CAPN2	TTG5QB7	Definitive	Altered Expression	[633]
CCR1	TTC24WT	Definitive	Biomarker	[634]
CD80	TT89Z17	Definitive	Biomarker	[635]
CHKA	TT10AWB	Definitive	Biomarker	[636]
CTNNB1	TTRPKQG	Definitive	Altered Expression	[637]
CXCL2	TTZF0K2	Definitive	Altered Expression	[638]
DNM2	TTVRA5G	Definitive	Biomarker	[639]
DUSP1	TTG8HIM	Definitive	Biomarker	[640]
E2F3	TTWIJYH	Definitive	Biomarker	[641]
EGLN1	TT9ISBX	Definitive	Biomarker	[642]
EZH2	TT9MZCQ	Definitive	Biomarker	[643]
F3	TT38MDJ	Definitive	Biomarker	[644]
FANCA	TTV5HJS	Definitive	Biomarker	[645]
G6PC	TTBQMJ8	Definitive	Altered Expression	[646]
GRPR	TTC1MVT	Definitive	Biomarker	[647]
HMGA2	TTSTVM0	Definitive	Biomarker	[241]
IGFBP2	TTU4QSN	Definitive	Biomarker	[436]
IL1R1	TTWOTEA	Definitive	Biomarker	[648]
ITGAE	TTH0Z37	Definitive	Biomarker	[649]
KLK1	TT5T3P6	Definitive	Genetic Variation	[650]
KLK8	TTH5MRS	Definitive	Altered Expression	[651]
KLRK1	TTLRN4A	Definitive	Biomarker	[652]
LDHA	TTW76JE	Definitive	Biomarker	[653]
LGALS3	TTFPQV7	Definitive	Biomarker	[654]
LHCGR	TT2O4W9	Definitive	Altered Expression	[655]
LPAR2	TTB7Y8I	Definitive	Biomarker	[445]
MAPK10	TT056SO	Definitive	Altered Expression	[656]
MMP8	TTGA1IV	Definitive	Genetic Variation	[657]
MTA1	TTO4HUS	Definitive	Altered Expression	[658]
MUC1	TTBHFYQ	Definitive	Biomarker	[659]
MVD	TTE5J6X	Definitive	Biomarker	[660]
NCOA4	TT8OY02	Definitive	Biomarker	[661]
NT5E	TTK0O6Y	Definitive	Altered Expression	[662]
NUAK1	TT65FL0	Definitive	Altered Expression	[663]
PGR	TTUV8G9	Definitive	Genetic Variation	[664]
PIK3CB	TT9H4P3	Definitive	Biomarker	[665]
PIM3	TTCGOIN	Definitive	Biomarker	[666]
PPAT	TTZFTY4	Definitive	Biomarker	[612]
PRDX5	TTLPJWH	Definitive	Biomarker	[667]
PTGER3	TTPNGDE	Definitive	Biomarker	[668]
REG4	TTVZEHU	Definitive	Altered Expression	[669]
SETD7	TTJ0FSU	Definitive	Altered Expression	[670]
SPOCK1	TTF23RE	Definitive	Biomarker	[671]
TNS4	TT1K65C	Definitive	Altered Expression	[672]
WNT5A	TTKG7F8	Definitive	Biomarker	[673]
WWP2	TT6TU05	Definitive	Altered Expression	[674]

This Disease Is Related to 18 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A37	DTLBGTZ	Limited	Biomarker	[675]
SLC2A3	DT9SQ3L	Limited	Altered Expression	[676]
SLC31A2	DT8Q56F	Limited	Altered Expression	[677]
ANXA11	DTGQ2CF	moderate	Biomarker	[678]
ABCA7	DTDVSJA	Strong	Altered Expression	[679]
ABCB9	DT68UV2	Strong	Altered Expression	[680]
ABCC10	DTPS120	Strong	Altered Expression	[681]
ATP7A	DT0LT17	Strong	Biomarker	[682]
SLC13A2	DTUO05P	Strong	Biomarker	[556]
SLC25A3	DTCRIWV	Strong	Biomarker	[683]
SLC26A3	DTN1FMD	Strong	Genetic Variation	[684]
SLC27A2	DTXK9WA	Strong	Biomarker	[685]
SLC2A5	DTOR02F	Strong	Biomarker	[686]
SLC30A1	DT1BO38	Strong	Biomarker	[687]
SLC31A1	DTP8L4F	Strong	Altered Expression	[688]
SLC35A2	DT0567K	Strong	Biomarker	[689]
SLC39A4	DTEZCUM	Strong	Biomarker	[690]
SLC4A11	DTH2J1G	Strong	Altered Expression	[691]

This Disease Is Related to 26 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTZ1	DEQPEMB	Limited	Genetic Variation	[142]
AKR1C1	DE7P2FB	moderate	Altered Expression	[692]
CYP27B1	DE3FYEM	moderate	Altered Expression	[693]
SULT1E1	DESTKG6	moderate	Genetic Variation	[198]
ABO	DESIA7R	Strong	Biomarker	[694]
ACP3	DEDW5H6	Strong	Biomarker	[695]
ADH1B	DEEN9RD	Strong	Biomarker	[283]
ALDH1A2	DEKN1H4	Strong	Biomarker	[696]
ASNS	DEXISVQ	Strong	Biomarker	[697]
CRMP1	DE0EUXB	Strong	Biomarker	[549]
EPHX1	DELB4KP	Strong	Genetic Variation	[698]
GFPT2	DERQCJM	Strong	Altered Expression	[699]
GGCT	DEKW6PB	Strong	Altered Expression	[700]
GSTO2	DEHMPZR	Strong	Genetic Variation	[142]
HIF1AN	DEY1CBW	Strong	Biomarker	[701]
HPRT1	DEVXTP5	Strong	Posttranslational Modification	[702]
HSD17B12	DE915QP	Strong	Altered Expression	[703]
HSD17B7	DEDMWFX	Strong	Genetic Variation	[704]
IPMK	DESA9EX	Strong	Biomarker	[705]
PCYT1A	DEQYXD4	Strong	Biomarker	[706]
PON2	DEHJU7E	Strong	Biomarker	[707]
PSAT1	DEBS17P	Strong	Biomarker	[708]
PTGDS	DER3H9C	Strong	Altered Expression	[709]
UBASH3B	DE10BJ5	Strong	Biomarker	[710]
ALDH1A1	DE2JP1Y	Definitive	Biomarker	[711]
CYP2C8	DES5XRU	Definitive	Genetic Variation	[712]

This Disease Is Related to 945 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
RRAS2	OT83NCEB	No Known	Unknown	[713]
ACSL3	OT3MWER1	Limited	Altered Expression	[714]
ACTN3	OT9DZ7JQ	Limited	Genetic Variation	[715]
AGO1	OTD3R434	Limited	Altered Expression	[716]
ANKLE1	OTQ7WN9J	Limited	Genetic Variation	[717]
ANXA3	OTDD8OI7	Limited	Biomarker	[718]
ASPM	OTKXQMNA	Limited	Biomarker	[719]
ATP11B	OTQOXTH2	Limited	Biomarker	[720]
AXIN2	OTRMGQNU	Limited	Genetic Variation	[721]
BAMBI	OTCEJ8W5	Limited	Biomarker	[722]
BCAR1	OTKT2C2N	Limited	Biomarker	[723]
BCCIP	OTFFKG79	Limited	Altered Expression	[724]
BMPR1B	OTGFN0OD	Limited	Biomarker	[725]
BNC2	OTU22H9Z	Limited	Biomarker	[726]
BOD1L1	OTTD5FJ8	Limited	Genetic Variation	[727]
BTN3A1	OTGZADIX	Limited	Biomarker	[728]
CAST	OTBXZZGF	Limited	Biomarker	[729]
CCNH	OTKDU3SR	Limited	Biomarker	[141]
CD164	OTZ7FIU8	Limited	Biomarker	[730]
CHAC1	OTJGE772	Limited	Altered Expression	[731]
CIP2A	OTVS2GXA	Limited	Altered Expression	[732]
CLDN1	OT27KV99	Limited	Altered Expression	[733]
CNMD	OTHND8EL	Limited	Biomarker	[734]
CORO1A	OTVAZOHC	Limited	Altered Expression	[735]
COX5A	OTP0961M	Limited	Altered Expression	[736]
CTNND2	OTYKE30Y	Limited	Biomarker	[737]
DLX5	OTEEFBEU	Limited	Altered Expression	[738]
DOC2A	OT5G9V94	Limited	Biomarker	[739]
DOK2	OTIJ38UF	Limited	Biomarker	[740]
DPH1	OT0QU3JY	Limited	Altered Expression	[741]
DVL1	OTD67RF1	Limited	Posttranslational Modification	[742]
EPB41L3	OTS6CHG2	Limited	Biomarker	[743]
EPS8	OTZ6ES6V	Limited	Biomarker	[744]
FANCC	OTTIDM3P	Limited	Autosomal dominant	[713]
FCN3	OTPRENLS	Limited	Altered Expression	[745]
FDCSP	OT8KGE9M	Limited	Biomarker	[746]
FRAT1	OT1PS84E	Limited	Altered Expression	[747]
GATA5	OTO81B63	Limited	Biomarker	[748]
GNAI2	OTTLGRGH	Limited	Genetic Variation	[749]
GPR150	OTTA9DF6	Limited	Biomarker	[147]
GPR4	OTIBF32I	Limited	Altered Expression	[750]
HOOK2	OTPO4NQV	Limited	Genetic Variation	[715]
HOXA4	OTNVTQDT	Limited	Altered Expression	[751]
HOXD11	OT9XGA4G	Limited	Biomarker	[147]
HUS1	OTY1XON9	Limited	Genetic Variation	[752]
IFFO1	OTQGJWI0	Limited	Biomarker	[753]
INTS2	OT2N5TCK	Limited	Genetic Variation	[754]
JAM3	OTX0F9QL	Limited	Biomarker	[755]
KLF8	OTUC5CDB	Limited	Altered Expression	[756]
KLK10	OTD573EL	Limited	Biomarker	[757]
LDOC1	OTWZH4O9	Limited	Biomarker	[758]
LIG4	OT40DNXU	Limited	Genetic Variation	[759]
LMX1B	OTM8145D	Limited	Biomarker	[760]
LRPPRC	OTXSK5LP	Limited	Biomarker	[761]
LRRC59	OT6BQJ5E	Limited	Biomarker	[141]
MACIR	OTPSW8Y8	Limited	Biomarker	[141]
MAL	OTBM30SW	Limited	Altered Expression	[762]
MECOM	OTP983W8	Limited	Biomarker	[763]
MED19	OTT9RT5N	Limited	Biomarker	[764]
MEST	OT8Q4U8Y	Limited	Biomarker	[458]
MLLT10	OTURMDV7	Limited	Genetic Variation	[586]
MNAT1	OTXLOYCB	Limited	Altered Expression	[132]
MTSS1	OT5DTDO2	Limited	Altered Expression	[765]
MXI1	OTUQ9E0D	Limited	Biomarker	[675]
NKD1	OTY3MO97	Limited	Posttranslational Modification	[742]
NLK	OT2LETFS	Limited	Biomarker	[766]
NOB1	OTW0YNSL	Limited	Altered Expression	[767]
NOLC1	OTKDZU0D	Limited	Biomarker	[768]
NR2F2	OTJFS67N	Limited	Altered Expression	[769]
OCLN	OTSUTVWL	Limited	Altered Expression	[133]
P4HB	OTTYNYPF	Limited	Biomarker	[770]
PES1	OTMZK7XE	Limited	Biomarker	[771]
PHF20	OTCBVH5P	Limited	Biomarker	[772]
PIK3R3	OTXGJ8N1	Limited	Altered Expression	[773]
PLXNB1	OTCA7JIT	Limited	Altered Expression	[774]
PNKD	OT6G9UXN	Limited	Biomarker	[775]
PPP1R13L	OTNCPLWE	Limited	Biomarker	[776]
PROCR	OTRHED17	Limited	Biomarker	[162]
PRSS22	OTANEFGM	Limited	Biomarker	[777]
PRTFDC1	OTKJ44KY	Limited	Biomarker	[147]
PSMC3IP	OT9UB5UO	Limited	Biomarker	[778]
RAB3GAP1	OT4DQ8F2	Limited	Biomarker	[768]
RAB5A	OTFR2KM4	Limited	Altered Expression	[779]
RAI14	OT6USGBK	Limited	Altered Expression	[769]
RBM38	OTPO8EXU	Limited	Altered Expression	[780]
RPS7	OTIK25WI	Limited	Biomarker	[781]
SEM1	OTASLBM1	Limited	Genetic Variation	[782]
SGTA	OTKOJ3JB	Limited	Altered Expression	[783]
SLC22A10	OTUVJI3H	Limited	Biomarker	[141]
SMAD4	OTWQWCKG	Limited	Altered Expression	[784]
SOX1	OTVI1RAR	Limited	Posttranslational Modification	[785]
SRSF10	OTY6IJ11	Limited	Biomarker	[786]
TBC1D9	OTSSCTB5	Limited	Genetic Variation	[787]
TES	OTL8PP6V	Limited	Posttranslational Modification	[788]
THOC1	OTVABJ4Z	Limited	Altered Expression	[789]
TMPRSS4	OTCCGY2K	Limited	Biomarker	[790]
TNFRSF6B	OTKAN9G7	Limited	Altered Expression	[791]
TNFSF9	OTV9L89D	Limited	Biomarker	[792]
TRMT11	OTRK0IOR	Limited	Biomarker	[141]
TTLL5	OTUKOVEM	Limited	Biomarker	[793]
CELSR3	OT8P6QNJ	Disputed	Genetic Variation	[181]
ERCC3	OTVAW3P1	Disputed	Biomarker	[794]
MTHFD1	OTMKHVWC	Disputed	Genetic Variation	[795]
PCDHA1	OT65E2NU	Disputed	Genetic Variation	[181]
PCDHB3	OTEDVXZY	Disputed	Altered Expression	[181]
PFN2	OT5SSSA7	Disputed	Genetic Variation	[181]
PPP1R15A	OTYG179K	Disputed	Biomarker	[796]
PRICKLE4	OT19NLJR	Disputed	Altered Expression	[181]
RASSF1	OTEZIPB7	Disputed	Biomarker	[797]
RBX1	OTYA1UIO	Disputed	Biomarker	[176]
SBSN	OT89RKJH	Disputed	Altered Expression	[798]
TARS1	OT0PWST5	Disputed	Altered Expression	[799]
TARS2	OTXQY23P	Disputed	Altered Expression	[799]
TARS3	OTPMDV66	Disputed	Altered Expression	[799]
ADAMDEC1	OTMT7ZMG	moderate	Biomarker	[800]
ADAMTSL4	OTBILJMW	moderate	Biomarker	[801]
AFM	OTPOR8IO	moderate	Biomarker	[802]
ANGPTL2	OTB6JG41	moderate	Posttranslational Modification	[803]
ARHGEF7	OT9BPJCL	moderate	Biomarker	[804]
ASCC1	OTH4VAP9	moderate	Biomarker	[804]
ASS1	OT4ZMG0Q	moderate	Posttranslational Modification	[805]
ATRIP	OT78O9LF	moderate	Biomarker	[806]
BAD	OT63ERYM	moderate	Altered Expression	[807]
BDH2	OTDD7G8S	moderate	Biomarker	[808]
BEX4	OT3LXD15	moderate	Biomarker	[809]
CABLES1	OTMN4XSX	moderate	Posttranslational Modification	[810]
CACNB1	OTV42SIT	moderate	Biomarker	[811]
CASP14	OTKY93H9	moderate	Altered Expression	[812]
CCDC80	OTOZSYEM	moderate	Biomarker	[813]
CDCA5	OTZLCQ5U	moderate	Altered Expression	[132]
CERT1	OTNUCNHX	moderate	Altered Expression	[814]
CHP2	OT4UMKUR	moderate	Altered Expression	[815]
CNTN4	OTULXVE0	moderate	Biomarker	[816]
DDB1	OTTR2L3Z	moderate	Altered Expression	[817]
EEF1A1	OT00THXS	moderate	Biomarker	[818]
ERCC5	OTQAKFJM	moderate	Biomarker	[819]
FANCD2	OTVEB5LF	moderate	Biomarker	[820]
FOXG1	OTAW57J4	moderate	Altered Expression	[821]
GCHFR	OTEOT8GI	moderate	Altered Expression	[132]
GEMIN2	OT4L6TLL	moderate	Biomarker	[822]
GIPC2	OT68YFO1	moderate	Genetic Variation	[823]
HLA-DOA	OTZE5Q7R	moderate	Biomarker	[824]
HNF1B	OTSYIC3T	moderate	Genetic Variation	[825]
HTRA2	OTC7616F	moderate	Altered Expression	[826]
IQGAP1	OTZRWTGA	moderate	Biomarker	[827]
IRF2	OTAZRUW3	moderate	Biomarker	[828]
LRRC3B	OT9VDGPR	moderate	Altered Expression	[829]
LZTS1	OTXXL864	moderate	Biomarker	[830]
MFAP5	OT46VXSG	moderate	Biomarker	[831]
MRPL23	OT7H7PM2	moderate	Genetic Variation	[832]
MTA3	OTIA6C79	moderate	Biomarker	[833]
MTUS1	OTBPALMU	moderate	Biomarker	[808]
NFKBIB	OTY1ZJXH	moderate	Genetic Variation	[834]
NMI	OTYVG3NM	moderate	Genetic Variation	[835]
NXPH2	OTHD8HPU	moderate	Genetic Variation	[832]
PDZRN3	OTQ891OS	moderate	Altered Expression	[836]
PEA15	OTKCKTSX	moderate	Altered Expression	[837]
PHF13	OT89FV4A	moderate	Altered Expression	[838]
PMS2	OTNLWTMI	Moderate	Autosomal dominant	[463]
POLD1	OTWO4UCJ	moderate	Genetic Variation	[839]
PPP1R12A	OT4AVU95	moderate	Biomarker	[840]
PRDM2	OT8L7CGX	moderate	Altered Expression	[841]
PRKN	OTJBN41W	moderate	Biomarker	[245]
PSD3	OTTN9B9O	moderate	Biomarker	[808]
PTBP2	OTF4S7NE	moderate	Altered Expression	[842]
QRSL1	OTJDU2UG	moderate	Altered Expression	[843]
RAD52	OT0OTDHI	moderate	Biomarker	[844]
SCAF11	OTX59D0X	moderate	Biomarker	[822]
SLPI	OTUNFUU8	moderate	Altered Expression	[845]
SOHLH2	OTB9EM6C	moderate	Posttranslational Modification	[846]
SPINT2	OTQV7BKQ	moderate	Altered Expression	[195]
SRA1	OTYOGMTG	moderate	Biomarker	[847]
STX1A	OTSBUZB4	moderate	Biomarker	[848]
THBS2	OTXET551	moderate	Altered Expression	[849]
TOPBP1	OT6UPZPD	moderate	Biomarker	[850]
TOX3	OTC9NR4W	moderate	Genetic Variation	[832]
TPD52	OTPKSK43	moderate	Biomarker	[851]
TRIT1	OTCU9FS5	moderate	Altered Expression	[852]
ABHD2	OTCRUOCS	Strong	Altered Expression	[853]
ABI1	OT5H4M62	Strong	Biomarker	[854]
ABRAXAS1	OT1K4J80	Strong	Genetic Variation	[855]
ACOT7	OT7C68YV	Strong	Genetic Variation	[215]
ACTBL2	OTD6B81U	Strong	Genetic Variation	[215]
ACTG2	OTRDWUO0	Strong	Genetic Variation	[215]
ACTL6A	OT0EC5BQ	Strong	Biomarker	[856]
ACTN4	OTCNZAJ5	Strong	Altered Expression	[857]
ACVR1C	OTOTYERF	Strong	Biomarker	[858]
ADAM19	OTH88TXU	Strong	Biomarker	[859]
ADGRE2	OTUYJVYG	Strong	Genetic Variation	[860]
ADGRE5	OTTSB84Q	Strong	Genetic Variation	[860]
ADNP	OTEGICWR	Strong	Biomarker	[861]
ADRM1	OTOU4EY6	Strong	Genetic Variation	[862]
AFDN	OTTRU341	Strong	Genetic Variation	[863]
AGBL2	OTCX9987	Strong	Biomarker	[864]
AGO2	OT4JY32Q	Strong	Biomarker	[865]
AGR3	OTONJPDP	Strong	Altered Expression	[218]
AK6	OT84OHHP	Strong	Biomarker	[847]
AKAP12	OTCVRDDX	Strong	Altered Expression	[866]
AKAP13	OTOZAR14	Strong	Biomarker	[867]
AKAP3	OT42QOFG	Strong	Altered Expression	[868]
ALPP	OTZU4G9W	Strong	Biomarker	[869]
AMBP	OTLU8GU8	Strong	Genetic Variation	[392]
AMPD3	OT5SP1KJ	Strong	Biomarker	[870]
ANAPC10	OTM03SME	Strong	Biomarker	[871]
ANKRD11	OTV0V70M	Strong	Genetic Variation	[872]
ANXA4	OTUCRYXL	Strong	Biomarker	[873]
ANXA6	OT9KIQ0Y	Strong	Altered Expression	[874]
APAF1	OTJWIVY0	Strong	Altered Expression	[875]
APBB1IP	OTN02KUV	Strong	Altered Expression	[876]
APC	OTKV0TIK	Strong	Biomarker	[877]
APELA	OTYY0P69	Strong	Biomarker	[878]
APOBEC3B	OTHLNI51	Strong	Altered Expression	[879]
AQP5	OT77GBY8	Strong	Altered Expression	[880]
ARHGAP10	OT84ATF5	Strong	Biomarker	[881]
ARHGEF28	OT3F32IU	Strong	Altered Expression	[882]
ARHGEF5	OTUVGFT9	Strong	Altered Expression	[883]
ARID3B	OTUP9MS4	Strong	Biomarker	[884]
ARID4B	OTYLPILE	Strong	Altered Expression	[885]
ARL11	OTF6UDDB	Strong	Genetic Variation	[886]
ARMCX1	OTOGL58Z	Strong	Altered Expression	[887]
ARMCX2	OT9Q95J5	Strong	Altered Expression	[887]
ARNT	OTMSIEZY	Strong	Altered Expression	[888]
ARR3	OTRZ00CH	Strong	Biomarker	[261]
ATAD5	OTI8ABKF	Strong	Genetic Variation	[889]
ATG5	OT4T5SMS	Strong	Altered Expression	[890]
BABAM1	OTCFPER6	Strong	Genetic Variation	[586]
BAG3	OTVXYUDQ	Strong	Biomarker	[891]
BARX2	OT0R3QD3	Strong	Altered Expression	[284]
BCL10	OT47MCLI	Strong	Biomarker	[892]
BCL2L11	OTNQQWFJ	Strong	Altered Expression	[893]
BCL3	OT1M5B95	Strong	Altered Expression	[894]
BCL7A	OTYFUJTP	Strong	Biomarker	[895]
BCL9	OTRBIPR4	Strong	Altered Expression	[167]
BIRC6	OTCQJAB0	Strong	Biomarker	[617]
BMS1	OTEGQ8ZO	Strong	Biomarker	[896]
BNIP3	OT4SO7J4	Strong	Biomarker	[897]
BNIP3L	OTJKOMXE	Strong	Biomarker	[898]
BRAP	OTB7BAFQ	Strong	Biomarker	[899]
BRMS1	OTV5A6LL	Strong	Biomarker	[900]
BRMS1L	OTJIW47U	Strong	Biomarker	[901]
BTG3	OT9ANHVT	Strong	Biomarker	[902]
BTN3A2	OT3DIBU3	Strong	Biomarker	[903]
BUD31	OTN3HZYF	Strong	Altered Expression	[904]
C12orf75	OTFVI3EY	Strong	Genetic Variation	[905]
C19orf12	OTVSJ1AR	Strong	Biomarker	[906]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[907]
C20orf204	OT0GVQPP	Strong	Biomarker	[908]
CACUL1	OT6P1ZVP	Strong	Biomarker	[909]
CALB1	OTM7IXDG	Strong	Biomarker	[910]
CALB2	OTSNMCG9	Strong	Biomarker	[255]
CAMKMT	OTLJBRUW	Strong	Biomarker	[911]
CAPNS1	OT95EBBD	Strong	Biomarker	[912]
CBFB	OTIAC6W4	Strong	Biomarker	[913]
CBLL2	OTB4AD3V	Strong	Biomarker	[245]
CBX2	OTOQ5WS4	Strong	Biomarker	[914]
CC2D1A	OTVPU04K	Strong	Biomarker	[915]
CCDC54	OTW5WCX9	Strong	Biomarker	[916]
CCL15	OTOGZ85M	Strong	Biomarker	[266]
CCL18	OT7JYSK9	Strong	Biomarker	[917]
CCL19	OTQ2UJMH	Strong	Biomarker	[918]
CCL25	OTLWJ8CJ	Strong	Biomarker	[271]
CCL8	OTCTWYN8	Strong	Altered Expression	[266]
CCNA1	OTX4HD45	Strong	Biomarker	[919]
CCND2	OTDULQF9	Strong	Altered Expression	[920]
CCNG1	OT17IA9L	Strong	Altered Expression	[921]
CCT4	OT5D452X	Strong	Biomarker	[922]
CD151	OTF3UZS7	Strong	Altered Expression	[923]
CD247	OT45FGUX	Strong	Altered Expression	[276]
CD82	OTH8MC64	Strong	Biomarker	[924]
CD99	OTPUZ5DE	Strong	Biomarker	[925]
CDC42	OT5QBC5M	Strong	Biomarker	[926]
CDC6	OTX93FE7	Strong	Biomarker	[927]
CDC73	OT6JASZ1	Strong	Altered Expression	[928]
CDCP1	OTD7RRWK	Strong	Biomarker	[929]
CDH13	OTD2CYM5	Strong	Biomarker	[930]
CDK14	OT385ZH1	Strong	Biomarker	[931]
CDK2AP1	OTNFOHDJ	Strong	Biomarker	[871]
CDKN3	OTBE3H07	Strong	Biomarker	[932]
CDR2	OTD3ZJST	Strong	Biomarker	[933]
CEMIP	OTK80FYN	Strong	Biomarker	[934]
CGB1	OT7NFGXF	Strong	Biomarker	[187]
CGB2	OTZJW4TH	Strong	Genetic Variation	[187]
CHAF1A	OTXSSY4H	Strong	Biomarker	[413]
CHD2	OTRKL6YC	Strong	Biomarker	[935]
CHD5	OTS5EVHH	Strong	Altered Expression	[936]
CHFR	OTRAD2TT	Strong	Biomarker	[937]
CHGB	OT7SAQT2	Strong	Altered Expression	[187]
CHIC1	OTAXICYD	Strong	Biomarker	[867]
CHMP2B	OTZA7RJB	Strong	Biomarker	[554]
CHMP4C	OT5X8A3O	Strong	Biomarker	[938]
CHPT1	OT4FJ0K3	Strong	Biomarker	[939]
CHRD	OTNM60Y1	Strong	Biomarker	[940]
CIB1	OT4BVCRU	Strong	Altered Expression	[291]
CIB2	OT9ZJX1I	Strong	Biomarker	[941]
CIC	OTFXCHNZ	Strong	Biomarker	[942]
CKAP2	OTCLTC0J	Strong	Altered Expression	[943]
CKB	OTUCKOTT	Strong	Biomarker	[944]
CLDN10	OT2CVAKY	Strong	Biomarker	[943]
CLDN11	OTNN6UTL	Strong	Biomarker	[945]
CLDN3	OT71MN9S	Strong	Biomarker	[946]
CLEC10A	OTD8HQT6	Strong	Biomarker	[947]
CLEC11A	OT9KBH7C	Strong	Altered Expression	[948]
CLIC4	OT6KTPKD	Strong	Biomarker	[949]
CNDP2	OTJR9436	Strong	Altered Expression	[950]
COL11A1	OTB0DRMS	Strong	Biomarker	[951]
COL5A1	OT24078H	Strong	Altered Expression	[952]
COMMD1	OT7WUD5R	Strong	Altered Expression	[953]
COX1	OTG3O9BN	Strong	Biomarker	[519]
COX5B	OTDP94F3	Strong	Biomarker	[954]
CPOX	OTIAY121	Strong	Genetic Variation	[392]
CPT2	OTIN6G20	Strong	Biomarker	[955]
CREB3	OT9617UO	Strong	Genetic Variation	[956]
CREB3L4	OTSGQGT2	Strong	Biomarker	[304]
CREBZF	OTO3TOEU	Strong	Biomarker	[382]
CRKL	OTOYSD1R	Strong	Biomarker	[957]
CSPP1	OTNX7GD4	Strong	Altered Expression	[958]
CST2	OTRKRW50	Strong	Altered Expression	[959]
CST5	OTHJXNJG	Strong	Altered Expression	[959]
CST6	OTZVHJTF	Strong	Altered Expression	[959]
CSTB	OT3U0JF8	Strong	Biomarker	[960]
CT45A1	OT80VTZO	Strong	Biomarker	[961]
CTBP1	OTVYH2DH	Strong	Altered Expression	[962]
CTBP2	OTGZGT87	Strong	Altered Expression	[963]
CTCF	OT8ZB70U	Strong	Biomarker	[964]
CTHRC1	OTV88X2G	Strong	Biomarker	[965]
CTNNAL1	OTESJ6JD	Strong	Biomarker	[966]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[967]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[968]
CTNND1	OTUMPSHR	Strong	Altered Expression	[969]
CTR9	OTP151PZ	Strong	Posttranslational Modification	[970]
CUL4A	OTTBV70J	Strong	Biomarker	[971]
CXADR	OT9ZP02A	Strong	Biomarker	[261]
CXCL16	OTD49T9R	Strong	Biomarker	[216]
CYGB	OTX153DQ	Strong	Altered Expression	[972]
CYP2A7	OTRJ3P2Z	Strong	Genetic Variation	[973]
DAAM1	OT0VHIYZ	Strong	Altered Expression	[974]
DACT1	OT19Z704	Strong	Biomarker	[975]
DAPK2	OTWODUQG	Strong	Biomarker	[549]
DAXX	OTX6O7PL	Strong	Biomarker	[976]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[977]
DCTN4	OTM7C943	Strong	Genetic Variation	[570]
DCTN6	OTI8PIN9	Strong	Biomarker	[978]
DDA1	OTAZIAIH	Strong	Biomarker	[979]
DDB2	OTO8HVVB	Strong	Biomarker	[980]
DDX10	OTH48438	Strong	Altered Expression	[981]
DDX4	OTQOV093	Strong	Biomarker	[982]
DENR	OTXP9HOY	Strong	Biomarker	[549]
DESI2	OTHUOKOC	Strong	Therapeutic	[983]
DGCR8	OT62LXE4	Strong	Biomarker	[984]
DHDDS	OTVLYBUS	Strong	Biomarker	[939]
DHRS2	OTFHWIY8	Strong	Biomarker	[985]
DLC1	OTP8LMCR	Strong	Altered Expression	[986]
DLG2	OTQ3BD8U	Strong	Altered Expression	[987]
DLX1	OT7BH057	Strong	Biomarker	[988]
DMP1	OTBWBWW7	Strong	Altered Expression	[989]
DMRT1	OT5PU9U1	Strong	Biomarker	[554]
DNA2	OT4DJFFU	Strong	Genetic Variation	[990]
DNAH8	OTGES2OU	Strong	Altered Expression	[991]
DNAJC15	OTNDUKAA	Strong	Altered Expression	[992]
DNER	OT2GH2E5	Strong	Biomarker	[993]
DOCK1	OTCFV3ON	Strong	Altered Expression	[994]
DOCK4	OTH3XY8B	Strong	Genetic Variation	[995]
DOK1	OTGVRLW6	Strong	Therapeutic	[996]
DPEP2	OTIKZDTG	Strong	Altered Expression	[950]
DSC3	OTYG47F8	Strong	Altered Expression	[997]
DYNLT3	OT26QKCI	Strong	Biomarker	[998]
E2F6	OT2PN28R	Strong	Altered Expression	[999]
ECHDC1	OTMS00PY	Strong	Genetic Variation	[1000]
EFNA1	OTU2NUA2	Strong	Biomarker	[1001]
EHF	OTY6TPWD	Strong	Altered Expression	[1002]
EIF1	OTB4GZ0V	Strong	Biomarker	[571]
EIF3A	OTFABY9G	Strong	Biomarker	[1003]
EIF5	OT79PQUN	Strong	Biomarker	[333]
EIF5AL1	OTLA4ONW	Strong	Biomarker	[333]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[1004]
ELF3	OTUTLEQO	Strong	Biomarker	[1005]
ELF5	OTLRU8YF	Strong	Biomarker	[1006]
ELK1	OTH9MXD6	Strong	Altered Expression	[1007]
ELOB	OTZ3X84T	Strong	Altered Expression	[1008]
ELP1	OTYEWBF7	Strong	Posttranslational Modification	[970]
EMILIN1	OT94R6M1	Strong	Biomarker	[1009]
EN2	OT7EZCM2	Strong	Biomarker	[1010]
ENOSF1	OT65D3ZK	Strong	Genetic Variation	[1011]
EPSTI1	OT75I1UH	Strong	Biomarker	[1012]
ERAS	OT528IZO	Strong	Biomarker	[1013]
ERV3-1	OT4CW64T	Strong	Biomarker	[1014]
ESRP1	OTNCS4SL	Strong	Biomarker	[1015]
ESRP2	OTVTKJ4I	Strong	Altered Expression	[1015]
ETFA	OTXX61VZ	Strong	Genetic Variation	[1016]
ETV4	OT8C98UZ	Strong	Altered Expression	[1017]
ETV5	OTE2OBM4	Strong	Altered Expression	[1018]
FAIM2	OT6QINVO	Strong	Biomarker	[1019]
FAM168A	OTDXQCS5	Strong	Biomarker	[1020]
FAM210B	OT2QHEQ6	Strong	Biomarker	[1021]
FAM53B	OTVD7OU6	Strong	Biomarker	[1022]
FANCG	OT7MC8TZ	Strong	Genetic Variation	[1023]
FANCM	OTNJG99Z	Strong	Genetic Variation	[1024]
FBLN5	OTLVNZ8U	Strong	Biomarker	[1025]
FBP1	OTQBANEP	Strong	Altered Expression	[1026]
FCN2	OTTHJBKZ	Strong	Altered Expression	[745]
FERMT3	OTFQOT3C	Strong	Biomarker	[543]
FGF3	OT9PK2SI	Strong	Genetic Variation	[1027]
FGF9	OT2SKDGM	Strong	Biomarker	[1028]
FGFBP2	OT3NBPQO	Strong	Biomarker	[1029]
FGFRL1	OT8HZ3ZL	Strong	Altered Expression	[1030]
FHL2	OT0OAYWT	Strong	Biomarker	[1031]
FHL5	OT6C00Z1	Strong	Genetic Variation	[215]
FILIP1L	OTPY8IMS	Strong	Biomarker	[1032]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[1033]
FNDC3A	OTUX3S2I	Strong	Biomarker	[1034]
FOXA2	OTJOCVOY	Strong	Biomarker	[1035]
FOXK1	OTLZGS7J	Strong	Biomarker	[1036]
FOXL2	OTFRQUYL	Strong	Genetic Variation	[1037]
FRS2	OTDMD800	Strong	Biomarker	[1038]
FSD1	OT8P6PT3	Strong	Altered Expression	[1039]
FSD1L	OTBQ48RF	Strong	Altered Expression	[1039]
FSTL1	OT6KEZUD	Strong	Genetic Variation	[905]
FUT1	OTODG57A	Strong	Altered Expression	[1040]
FXYD5	OT81DIOD	Strong	Biomarker	[1041]
GAB1	OTQKE6V4	Strong	Biomarker	[1042]
GAB2	OTBFN705	Strong	Biomarker	[665]
GADD45A	OTDRV63V	Strong	Genetic Variation	[1043]
GALNT14	OT9BSDDQ	Strong	Biomarker	[1044]
GALNT6	OTOQQVH1	Strong	Altered Expression	[1045]
GATA6	OTO2BC0F	Strong	Genetic Variation	[1046]
GCNT3	OTQ9ALTR	Strong	Biomarker	[1047]
GDE1	OTU6FSBF	Strong	Biomarker	[1048]
GEN1	OT1XFQXF	Strong	Altered Expression	[1049]
GGNBP2	OT7K9YZV	Strong	Biomarker	[1050]
GHRH	OT94U6MO	Strong	Biomarker	[1051]
GINS2	OT974IYI	Strong	Altered Expression	[1052]
GIPC1	OTXLVCPJ	Strong	Biomarker	[1053]
GNA12	OT3IRZH3	Strong	Altered Expression	[211]
GOLGA6A	OTHU9MRX	Strong	Biomarker	[701]
GOLPH3	OTDLGYM3	Strong	Biomarker	[1054]
GOLPH3L	OTT2K3LQ	Strong	Biomarker	[1055]
GPR42	OTEB0ROY	Strong	Biomarker	[128]
GRB7	OTF8Y9XY	Strong	Altered Expression	[1056]
GREB1	OTU6ZA26	Strong	Biomarker	[1057]
GRP	OT8JDFNI	Strong	Biomarker	[1058]
GTF2H1	OTCRXC6B	Strong	Genetic Variation	[570]
GTF2H5	OTRL219S	Strong	Biomarker	[1059]
GULP1	OT1WMVDH	Strong	Genetic Variation	[1060]
H2AC11	OTN9P0BO	Strong	Biomarker	[1034]
H2AX	OT18UX57	Strong	Genetic Variation	[1034]
H2BC12	OTQ8V0KG	Strong	Genetic Variation	[1034]
H2BC21	OT0FDCUC	Strong	Genetic Variation	[1034]
H3C1	OTGBGOZW	Strong	Biomarker	[1034]
H4C1	OTB71W46	Strong	Biomarker	[1034]
HAPLN1	OTXWR9TJ	Strong	Biomarker	[1061]
HARS1	OTHOEOTS	Strong	Biomarker	[933]
HAUS6	OT7ZVR57	Strong	Biomarker	[938]
HCFC1R1	OTGDPS5C	Strong	Biomarker	[1062]
HEATR6	OTD3MYS0	Strong	Biomarker	[476]
HECTD3	OTTGP4OK	Strong	Altered Expression	[1063]
HELQ	OTL1STJT	Strong	Biomarker	[1064]
HIF3A	OTPWAAMC	Strong	Altered Expression	[1065]
HLA-DRB3	OT5PM9N7	Strong	Genetic Variation	[1066]
HLA-E	OTX1CTFB	Strong	Biomarker	[1067]
HM13	OTGEO1LP	Strong	Biomarker	[1068]
HMBOX1	OTPKTBVI	Strong	Altered Expression	[1069]
HMCN1	OTLZAS0P	Strong	Biomarker	[1070]
HMGB3	OTCJ2EZY	Strong	Biomarker	[1071]
HMMR	OT4M0JTZ	Strong	Biomarker	[1072]
HOXA1	OTMSOJ7D	Strong	Biomarker	[1073]
HOXB3	OT9UC5PE	Strong	Altered Expression	[1074]
HOXB9	OTMVHQOU	Strong	Biomarker	[1075]
HOXD1	OTN4V9ZF	Strong	Genetic Variation	[1076]
HOXD3	OTBUZ35T	Strong	Genetic Variation	[1076]
HPR	OTXSC9UB	Strong	Altered Expression	[1077]
HSDL2	OT4IN0MV	Strong	Altered Expression	[1078]
HSPA14	OTZCA5LK	Strong	Biomarker	[1079]
HSPA1A	OTKGIE76	Strong	Biomarker	[1080]
HSPA2	OTSDET7B	Strong	Biomarker	[1081]
HTRA3	OTXJ0H4X	Strong	Altered Expression	[1082]
HUWE1	OTFH6BJS	Strong	Biomarker	[1083]
ICMT	OT8CNKBO	Strong	Altered Expression	[1084]
ID4	OTPMJ39I	Strong	Biomarker	[1085]
IFI27	OTI2XGIT	Strong	Biomarker	[978]
IFT80	OTMH0MBI	Strong	Altered Expression	[234]
IGF2BP1	OT9G360P	Strong	Biomarker	[1068]
IKBKE	OT5VYOSM	Strong	Altered Expression	[391]
IL17RB	OT0KDNSF	Strong	Biomarker	[245]
IL6ST	OT1N9C70	Strong	Biomarker	[761]
ILF3	OTKMZ5K5	Strong	Altered Expression	[323]
IMMP1L	OTA6LOLR	Strong	Biomarker	[1068]
IMPA1	OTBUVW1Z	Strong	Biomarker	[1086]
INCENP	OT9HFRYK	Strong	Genetic Variation	[431]
ING1	OTEZBRKW	Strong	Altered Expression	[1087]
ING4	OT0VVG4V	Strong	Biomarker	[405]
ING5	OTRNNSFM	Strong	Altered Expression	[1088]
INHA	OT7HWCO3	Strong	Biomarker	[1089]
INPP4B	OTLROA7G	Strong	Genetic Variation	[1090]
IP6K2	OTCUMUUP	Strong	Altered Expression	[1091]
IQGAP2	OTX2UA7P	Strong	Biomarker	[1092]
ISG20	OTCWRJJW	Strong	Biomarker	[162]
ITGB4	OT28UK84	Strong	Biomarker	[411]
ITGBL1	OTJDHE17	Strong	Altered Expression	[1093]
ITM2A	OT590V63	Strong	Biomarker	[1094]
JAG1	OT3LGT6K	Strong	Biomarker	[1095]
JARID2	OT14UM8H	Strong	Biomarker	[1096]
JMJD6	OTILR7E4	Strong	Altered Expression	[1097]
JRK	OTO8E77P	Strong	Altered Expression	[1098]
KANSL1	OTYNSNNZ	Strong	Biomarker	[938]
KAT2A	OTN0W2SW	Strong	Altered Expression	[1099]
KAT7	OTUN98IC	Strong	Altered Expression	[1100]
KAT8	OT5LPQTR	Strong	Altered Expression	[1101]
KATNA1	OTISKGMK	Strong	Biomarker	[1102]
KCNIP3	OTCQPEM4	Strong	Biomarker	[1103]
KDM2B	OTDMCVW7	Strong	Biomarker	[1104]
KDM4B	OT5P1UPY	Strong	Biomarker	[1105]
KIF14	OTXHT4JM	Strong	Biomarker	[1102]
KIF23	OTY850JC	Strong	Altered Expression	[1106]
KIF2A	OT2WQ6QD	Strong	Biomarker	[1107]
KIFC1	OTNQDS00	Strong	Biomarker	[1108]
KLF2	OTIP1UFX	Strong	Biomarker	[1109]
KLF6	OTQY9S7F	Strong	Altered Expression	[1110]
KLF9	OTBFEJRQ	Strong	Biomarker	[1111]
KLHL1	OTAX6SAD	Strong	Altered Expression	[212]
KLK11	OT5PKX7Y	Strong	Altered Expression	[1112]
KLK13	OT8LOD2U	Strong	Altered Expression	[423]
KLK15	OT7BVG17	Strong	Genetic Variation	[1113]
KLK9	OTGJWBIF	Strong	Altered Expression	[1114]
KRIT1	OT58AP1I	Strong	Biomarker	[911]
KRT5	OTVGI9HT	Strong	Altered Expression	[1115]
KRT6C	OT9RXMPK	Strong	Altered Expression	[1115]
KRT9	OTA10UCH	Strong	Genetic Variation	[1116]
LAMA3	OTFME7HT	Strong	Biomarker	[1117]
LAMP3	OTN0XL3W	Strong	Altered Expression	[1118]
LARP4	OTB10IJH	Strong	Biomarker	[1119]
LCP1	OTK61F2A	Strong	Biomarker	[1120]
LGALS8	OT71LJ8T	Strong	Biomarker	[363]
LGR6	OTPZ1PWR	Strong	Biomarker	[1121]
LIMD2	OTSIFTD8	Strong	Altered Expression	[1122]
LIN28B	OTVWP0FN	Strong	Biomarker	[1123]
LIN7A	OTFL3PUX	Strong	Altered Expression	[1124]
LMX1A	OTEEYD5L	Strong	Biomarker	[1125]
LPP	OT6TU8SE	Strong	Biomarker	[1126]
LRP1B	OT4YZG2N	Strong	Genetic Variation	[1127]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[1128]
LRRC46	OTXU2A9W	Strong	Biomarker	[938]
LSR	OTR8Y32X	Strong	Biomarker	[1129]
LTBP1	OTR7Q75L	Strong	Biomarker	[1130]
LUM	OTSRC874	Strong	Biomarker	[1131]
LYPD4	OTYNO8BS	Strong	Biomarker	[1132]
MACC1	OTV3DLX0	Strong	Biomarker	[1133]
MAGED4B	OTO37U7W	Strong	Altered Expression	[242]
MAGI2	OTXDDKZS	Strong	Biomarker	[1134]
MAK16	OTD546E5	Strong	Altered Expression	[506]
MAN1A1	OT6LIGJP	Strong	Biomarker	[1135]
MAP1LC3B	OTUYHB84	Strong	Biomarker	[1136]
MAP2K6	OTK13JKC	Strong	Biomarker	[1137]
MARCHF5	OTBK6BBM	Strong	Biomarker	[1138]
MARCHF7	OTG9SF10	Strong	Biomarker	[1139]
MBD2	OTUQPP0R	Strong	Biomarker	[416]
MCAT	OTH07FIW	Strong	Altered Expression	[302]
MCM3	OTOOHQPM	Strong	Biomarker	[1052]
MCPH1	OTYT3TT5	Strong	Biomarker	[1140]
MCTS1	OT7SAOJP	Strong	Altered Expression	[302]
MDC1	OTEUQH4J	Strong	Biomarker	[1141]
MED13	OTP5LEJE	Strong	Genetic Variation	[754]
MEF2A	OTV2SF6E	Strong	Altered Expression	[391]
MEF2D	OT7CEIG0	Strong	Biomarker	[391]
MEGF8	OT5G38CH	Strong	Biomarker	[1142]
MEOX1	OTJEMT2D	Strong	Biomarker	[1143]
METTL3	OTSXP1M3	Strong	Biomarker	[1144]
MGAT3	OTXI5X4T	Strong	Biomarker	[1145]
MIB1	OT5C404P	Strong	Altered Expression	[151]
MICALL2	OT1IQM3K	Strong	Biomarker	[1146]
MICU1	OTS7N0LE	Strong	Biomarker	[1147]
MINDY4	OTBZ2SZB	Strong	Biomarker	[880]
MLH1	OTG5XDD8	Strong	Autosomal dominant	[463]
MLIP	OTMT7AII	Strong	Biomarker	[847]
MLLT11	OTG5RVHC	Strong	Altered Expression	[1148]
MMP19	OTLSTT2B	Strong	Altered Expression	[1149]
MOAP1	OTVF3LUG	Strong	Biomarker	[1150]
MPP2	OTPH8CZY	Strong	Altered Expression	[987]
MPZL1	OTJSUUHR	Strong	Altered Expression	[1151]
MRE11	OTGU8TZM	Strong	Altered Expression	[1152]
MSC	OTBRPZL5	Strong	Biomarker	[441]
MSH2	OT10H1AB	Strong	Autosomal dominant	[463]
MSH3	OTD3YPVL	Strong	Altered Expression	[390]
MSH6	OT46FP09	Strong	Autosomal dominant	[463]
MSN	OTZJ4J6G	Strong	Biomarker	[429]
MSX1	OT5U41ZP	Strong	Altered Expression	[1153]
MTBP	OTWLCW9C	Strong	Altered Expression	[1154]
MUC13	OTWKS9MF	Strong	Posttranslational Modification	[1155]
MUC3A	OTI4XUDY	Strong	Biomarker	[470]
MUC4	OTLT11V1	Strong	Altered Expression	[1156]
MUL1	OT2JC9YR	Strong	Biomarker	[245]
MUS81	OTVZ4E60	Strong	Altered Expression	[1157]
MYBL2	OTZ3JX8Q	Strong	Altered Expression	[1103]
MYCL	OT1MFQ5U	Strong	Altered Expression	[1158]
MYH6	OT3YNCH1	Strong	Biomarker	[1159]
MYLK3	OTC58V2Q	Strong	Biomarker	[1160]
MYO18B	OTGYY4NK	Strong	Altered Expression	[1161]
MYO6	OTJQYRC7	Strong	Biomarker	[1159]
MYOD1	OTV2S79X	Strong	Genetic Variation	[1162]
MYPN	OTHTOFDU	Strong	Biomarker	[1163]
N4BP1	OTN2TL6N	Strong	Biomarker	[1164]
NAALADL2	OT2HOGPQ	Strong	Genetic Variation	[973]
NANOG	OTUEY1FM	Strong	Biomarker	[1165]
NAPSA	OT6F8IAL	Strong	Biomarker	[1166]
NBR1	OTVRL7J9	Strong	Biomarker	[1167]
NCALD	OTJZ8UEL	Strong	Altered Expression	[1168]
NCK2	OTUYPF55	Strong	Biomarker	[411]
NDC80	OTS7D306	Strong	Altered Expression	[1169]
NDN	OTYBYJ82	Strong	Biomarker	[1170]
NECTIN2	OTIE0W6O	Strong	Biomarker	[1171]
NECTIN3	OTS8N7MK	Strong	Biomarker	[1172]
NEU3	OTQ5PQOW	Strong	Altered Expression	[1173]
NFATC1	OT4TMERS	Strong	Biomarker	[1174]
NFE2	OTLM94BI	Strong	Biomarker	[1175]
NIBAN1	OTYOLI12	Strong	Biomarker	[308]
NID1	OTKLBLS6	Strong	Biomarker	[1176]
NID2	OTHC33FF	Strong	Biomarker	[1177]
NKX2-1	OTCMEJTA	Strong	Biomarker	[1178]
NME2	OTCYGLHV	Strong	Therapeutic	[235]
NME3	OT0CA0GF	Strong	Altered Expression	[1179]
NR2F6	OTNVO2B6	Strong	Biomarker	[979]
NR5A1	OTOULYR4	Strong	Altered Expression	[1180]
NRSN2	OT4OS3M2	Strong	Biomarker	[1181]
NSD2	OTQ6SW4R	Strong	Altered Expression	[1182]
NSUN2	OTZCNM33	Strong	Biomarker	[144]
NSUN4	OTY6O37Z	Strong	Genetic Variation	[431]
NTS	OTPGDNQS	Strong	Altered Expression	[488]
NUCKS1	OTL4VJC5	Strong	Altered Expression	[1183]
NUDT1	OTZSES3W	Strong	Biomarker	[307]
NUP107	OTG4RDYS	Strong	Genetic Variation	[1184]
NUP62	OTMN63DH	Strong	Genetic Variation	[570]
NXF3	OTI0RW72	Strong	Biomarker	[1185]
OGA	OT7ZBWT1	Strong	Biomarker	[1186]
OPCML	OT93PQ6Y	Strong	Posttranslational Modification	[1187]
OPN5	OTCYGHDA	Strong	Genetic Variation	[1188]
OTUB1	OT8WWM9O	Strong	Biomarker	[1189]
OVGP1	OTL2W9M5	Strong	Biomarker	[943]
PAEP	OTQA0NV4	Strong	Biomarker	[1190]
PAF1	OTDDGUBQ	Strong	Biomarker	[1191]
PAK3	OT80M3BV	Strong	Biomarker	[1192]
PAK5	OT32WQGL	Strong	Altered Expression	[1193]
PALM2AKAP2	OTI618VF	Strong	Altered Expression	[1194]
PAPPA	OTTTG9PG	Strong	Biomarker	[1195]
PARD3	OTH5BPLO	Strong	Altered Expression	[345]
PAX1	OT0Y3MIM	Strong	Biomarker	[1196]
PAX2	OTKP1N8F	Strong	Biomarker	[1197]
PBOV1	OT67PERT	Strong	Biomarker	[1198]
PBX1	OTORABGO	Strong	Biomarker	[1199]
PBXIP1	OTEAAUBY	Strong	Biomarker	[1062]
PCDH17	OTRK0M05	Strong	Posttranslational Modification	[1200]
PCDH8	OTDDOQM2	Strong	Altered Expression	[1201]
PCDH9	OTX3BFV4	Strong	Biomarker	[1202]
PCLAF	OTMVIOUU	Strong	Altered Expression	[1203]
PCM1	OTFM133C	Strong	Genetic Variation	[1204]
PCNT	OTW4Z65J	Strong	Biomarker	[1205]
PDIA3	OTHPQ0Q3	Strong	Biomarker	[1206]
PDIA4	OTVFUJ13	Strong	Biomarker	[1207]
PDK4	OTCMHMBZ	Strong	Biomarker	[1208]
PDLIM2	OTEURRPD	Strong	Biomarker	[1122]
PDLIM4	OT23LZYY	Strong	Altered Expression	[1209]
PDLIM5	OTLQVV22	Strong	Altered Expression	[1210]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[1211]
PEG3	OTHQW98S	Strong	Altered Expression	[1212]
PELP1	OTVXQNOT	Strong	Biomarker	[1213]
PHB2	OTCAX3AW	Strong	Altered Expression	[552]
PHF19	OTF6RUCR	Strong	Altered Expression	[1214]
PHLDA1	OTFTWMIQ	Strong	Biomarker	[1215]
PI3	OT47MTC3	Strong	Altered Expression	[1216]
PIK3R1	OT5BZ1J9	Strong	Genetic Variation	[1217]
PIK3R4	OTRL8QP8	Strong	Posttranslational Modification	[970]
PITX2	OTWMXAOY	Strong	Biomarker	[1218]
PKP3	OTPL1HRB	Strong	Biomarker	[1219]
PLAA	OTZ7NJGA	Strong	Biomarker	[869]
PLAAT3	OTVXXJ5K	Strong	Biomarker	[1220]
PLAG1	OTT9AJQY	Strong	Genetic Variation	[424]
PLAGL1	OTZAO900	Strong	Altered Expression	[1221]
PLAGL2	OT6AP4V2	Strong	Biomarker	[929]
PLEC	OTU4XDEG	Strong	Biomarker	[1205]
PLEKHF1	OT9OL16U	Strong	Biomarker	[906]
PLXNB2	OT56I2VD	Strong	Biomarker	[1222]
PMAIP1	OTXEE550	Strong	Biomarker	[446]
PMEPA1	OTY8Z9UF	Strong	Altered Expression	[1223]
PNO1	OT010GIS	Strong	Altered Expression	[506]
PNPLA2	OTR3ERMR	Strong	Biomarker	[1224]
POLD2	OTBNASP6	Strong	Biomarker	[1029]
POLE	OTFM3MMU	Strong	Genetic Variation	[872]
POLR2A	OTHJQ1DZ	Strong	Biomarker	[1225]
POP4	OTN0XJZJ	Strong	Biomarker	[906]
POTED	OTAUSTUK	Strong	Biomarker	[1226]
POTEM	OT7L2HGH	Strong	Genetic Variation	[215]
POU4F3	OTILD0XS	Strong	Altered Expression	[1134]
PPA1	OTHZK1QB	Strong	Altered Expression	[1227]
PPP1CC	OTRZO26U	Strong	Biomarker	[906]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[1228]
PPP2R2A	OT9297OG	Strong	Biomarker	[1229]
PPP2R2C	OTXK0SDM	Strong	Biomarker	[1230]
PPRC1	OT6GB3WR	Strong	Biomarker	[1231]
PRB2	OTAD4JZ0	Strong	Altered Expression	[1232]
PRC1	OTHD0XS0	Strong	Biomarker	[938]
PRDX1	OTZ3BEC4	Strong	Altered Expression	[1233]
PRKAA1	OT7TNF0L	Strong	Biomarker	[1234]
PRKAA2	OTU1KZPV	Strong	Biomarker	[1234]
PRKAB1	OT1OG4QZ	Strong	Biomarker	[1234]
PRKRA	OTUTVZZU	Strong	Biomarker	[1235]
PROS1	OTXQWNOI	Strong	Genetic Variation	[424]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[1236]
PRR11	OT2JJ08Z	Strong	Altered Expression	[1237]
PRSS21	OT8ZYC7G	Strong	Biomarker	[1238]
PRSS3	OTN3S5YB	Strong	Altered Expression	[1239]
PSG5	OTHTU98X	Strong	Genetic Variation	[973]
PSMB4	OTOJ9OHA	Strong	Altered Expression	[1240]
PSMD9	OT6Y5CC3	Strong	Biomarker	[978]
PTCH1	OTMG07H5	Strong	Altered Expression	[1241]
PTPRU	OTHDO0QG	Strong	Biomarker	[683]
PTTG1	OTIMYS4W	Strong	Biomarker	[1242]
PUM1	OTTMWP8L	Strong	Biomarker	[1243]
PXDN	OTFGGM9R	Strong	Altered Expression	[1244]
PYCARD	OT67RON3	Strong	Biomarker	[1245]
RAB23	OTBAKFBR	Strong	Altered Expression	[1246]
RAB3GAP2	OTQTE0GI	Strong	Posttranslational Modification	[970]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[995]
RAD21	OTQS84ZF	Strong	Genetic Variation	[1247]
RAD50	OTYMU9G1	Strong	Biomarker	[1248]
RAD51B	OTCJVRMY	Strong	Biomarker	[1064]
RAP1A	OT5RH6TI	Strong	Biomarker	[995]
RAP1B	OTHEIIMM	Strong	Altered Expression	[1249]
RAPGEF1	OTZ0TBN1	Strong	Posttranslational Modification	[1250]
RASSF7	OT0V4EIZ	Strong	Genetic Variation	[1251]
RB1CC1	OTZK8PFX	Strong	Biomarker	[1252]
RBBP6	OTTVG4HU	Strong	Biomarker	[1235]
RBFOX2	OTXY1WVH	Strong	Biomarker	[1253]
RBL2	OTBQSOE6	Strong	Biomarker	[768]
RBM3	OTAJ7R31	Strong	Altered Expression	[1254]
RBMS3	OTFSC9MR	Strong	Altered Expression	[506]
RBP1	OTRP1MFC	Strong	Altered Expression	[1255]
RCBTB1	OTAYELI8	Strong	Biomarker	[701]
RCC2	OTUJVTLS	Strong	Biomarker	[1256]
RCCD1	OT60N06L	Strong	Genetic Variation	[431]
RECQL	OTPCH3JH	Strong	Genetic Variation	[1024]
REST	OTLL92LQ	Strong	Biomarker	[1257]
RGS10	OTQ8N1QH	Strong	Altered Expression	[1258]
RGS5	OTUY0Q2I	Strong	Altered Expression	[1259]
RHOC	OTOLE1FT	Strong	Biomarker	[1260]
RIF1	OTPE49OE	Strong	Altered Expression	[1261]
RMI1	OT1ZVTFL	Strong	Biomarker	[1262]
RNASE3	OTVE2XD1	Strong	Altered Expression	[1263]
RNASET2	OTWY64L7	Strong	Biomarker	[1264]
RNF146	OTE4CO7E	Strong	Biomarker	[1000]
RNF2	OTFPLOIN	Strong	Altered Expression	[1265]
RNF20	OT9NK6ZT	Strong	Biomarker	[1266]
RNF8	OTRR43PZ	Strong	Altered Expression	[1267]
ROBO3	OTPVG40S	Strong	Altered Expression	[320]
RPH3AL	OT9VFJEL	Strong	Biomarker	[1268]
RPL22L1	OTNWGF5C	Strong	Altered Expression	[1269]
RPL23A	OTPYLCCX	Strong	Biomarker	[955]
RPL39L	OTAV1MJQ	Strong	Biomarker	[1270]
RSAD2	OTCA9WCM	Strong	Altered Expression	[1271]
RTKN2	OTV2AXQM	Strong	Altered Expression	[1272]
RUNX1T1	OT30DED5	Strong	Altered Expression	[1273]
RUVBL1	OTWV19L7	Strong	Genetic Variation	[1274]
RYK	OTZ3WWZH	Strong	Altered Expression	[1275]
S100A1	OT1F2G4J	Strong	Biomarker	[1276]
S100A10	OTI71243	Strong	Biomarker	[1277]
S100A11	OTI57KDN	Strong	Altered Expression	[1278]
S100A7	OTJFVJRF	Strong	Biomarker	[1279]
SAA4	OTCE1WXO	Strong	Altered Expression	[538]
SALL2	OTQWI68Q	Strong	Biomarker	[1280]
SALL4	OTC08PR5	Strong	Altered Expression	[1281]
SCAF1	OT16TM3N	Strong	Altered Expression	[1282]
SCAI	OTAK3TMO	Strong	Biomarker	[1283]
SCGB2A1	OT9L87U9	Strong	Biomarker	[1284]
SCO2	OTJQQDRS	Strong	Altered Expression	[611]
SELENBP1	OT3NZNTR	Strong	Biomarker	[1285]
SEMG1	OT6Z4BPQ	Strong	Posttranslational Modification	[1286]
SERBP1	OTZVSU0X	Strong	Biomarker	[1287]
SERPINA3	OT9BP2S0	Strong	Genetic Variation	[215]
SERPINA5	OTTZXPGD	Strong	Biomarker	[1288]
SERPINB2	OT72QLZB	Strong	Biomarker	[1289]
SERTAD1	OTBHKZQP	Strong	Altered Expression	[1290]
SESN2	OT889IXY	Strong	Genetic Variation	[1291]
SETDB1	OTWVUA1B	Strong	Altered Expression	[1292]
SFRP1	OT0U9G41	Strong	Altered Expression	[1293]
SFRP5	OTLCVVSH	Strong	Biomarker	[1294]
SHARPIN	OTU1J2KH	Strong	Altered Expression	[1295]
SHBG	OTPWU5IW	Strong	Biomarker	[1296]
SIM2	OT0QWHK4	Strong	Altered Expression	[1297]
SIX1	OT70YYWM	Strong	Biomarker	[596]
SKAP1	OTD4ZKAL	Strong	Genetic Variation	[586]
SLIT3	OTU8MKEU	Strong	Biomarker	[1298]
SMURF1	OT5UIZR8	Strong	Biomarker	[1299]
SNAI1	OTDPYAMC	Strong	Altered Expression	[1300]
SNAI2	OT7Y8EJ2	Strong	Altered Expression	[1300]
SNAP23	OTY2MYBX	Strong	Altered Expression	[1301]
SNAP29	OTT30ZON	Strong	Biomarker	[1302]
SORBS2	OTJSX44Y	Strong	Biomarker	[1303]
SOX11	OT4LG7LA	Strong	Altered Expression	[1304]
SOX18	OTPUMHWA	Strong	Altered Expression	[1305]
SOX3	OT1CRCOB	Strong	Biomarker	[1306]
SOX6	OTT0W0LE	Strong	Biomarker	[486]
SPA17	OT8J7T7U	Strong	Biomarker	[916]
SPAG7	OTSDFA2D	Strong	Biomarker	[966]
SPAG9	OT45AHMB	Strong	Biomarker	[1307]
SPATA2	OTOA45GL	Strong	Altered Expression	[1308]
SPDYA	OTYKC1AJ	Strong	Altered Expression	[1309]
SPECC1	OTPEML48	Strong	Biomarker	[1248]
SPG7	OT8OY9ST	Strong	Biomarker	[261]
SPINK13	OTEU2OSU	Strong	Altered Expression	[1310]
SPINT1	OT1CLR5L	Strong	Biomarker	[572]
SPOCK2	OTXSVTSA	Strong	Biomarker	[1311]
SPOP	OTP0107S	Strong	Biomarker	[1312]
SPRY4	OT2VK9N0	Strong	Altered Expression	[1313]
SPSB1	OTGY26U4	Strong	Biomarker	[1314]
SRPX	OT5B9LXS	Strong	Biomarker	[1070]
SRRM2	OTSIMMC9	Strong	Altered Expression	[506]
SRSF3	OTOFT707	Strong	Biomarker	[1315]
SSH3	OT83V0ZK	Strong	Genetic Variation	[1316]
ST3GAL1	OTFCO8QX	Strong	Biomarker	[1317]
ST6GAL1	OT7US3NO	Strong	Biomarker	[1318]
ST6GALNAC1	OT3JQD99	Strong	Biomarker	[1319]
STAG1	OT564IX4	Strong	Altered Expression	[1223]
STAG3	OTEV0AOD	Strong	Genetic Variation	[1320]
STIL	OT9799VN	Strong	Biomarker	[1321]
STING1	OTDAP4G0	Strong	Biomarker	[1322]
STIP1	OT7TXLOX	Strong	Biomarker	[1323]
STK11	OT1YZSP3	Strong	Biomarker	[1324]
STOML3	OTLQGALK	Strong	Biomarker	[1325]
STUB1	OTSUYI9A	Strong	Biomarker	[1326]
SULF1	OTJCNCO0	Strong	Biomarker	[1136]
SUSD2	OTSJTAZP	Strong	Biomarker	[1327]
SWAP70	OTPHT2QD	Strong	Genetic Variation	[1328]
SWSAP1	OTYI33WH	Strong	Genetic Variation	[1329]
SYCE1L	OTXU44F3	Strong	Altered Expression	[212]
SYCP2	OTBH622S	Strong	Biomarker	[1330]
SYTL2	OTUIOWKL	Strong	Biomarker	[576]
TAB1	OTPM6F85	Strong	Altered Expression	[1007]
TAB3	OT1ECMDL	Strong	Altered Expression	[1331]
TBC1D8	OT2011SS	Strong	Biomarker	[1332]
TBX15	OTAZ9QDX	Strong	Biomarker	[870]
TCEAL7	OTNPDZCN	Strong	Altered Expression	[1333]
TCF12	OTZVONNU	Strong	Biomarker	[1334]
TCF21	OT393IMA	Strong	Biomarker	[1335]
TCHP	OTVDMHSY	Strong	Altered Expression	[266]
TCTN2	OTKR3I3L	Strong	Altered Expression	[1336]
TEAD1	OTK6971C	Strong	Biomarker	[1337]
TENM2	OTPLUYEF	Strong	Altered Expression	[1338]
TENM4	OT91K3FC	Strong	Altered Expression	[1338]
TERF2IP	OT3M5P3G	Strong	Biomarker	[995]
TET1	OTZDHT1D	Strong	Biomarker	[1339]
TET3	OT76U3YF	Strong	Altered Expression	[1340]
TEX11	OTJDBGSS	Strong	Biomarker	[690]
TEX19	OTY6MIZ9	Strong	Altered Expression	[1341]
TFAM	OTXXV5V7	Strong	Altered Expression	[552]
TFPI2	OTZCRWOR	Strong	Biomarker	[1337]
TGFBI	OTR443C5	Strong	Altered Expression	[1342]
TGIF2	OTMKKE3W	Strong	Biomarker	[1343]
THEMIS2	OTI1OBLN	Strong	Genetic Variation	[1344]
THY1	OTVONVTB	Strong	Biomarker	[1345]
TICAM2	OTK7GIJ5	Strong	Biomarker	[978]
TIMELESS	OTD8DCBJ	Strong	Altered Expression	[883]
TIMM8A	OTDX9687	Strong	Biomarker	[475]
TLE3	OTR9PH95	Strong	Biomarker	[1346]
TM4SF1	OTY0ECQN	Strong	Biomarker	[1347]
TMED2	OTBLO7RW	Strong	Biomarker	[1348]
TMED7	OTONO8E6	Strong	Biomarker	[978]
TMEM14A	OTANQA6G	Strong	Altered Expression	[1349]
TMEM158	OT0KUBBI	Strong	Altered Expression	[1350]
TMEM45A	OT54KJG6	Strong	Altered Expression	[1351]
TMEM88	OTA96YEL	Strong	Altered Expression	[1316]
TMPRSS3	OT0GTO1Z	Strong	Altered Expression	[1352]
TMSB10	OTLVZ13T	Strong	Altered Expression	[1353]
TNFAIP8	OT1G9297	Strong	Altered Expression	[1354]
TNFRSF10C	OTVHOL9B	Strong	Posttranslational Modification	[1355]
TNXB	OTVBWAV5	Strong	Biomarker	[1356]
TOMM34	OTH6MITE	Strong	Altered Expression	[1357]
TOR2A	OT1EGCDU	Strong	Biomarker	[1358]
TPM4	OTN4YLYR	Strong	Biomarker	[1359]
TRAF2	OT1MEZZN	Strong	Biomarker	[614]
TRIAP1	OTEAUJXN	Strong	Biomarker	[705]
TRIM13	OTQIUACB	Strong	Biomarker	[261]
TRIM16	OTLRXYOZ	Strong	Biomarker	[1360]
TRIM44	OT0B1T2B	Strong	Biomarker	[1361]
TRIM50	OTXA2IXF	Strong	Biomarker	[1362]
TRIM52	OTKTKCT1	Strong	Biomarker	[480]
TRIM56	OTFGU8E3	Strong	Altered Expression	[1363]
TRMT9B	OTU3UPEE	Strong	Biomarker	[1364]
TRRAP	OT68OI2Y	Strong	Biomarker	[1365]
TSGA10	OTIF1O1T	Strong	Altered Expression	[1366]
TSPAN12	OTF9I3CX	Strong	Biomarker	[1367]
TSPYL5	OT7QEI2X	Strong	Biomarker	[1368]
ARID1A	OTRWDV3P	Definitive	Altered Expression	[1369]
ATG9A	OTAZWZH7	Definitive	Altered Expression	[656]
B4GALNT3	OT6BFB22	Definitive	Altered Expression	[1370]
B4GALNT4	OTKSQD3S	Definitive	Altered Expression	[1370]
BHLHE22	OTZUQY5L	Definitive	Altered Expression	[1371]
CAPG	OTJ86KI6	Definitive	Biomarker	[1372]
CATSPERZ	OTQVGMG4	Definitive	Genetic Variation	[1373]
CDKN2D	OT2TTZPZ	Definitive	Biomarker	[1374]
CHST11	OTNJJ5Q1	Definitive	Biomarker	[296]
CKAP4	OTDUC9ME	Definitive	Altered Expression	[1375]
CNN1	OTVPG39Z	Definitive	Biomarker	[1376]
COX2	OTTMVBJJ	Definitive	Biomarker	[1377]
CTAG1B	OTIQGW6U	Definitive	Biomarker	[1378]
CYLD	OT37FKH0	Definitive	Biomarker	[1379]
DIRAS3	OT3XHLQA	Definitive	Altered Expression	[1380]
DLX4	OTLWVCN4	Definitive	Altered Expression	[1381]
EEF1A2	OT9Z23K5	Definitive	Biomarker	[1382]
EIF6	OTEXMUED	Definitive	Biomarker	[1003]
ELMO1	OTY2ORXK	Definitive	Biomarker	[994]
ERVW-1	OTWV8DXJ	Definitive	Altered Expression	[1383]
FBLN1	OT5MHHOP	Definitive	Altered Expression	[1384]
FEN1	OT6QGG7O	Definitive	Biomarker	[1385]
FMR1	OTWEV0T5	Definitive	Biomarker	[1386]
FOXO3	OTHXQG4P	Definitive	Altered Expression	[243]
GBGT1	OTRB3JK7	Definitive	Posttranslational Modification	[1387]
GSTM2	OTG4WT05	Definitive	Genetic Variation	[1388]
HIC1	OTI9TWY4	Definitive	Biomarker	[1389]
HOXA10	OTB6GQ09	Definitive	Biomarker	[663]
HOXA9	OTKNK5H0	Definitive	Biomarker	[1390]
HOXC6	OTBCRAZV	Definitive	Altered Expression	[1391]
HOXD9	OTZ4GVR1	Definitive	Biomarker	[1392]
IFITM1	OTECO1G8	Definitive	Biomarker	[1393]
IGF2BP2	OT4ZSEEE	Definitive	Biomarker	[1068]
IGF2BP3	OTB97VIK	Definitive	Biomarker	[1123]
IMMP2L	OT9WGAFD	Definitive	Biomarker	[1068]
KRT10	OTSVRD3Q	Definitive	Altered Expression	[1394]
MAP2K4	OTZPZX11	Definitive	Altered Expression	[1395]
MSH5	OTDARQT3	Definitive	Genetic Variation	[1396]
NEFH	OTMSCW5I	Definitive	Genetic Variation	[1397]
NEK11	OTMYENTC	Definitive	Biomarker	[1398]
NMBR	OTBJEGPN	Definitive	Biomarker	[647]
NUDCD1	OT8DS3CX	Definitive	Biomarker	[1399]
PDCD4	OTZ6NXUX	Definitive	Biomarker	[1400]
PGK1	OT6V1ICH	Definitive	Altered Expression	[1401]
PIAS2	OTJLSC3V	Definitive	Biomarker	[1402]
PPP2R1A	OTYA3GB4	Definitive	Genetic Variation	[1403]
PTPA	OTRGFOI7	Definitive	Biomarker	[1404]
RAB25	OTW0W6NP	Definitive	Biomarker	[1405]
RASAL2	OTGMMX6W	Definitive	Biomarker	[1406]
RFC3	OT1MS7AO	Definitive	Biomarker	[1407]
S100A14	OTVFJJ91	Definitive	Biomarker	[1408]
SFN	OTLJCZ1U	Definitive	Altered Expression	[1409]
SOX17	OT9H4WWE	Definitive	Biomarker	[581]
SOX7	OTOZOFAG	Definitive	Altered Expression	[1410]
SPINK1	OTSUVAL2	Definitive	Biomarker	[1411]
SPPL3	OT2HLJF6	Definitive	Biomarker	[1068]
TNMD	OTHLVA9G	Definitive	Biomarker	[1379]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
• [5] ClinicalTrials.gov (NCT00377429) Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy. U.S. National Institutes of Health.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
• [8] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [9] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [10] ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
• [11] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201379.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033866)
• [13] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761310.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7519).
• [15] The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
• [16] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] ClinicalTrials.gov (NCT03245736) Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.. U.S. National Institutes of Health.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7101).
• [20] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT04729608) A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). U.S.National Institutes of Health.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020691)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022740)
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer. U.S. National Institutes of Health.
• [26] ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
• [27] Clinical pipeline report, company report or official report of Endocyte.
• [28] ClinicalTrials.gov (NCT05092360) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7). U.S.National Institutes of Health.
• [29] ClinicalTrials.gov (NCT03398655) A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL). U.S. National Institutes of Health.
• [30] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
• [31] ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
• [32] ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
• [34] ClinicalTrials.gov (NCT05329545) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). U.S.National Institutes of Health.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8265).
• [36] ClinicalTrials.gov (NCT02232633) A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT03933761) Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). U.S. National Institutes of Health.
• [38] ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7881).
• [40] Dendritic cell-targeted vaccines--hope or hype. Nat Rev Immunol. 2014 Oct;14(10):705-11.
• [41] ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth.
• [42] ClinicalTrials.gov (NCT04669002) Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance. U.S.National Institutes of Health.
• [43] Clinical pipeline report, company report or official report of Galena Biopharma.
• [44] ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
• [45] ClinicalTrials.gov (NCT05243524) Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer. U.S.National Institutes of Health.
• [46] Clinical pipeline report, company report or official report of BioAtla
• [47] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8258).
• [48] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
• [49] CVAC SHOWS OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER IN PHASE II STUDY. 19 May 2015.
• [50] ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT05261490) A Phase 1/2 Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. U.S.National Institutes of Health.
• [52] ClinicalTrials.gov (NCT03878849) Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP (PREDICT 2X-121). U.S. National Institutes of Health.
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8405).
• [54] ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
• [55] ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.
• [56] Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
• [57] Clinical pipeline report, company report or official report of Allarity Therapeutics.
• [58] ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [59] ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
• [60] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [61] ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
• [62] ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• [63] 2011 Pipeline of Immunovaccine.
• [64] ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health.
• [65] ClinicalTrials.gov (NCT02336984) A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS. U.S. National Institutes of Health.
• [66] ClinicalTrials.gov (NCT00062036) Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma. U.S. National Institutes of Health.
• [67] ClinicalTrials.gov (NCT01648452) CNTF Implants for CNGB3 Achromatopsia. U.S. National Institutes of Health.
• [68] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [69] ClinicalTrials.gov (NCT00660101) Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer. U.S. National Institutes of Health.
• [70] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027639)
• [71] ClinicalTrials.gov (NCT00382811) OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [74] ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
• [75] ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health.
• [76] ClinicalTrials.gov (NCT04396340) First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b. U.S. National Institutes of Health.
• [77] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037354)
• [78] ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [79] ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
• [80] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [81] ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
• [82] ClinicalTrials.gov (NCT04163094) Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy. U.S.National Institutes of Health.
• [83] ClinicalTrials.gov (NCT05107739) A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies. U.S.National Institutes of Health.
• [84] ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT04707248) Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors. U.S.National Institutes of Health.
• [86] ClinicalTrials.gov (NCT04711161) Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. U.S.National Institutes of Health.
• [87] ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
• [88] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008435)
• [89] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023517)
• [90] Clinical pipeline report, company report or official report of Immunotope.
• [91] Clinical pipeline report, company report or official report of INmune Bio
• [92] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036367)
• [93] ClinicalTrials.gov (NCT05397093) A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
• [94] ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health.
• [96] ClinicalTrials.gov (NCT01248949) A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [97] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2522).
• [98] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [99] ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health.
• [100] ClinicalTrials.gov (NCT01322802) Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer. U.S. National Institutes of Health.
• [101] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028960)
• [102] ClinicalTrials.gov (NCT04406623) Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer. U.S. National Institutes of Health.
• [103] ClinicalTrials.gov (NCT01578564) Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel. U.S. National Institutes of Health.
• [104] ClinicalTrials.gov (NCT03748186) Study of STRO-002, an Anti-Folate Receptor Alpha (FolRalpha) Antibody Drug Conjugate in Ovarian & Endometrial Cancers. U.S. National Institutes of Health.
• [105] ClinicalTrials.gov (NCT03839524) A Trial Evaluating TG4050 in Ovarian Carcinoma.. U.S. National Institutes of Health.
• [106] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [107] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014322)
• [108] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009455)
• [109] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
• [110] R&D Pipeline (February 2011).
• [111] ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
• [112] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004939)
• [113] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020371)
• [114] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034152)
• [115] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
• [116] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013518)
• [117] Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med. 1987 Dec;28(12):1807-19.
• [118] Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
• [119] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [120] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [121] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [122] Effect of inhibition of the adrenomedullin gene on the growth and chemosensitivity of ovarian cancer cells.Oncol Rep. 2012 May;27(5):1461-6. doi: 10.3892/or.2012.1655. Epub 2012 Jan 26.
• [123] Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.Cancer Chemother Pharmacol. 2011 Nov;68(5):1273-83. doi: 10.1007/s00280-011-1595-y. Epub 2011 Mar 29.
• [124] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [125] Expression of AMHR2 and C-KIT in cervical lesions in Uyghur Women of Xinjiang, China.Medicine (Baltimore). 2018 Jun;97(22):e10793. doi: 10.1097/MD.0000000000010793.
• [126] miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Oncogenesis. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25.
• [127] Inhibition of the inflammatory cytokine TNF- increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.
• [128] Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.Mol Cancer Res. 2008 Nov;6(11):1775-85. doi: 10.1158/1541-7786.MCR-08-0214.
• [129] Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework.BMC Syst Biol. 2013 Feb 6;7:12. doi: 10.1186/1752-0509-7-12.
• [130] Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.Clin Exp Metastasis. 2011 Oct;28(7):689-700. doi: 10.1007/s10585-011-9401-0. Epub 2011 Jul 2.
• [131] E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.PLoS One. 2017 Sep 21;12(9):e0184439. doi: 10.1371/journal.pone.0184439. eCollection 2017.
• [132] High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.Gynecol Oncol. 2010 Sep;118(3):244-50. doi: 10.1016/j.ygyno.2010.05.024. Epub 2010 Jun 17.
• [133] Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.Diagn Pathol. 2013 Nov 19;8:190. doi: 10.1186/1746-1596-8-190.
• [134] AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.Exp Cell Res. 2013 Oct 15;319(17):2627-36. doi: 10.1016/j.yexcr.2013.07.030. Epub 2013 Aug 13.
• [135] Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.J Pharm Sci. 2011 Oct;100(10):4205-9. doi: 10.1002/jps.22680. Epub 2011 Jun 23.
• [136] Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.Biochem Pharmacol. 2004 Aug 15;68(4):601-9. doi: 10.1016/j.bcp.2004.05.007.
• [137] Targeting endothelin-1 receptor/-arrestin1 network for the treatment of ovarian cancer.Expert Opin Ther Targets. 2017 Oct;21(10):925-932. doi: 10.1080/14728222.2017.1361930. Epub 2017 Sep 5.
• [138] FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.J Clin Invest. 2013 Oct;123(10):4435-48. doi: 10.1172/JCI70625. Epub 2013 Sep 9.
• [139] Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Cell Physiol Biochem. 2016;39(1):242-52.
• [140] hsa_circ_0061140 Knockdown Reverses FOXM1-Mediated Cell Growth and Metastasis in Ovarian Cancer through miR-370 Sponge Activity.Mol Ther Nucleic Acids. 2018 Dec 7;13:55-63. doi: 10.1016/j.omtn.2018.08.010. Epub 2018 Aug 22.
• [141] Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
• [142] No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.Breast Cancer Res Treat. 2010 Jun;121(2):497-502. doi: 10.1007/s10549-009-0589-5. Epub 2009 Oct 27.
• [143] Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma.Gene. 2019 May 15;696:63-71. doi: 10.1016/j.gene.2019.02.033. Epub 2019 Feb 15.
• [144] Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.Future Oncol. 2017 Sep;13(22):1981-1990. doi: 10.2217/fon-2017-0084. Epub 2017 Aug 22.
• [145] Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-B-mediated IKK expression.Int J Cancer. 2017 Dec 1;141(11):2305-2317. doi: 10.1002/ijc.30932. Epub 2017 Aug 30.
• [146] Interleukin 16 expression changes in association with ovarian malignant transformation.Am J Obstet Gynecol. 2014 Mar;210(3):272.e1-10. doi: 10.1016/j.ajog.2013.12.041. Epub 2013 Dec 28.
• [147] Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.Life Sci. 2007 Mar 27;80(16):1458-65. doi: 10.1016/j.lfs.2007.01.015. Epub 2007 Jan 20.
• [148] Study of kallikrein-related peptidase 6 (KLK6) and its complex with 1-antitrypsin in biological fluids.Clin Chem Lab Med. 2017 Aug 28;55(9):1385-1396. doi: 10.1515/cclm-2017-0017.
• [149] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.Gynecol Oncol. 2005 Jul;98(1):11-8. doi: 10.1016/j.ygyno.2005.03.043.
• [150] The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer.Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):884-90. doi: 10.1093/abbs/gmr089. Epub 2011 Sep 20.
• [151] Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.
• [152] Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression.Hum Immunol. 2013 Apr;74(4):439-46. doi: 10.1016/j.humimm.2012.11.021. Epub 2012 Dec 8.
• [153] Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.Virchows Arch. 2019 May;474(5):599-608. doi: 10.1007/s00428-019-02528-6. Epub 2019 Feb 7.
• [154] Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.
• [155] Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma.Mol Med Rep. 2015 Aug;12(2):2114-20. doi: 10.3892/mmr.2015.3580. Epub 2015 Apr 1.
• [156] Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.
• [157] Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.Int J Cancer. 2010 Jul 1;127(1):21-31. doi: 10.1002/ijc.25005.
• [158] p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.
• [159] Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.J Histochem Cytochem. 2013 Mar;61(3):206-17. doi: 10.1369/0022155413475452. Epub 2013 Jan 4.
• [160] Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.Cell Physiol Biochem. 2018;46(4):1716-1726. doi: 10.1159/000489586. Epub 2018 Apr 28.
• [161] Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing.Hum Immunol. 2014 Mar;75(3):239-44. doi: 10.1016/j.humimm.2013.12.006. Epub 2013 Dec 27.
• [162] Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.Int J Oncol. 2013 Oct;43(4):1011-8. doi: 10.3892/ijo.2013.2021. Epub 2013 Jul 18.
• [163] PRL-3 suppresses c-Fos and integrin 2 expression in ovarian cancer cells.BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.
• [164] Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.Pathol Oncol Res. 2012 Apr;18(2):135-48. doi: 10.1007/s12253-011-9482-8. Epub 2011 Dec 9.
• [165] ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
• [166] SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.PLoS One. 2012;7(11):e49869. doi: 10.1371/journal.pone.0049869. Epub 2012 Nov 21.
• [167] Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.DNA Cell Biol. 2019 Apr;38(4):341-351. doi: 10.1089/dna.2018.4396. Epub 2019 Mar 6.
• [168] Annexin A2 inhibition suppresses ovarian cancer progression via regulating -catenin/EMT. Oncol Rep. 2017 Jun;37(6):3643-3650.
• [169] Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.Anticancer Res. 2011 Mar;31(3):897-906.
• [170] Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells.Anticancer Res. 2010 Jul;30(7):2577-81.
• [171] Manganese superoxide dismutase gene polymorphism, MnSOD plasma levels and risk of epithelial ovarian cancer.J Obstet Gynaecol Res. 2008 Oct;34(5):878-84. doi: 10.1111/j.1447-0756.2008.00851.x.
• [172] TLR4 activates NF-B in human ovarian granulosa tumor cells.Biochem Biophys Res Commun. 2011 Jun 17;409(4):675-80. doi: 10.1016/j.bbrc.2011.05.063. Epub 2011 May 17.
• [173] Placental Growth Factor Promotes Ovarian Cancer Cell Invasion via ZEB2.Cell Physiol Biochem. 2016;38(1):351-8. doi: 10.1159/000438635. Epub 2016 Jan 29.
• [174] Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma.Clin Cancer Res. 2014 Feb 1;20(3):565-75. doi: 10.1158/1078-0432.CCR-13-1271. Epub 2013 Nov 6.
• [175] Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.PLoS One. 2014 Dec 29;9(12):e115708. doi: 10.1371/journal.pone.0115708. eCollection 2014.
• [176] Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.Biomed Res Int. 2014;2014:159459. doi: 10.1155/2014/159459. Epub 2014 Jul 9.
• [177] M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.Cancer Biol Ther. 2019;20(7):956-966. doi: 10.1080/15384047.2018.1564567. Epub 2019 May 7.
• [178] Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.Gynecol Obstet Invest. 2018;83(4):381-387. doi: 10.1159/000488088. Epub 2018 Apr 5.
• [179] Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.Transl Oncol. 2019 Jul;12(7):917-924. doi: 10.1016/j.tranon.2019.04.009. Epub 2019 May 10.
• [180] Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.PLoS One. 2019 Jun 26;14(6):e0217521. doi: 10.1371/journal.pone.0217521. eCollection 2019.
• [181] FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway.Cell Death Dis. 2014 Jul 17;5(7):e1346. doi: 10.1038/cddis.2014.302.
• [182] MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.PLoS One. 2017 Mar 14;12(3):e0173912. doi: 10.1371/journal.pone.0173912. eCollection 2017.
• [183] Vascular marker expression during the development of various types of gynaecological malignancy.Tumour Biol. 2014 Nov;35(11):11229-35. doi: 10.1007/s13277-014-2447-2. Epub 2014 Aug 12.
• [184] Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867. doi: 10.1007/s00280-017-3401-y. Epub 2017 Jul 29.
• [185] Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.Exp Biol Med (Maywood). 2017 Mar;242(5):497-504. doi: 10.1177/1535370216685007. Epub 2017 Jan 5.
• [186] Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.Clin Cancer Res. 2009 Apr 1;15(7):2417-25. doi: 10.1158/1078-0432.CCR-08-1276. Epub 2009 Mar 24.
• [187] Regulation of human chorionic gonadotropin beta subunit expression in ovarian cancer.BMC Cancer. 2019 Jul 30;19(1):746. doi: 10.1186/s12885-019-5960-2.
• [188] Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?.Anticancer Agents Med Chem. 2008 Feb;8(2):232-9. doi: 10.2174/187152008783497000.
• [189] NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.Clin Cancer Res. 2007 Mar 1;13(5):1584-90. doi: 10.1158/1078-0432.CCR-06-1416.
• [190] Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts.Nat Commun. 2019 Jan 10;10(1):130. doi: 10.1038/s41467-018-07987-0.
• [191] Dipeptidyl peptidase IV in tumor progression.Biochim Biophys Acta. 2005 Aug 1;1751(1):45-51. doi: 10.1016/j.bbapap.2004.09.028. Epub 2004 Oct 22.
• [192] Characterization of a selective inverse agonist for estrogen related receptor as a potential agent for breast cancer.Eur J Pharmacol. 2016 Oct 15;789:439-448. doi: 10.1016/j.ejphar.2016.08.008. Epub 2016 Aug 4.
• [193] Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.Cancer Res. 2005 Feb 1;65(3):925-32.
• [194] Recent Advances of Molecular Optical Probes in Imaging of -Galactosidase.Bioconjug Chem. 2019 Aug 21;30(8):2089-2101. doi: 10.1021/acs.bioconjchem.9b00391. Epub 2019 Jul 22.
• [195] Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.Int J Oncol. 2009 Feb;34(2):345-53.
• [196] HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer.Int J Cancer. 2008 Aug 1;123(3):725-9. doi: 10.1002/ijc.23563.
• [197] Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.Cancer Sci. 2007 Jun;98(6):844-9. doi: 10.1111/j.1349-7006.2007.00461.x. Epub 2007 Apr 5.
• [198] SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.Fam Cancer. 2009;8(2):135-44. doi: 10.1007/s10689-008-9218-4. Epub 2008 Sep 27.
• [199] High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.Nucleic Acids Res. 2006 Jan 23;34(2):555-63. doi: 10.1093/nar/gkj468. Print 2006.
• [200] Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.Cancer. 2006 Sep 15;107(6):1407-18. doi: 10.1002/cncr.22134.
• [201] Mannan-binding lectin (MBL) in women with tumours of the reproductive system.Cancer Immunol Immunother. 2007 Jul;56(7):959-71. doi: 10.1007/s00262-006-0250-7. Epub 2006 Nov 28.
• [202] Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.J Clin Endocrinol Metab. 2008 May;93(5):1592-9. doi: 10.1210/jc.2007-2771. Epub 2008 Mar 4.
• [203] RUNX3 functions as an oncogene in ovarian cancer.Gynecol Oncol. 2011 Aug;122(2):410-7. doi: 10.1016/j.ygyno.2011.04.044. Epub 2011 May 25.
• [204] Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.Int J Gynecol Pathol. 2007 Jul;26(3):334-40. doi: 10.1097/01.pgp.0000236951.33914.1b.
• [205] Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. doi: 10.1158/1055-9965.EPI-07-0542.
• [206] STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.Cancer Immunol Immunother. 2006 Dec;55(12):1515-23. doi: 10.1007/s00262-006-0165-3. Epub 2006 Apr 19.
• [207] The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.PLoS One. 2019 Jan 22;14(1):e0210879. doi: 10.1371/journal.pone.0210879. eCollection 2019.
• [208] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [209] Amplification of ACK1 promotes gastric tumorigenesis via ECD-dependent p53 ubiquitination degradation.Oncotarget. 2017 Feb 21;8(8):12705-12716. doi: 10.18632/oncotarget.6194.
• [210] SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.Int J Oncol. 2017 Dec;51(6):1920-1928. doi: 10.3892/ijo.2017.4168. Epub 2017 Oct 19.
• [211] The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.Mol Ther Oncolytics. 2018 Dec 8;12:9-15. doi: 10.1016/j.omto.2018.12.002. eCollection 2019 Mar 29.
• [212] ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.
• [213] Hypoxia-inducible factor-2 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.Mol Oncol. 2019 Feb;13(2):403-421. doi: 10.1002/1878-0261.12419. Epub 2019 Jan 14.
• [214] ACR Appropriateness Criteria() StagingandFollow-Up of Ovarian Cancer.J Am Coll Radiol. 2018 May;15(5S):S198-S207. doi: 10.1016/j.jacr.2018.03.015.
• [215] Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?.Intern Med J. 2017 Mar;47(3):311-317. doi: 10.1111/imj.13357.
• [216] Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation.Sci Rep. 2019 Feb 21;9(1):2527. doi: 10.1038/s41598-019-38766-6.
• [217] ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23.
• [218] Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.J Immunol Methods. 2012 Apr 30;378(1-2):20-32. doi: 10.1016/j.jim.2012.01.013. Epub 2012 Feb 15.
• [219] Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress.J Exp Clin Cancer Res. 2019 Mar 7;38(1):116. doi: 10.1186/s13046-019-1127-x.
• [220] Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
• [221] AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-B axis.Cell Signal. 2018 May;45:122-131. doi: 10.1016/j.cellsig.2018.01.021. Epub 2018 Jan 31.
• [222] Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.Cancer Biol Ther. 2017 Apr 3;18(4):245-251. doi: 10.1080/15384047.2017.1295175. Epub 2017 Mar 27.
• [223] Profiling of selected angiogenesis-related genes in serous ovarian cancer patients.Adv Med Sci. 2017 Mar;62(1):116-120. doi: 10.1016/j.advms.2016.11.005. Epub 2017 Feb 21.
• [224] Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.Int J Cancer. 2019 May 1;144(9):2215-2226. doi: 10.1002/ijc.31887. Epub 2019 Feb 12.
• [225] Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.
• [226] Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.J Transl Med. 2019 Sep 2;17(1):275. doi: 10.1186/s12967-019-2023-z.
• [227] Human APC2 localization and allelic imbalance.Cancer Res. 2001 Nov 1;61(21):7978-84.
• [228] Silencing of Apurinic/Apyrimidinic Endonuclease 1 Inhibits the Growth and Migration in Ovarian Cancer Cell via Activator-Protein-1 Signaling.Gynecol Obstet Invest. 2017;82(2):188-199. doi: 10.1159/000447261. Epub 2016 Aug 24.
• [229] Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.Mol Cancer Res. 2019 Jun;17(6):1378-1390. doi: 10.1158/1541-7786.MCR-18-0989. Epub 2019 Mar 11.
• [230] APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910. Epub 2016 Mar 25.
• [231] Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008 Oct;62(5):857-65. doi: 10.1007/s00280-007-0674-6. Epub 2008 Jan 23.
• [232] Targeting Endothelin-1 Receptor/-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.Front Endocrinol (Lausanne). 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609. eCollection 2019.
• [233] L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2369-78. doi: 10.1111/j.1582-4934.2012.01547.x.
• [234] ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.Int J Oncol. 2020 Jan;56(1):219-231. doi: 10.3892/ijo.2019.4913. Epub 2019 Nov 14.
• [235] Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene. 2005 Mar 3;24(10):1774-87. doi: 10.1038/sj.onc.1207991.
• [236] Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy.J BUON. 2018 Sep-Oct;23(5):1396-1401.
• [237] Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.J Exp Clin Cancer Res. 2015 Jan 16;34(1):2. doi: 10.1186/s13046-015-0124-y.
• [238] Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.
• [239] Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.J Mol Med (Berl). 2015 Apr;93(4):427-38. doi: 10.1007/s00109-014-1228-0. Epub 2014 Nov 21.
• [240] Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.
• [241] BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.Cancer Lett. 2019 Mar 31;445:45-56. doi: 10.1016/j.canlet.2019.01.003. Epub 2019 Jan 14.
• [242] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010 Apr 27;10:163.
• [243] Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.Cancer Med. 2019 May;8(5):2442-2448. doi: 10.1002/cam4.2116. Epub 2019 Apr 2.
• [244] BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Oncotarget. 2015 Oct 13;6(31):31522-43. doi: 10.18632/oncotarget.5159.
• [245] Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.Cell Death Dis. 2019 Feb 4;10(2):104. doi: 10.1038/s41419-018-1200-y.
• [246] Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining.Pathol Res Pract. 2018 Mar;214(3):385-401. doi: 10.1016/j.prp.2017.12.020. Epub 2018 Jan 2.
• [247] Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.
• [248] Loss of BMP-10 is correlated with poor survival in ovarian cancer.Pathol Res Pract. 2019 Jan;215(1):121-126. doi: 10.1016/j.prp.2018.10.025. Epub 2018 Oct 28.
• [249] Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells.Onco Targets Ther. 2019 Sep 26;12:7897-7909. doi: 10.2147/OTT.S217975. eCollection 2019.
• [250] DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
• [251] Altered uterine contractility in response to -adrenoceptor agonists in ovarian cancer.J Physiol Sci. 2017 Nov;67(6):711-722. doi: 10.1007/s12576-016-0500-1. Epub 2016 Nov 12.
• [252] Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.J Mol Recognit. 2018 Feb;31(2). doi: 10.1002/jmr.2679. Epub 2017 Oct 6.
• [253] Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.
• [254] microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.Open Med (Wars). 2019 Jul 31;14:577-585. doi: 10.1515/med-2019-0065. eCollection 2019.
• [255] Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.Int J Cancer. 2020 May 1;146(9):2608-2618. doi: 10.1002/ijc.32676. Epub 2019 Nov 6.
• [256] Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
• [257] Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1.Exp Ther Med. 2017 Jul;14(1):499-506. doi: 10.3892/etm.2017.4546. Epub 2017 Jun 6.
• [258] CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.Nat Commun. 2018 Feb 12;9(1):631. doi: 10.1038/s41467-018-03031-3.
• [259] The association of taxane resistance genes with the clinical course of ovarian carcinoma.Genomics. 2013 Aug;102(2):96-101. doi: 10.1016/j.ygeno.2013.03.005. Epub 2013 Mar 28.
• [260] Costunolide Inhibits the Growth of OAW42-A Multidrug-Resistant Human Ovarian Cancer Cells by Activating Apoptotic and Autophagic Pathways, Production of Reactive Oxygen Species (ROS), Cleaved Caspase-3 and Cleaved Caspase-9.Med Sci Monit. 2019 May 2;25:3231-3237. doi: 10.12659/MSM.914029.
• [261] Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.Onco Targets Ther. 2019 Sep 30;12:8015-8022. doi: 10.2147/OTT.S203550. eCollection 2019.
• [262] miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1.J Ovarian Res. 2019 Jun 22;12(1):57. doi: 10.1186/s13048-019-0533-1.
• [263] Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.Mol Biol Rep. 2019 Oct;46(5):4685-4697. doi: 10.1007/s11033-019-04788-6. Epub 2019 Apr 25.
• [264] Targeting Glutathione and Cystathionine -Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.Nutrients. 2019 Oct 19;11(10):2523. doi: 10.3390/nu11102523.
• [265] CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.Cell Struct Funct. 2019;44(1):21-28. doi: 10.1247/csf.18029.
• [266] Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer.Immune Netw. 2018 Aug 13;18(4):e29. doi: 10.4110/in.2018.18.e29. eCollection 2018 Aug.
• [267] Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.Tumour Biol. 2015 Jun;36(6):4811-7. doi: 10.1007/s13277-015-3133-8. Epub 2015 Feb 3.
• [268] CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.BMC Cancer. 2019 Nov 25;19(1):1140. doi: 10.1186/s12885-019-6321-x.
• [269] Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.Int J Cancer. 2020 Feb 15;146(4):1086-1098. doi: 10.1002/ijc.32559. Epub 2019 Jul 22.
• [270] Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.Gynecol Oncol. 2010 Aug 1;118(2):189-95. doi: 10.1016/j.ygyno.2010.04.007. Epub 2010 May 11.
• [271] Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
• [272] Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1509-1517. doi: 10.1158/1055-9965.EPI-18-0346. Epub 2018 Oct 30.
• [273] Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Clin Transl Oncol. 2017 Dec;19(12):1489-1497. doi: 10.1007/s12094-017-1686-2. Epub 2017 Jun 6.
• [274] Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.Int J Mol Sci. 2019 Feb 3;20(3):660. doi: 10.3390/ijms20030660.
• [275] B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models.Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.
• [276] Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.J Clin Invest. 1998 Jun 1;101(11):2579-88. doi: 10.1172/JCI1518.
• [277] CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.Front Oncol. 2019 Aug 21;9:802. doi: 10.3389/fonc.2019.00802. eCollection 2019.
• [278] CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.Oncotarget. 2017 Jun 13;8(24):39021-39032. doi: 10.18632/oncotarget.16547.
• [279] Differential expression of adhesion molecules (CD44, ICAM-1 and LFA-3) in cancer cells grown in monolayer or as multicellular spheroids.Anticancer Res. 1999 May-Jun;19(3A):1769-78.
• [280] Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.Eur J Med Chem. 2019 Jan 1;161:594-606. doi: 10.1016/j.ejmech.2018.10.042. Epub 2018 Oct 23.
• [281] CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.J Cancer. 2019 Jun 2;10(13):2874-2884. doi: 10.7150/jca.31329. eCollection 2019.
• [282] Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.Front Oncol. 2019 Apr 8;9:236. doi: 10.3389/fonc.2019.00236. eCollection 2019.
• [283] Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.Medicine (Baltimore). 2019 Nov;98(44):e17803. doi: 10.1097/MD.0000000000017803.
• [284] BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.Cancer Res. 2001 Oct 1;61(19):6977-81.
• [285] DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression.J Cell Mol Med. 2017 Nov;21(11):3055-3065. doi: 10.1111/jcmm.13217. Epub 2017 Jun 9.
• [286] Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.Cancer Res. 2016 Apr 1;76(7):1882-91. doi: 10.1158/0008-5472.CAN-15-2128. Epub 2016 Jan 19.
• [287] Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.Mol Cancer Ther. 2016 Jul;15(7):1691-701. doi: 10.1158/1535-7163.MCT-16-0032. Epub 2016 May 20.
• [288] Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population.Cell Mol Biol (Noisy-le-grand). 2016 Jan 22;62(1):67-72.
• [289] SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.Nat Commun. 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
• [290] Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.Elife. 2018 Nov 13;7:e39030. doi: 10.7554/eLife.39030.
• [291] The prognostic of p27(kip1) in ovarian cancer: a meta-analysis.Arch Gynecol Obstet. 2016 Jan;293(1):169-176. doi: 10.1007/s00404-015-3817-8. Epub 2015 Jul 22.
• [292] Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.
• [293] An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.Int J Mol Sci. 2019 Oct 5;20(19):4938. doi: 10.3390/ijms20194938.
• [294] Chemiluminescence noncompetitive immunoassay based on microchip electrophoresis for the determination of -subunit of human chorionic gonadotropin.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:42-47. doi: 10.1016/j.jchromb.2017.03.031. Epub 2017 Mar 29.
• [295] Directing the use of DDR kinase inhibitors in cancer treatment.Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14.
• [296] Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.
• [297] The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer.Anticancer Res. 2019 Apr;39(4):1661-1666. doi: 10.21873/anticanres.13271.
• [298] Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.
• [299] Expression and prognostic value of CLIC1 in epithelial ovarian cancer.Exp Ther Med. 2018 Jun;15(6):4943-4949. doi: 10.3892/etm.2018.6000. Epub 2018 Mar 28.
• [300] RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.Mol Med Rep. 2015 Nov;12(5):6635-41. doi: 10.3892/mmr.2015.4238. Epub 2015 Aug 21.
• [301] Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.Cancers (Basel). 2019 Sep 18;11(9):1389. doi: 10.3390/cancers11091389.
• [302] Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSAB1 in ovarian cancer.Oncol Rep. 2018 Nov;40(5):2788-2797. doi: 10.3892/or.2018.6658. Epub 2018 Aug 17.
• [303] Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer.PLoS One. 2012;7(7):e39119. doi: 10.1371/journal.pone.0039119. Epub 2012 Jul 24.
• [304] Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.J Cell Biochem. 2018 Dec;119(12):9764-9780. doi: 10.1002/jcb.27295. Epub 2018 Aug 13.
• [305] Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.Gynecol Oncol. 2012 Feb;124(2):325-34. doi: 10.1016/j.ygyno.2011.10.013. Epub 2011 Oct 15.
• [306] Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
• [307] Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.
• [308] The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.Oncogenesis. 2019 Aug 12;8(8):41. doi: 10.1038/s41389-019-0150-2.
• [309] Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.Histol Histopathol. 2018 Jul;33(7):673-680. doi: 10.14670/HH-11-960. Epub 2018 Jan 5.
• [310] Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.Oncotarget. 2016 Jul 19;7(29):45995-46001. doi: 10.18632/oncotarget.10276.
• [311] A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.
• [312] Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.
• [313] IL-8 promotes cell migration through regulating EMT by activating the Wnt/-catenin pathway in ovarian cancer.J Cell Mol Med. 2020 Jan;24(2):1588-1598. doi: 10.1111/jcmm.14848. Epub 2019 Dec 2.
• [314] CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.Oncotarget. 2018 Jan 15;9(11):9751-9765. doi: 10.18632/oncotarget.24231. eCollection 2018 Feb 9.
• [315] Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor in ovarian cancer.Mol Oncol. 2018 Oct;12(10):1689-1705. doi: 10.1002/1878-0261.12362. Epub 2018 Aug 23.
• [316] Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.Medicine (Baltimore). 2019 Mar;98(13):e15052. doi: 10.1097/MD.0000000000015052.
• [317] Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.Gene. 2013 Jul 25;524(2):168-74. doi: 10.1016/j.gene.2013.04.038. Epub 2013 Apr 26.
• [318] CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.Int J Mol Med. 2015 Feb;35(2):340-8. doi: 10.3892/ijmm.2014.2041. Epub 2014 Dec 16.
• [319] TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Oncogene. 2018 Mar;37(13):1714-1729. doi: 10.1038/s41388-017-0043-9. Epub 2018 Jan 19.
• [320] High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.
• [321] Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.Int J Mol Med. 2019 Jan;43(1):47-56. doi: 10.3892/ijmm.2018.3967. Epub 2018 Oct 31.
• [322] Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.Tumour Biol. 2015 Jun;36(6):4157-65. doi: 10.1007/s13277-015-3050-x. Epub 2015 Jan 12.
• [323] An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.Cell Res. 2018 May;28(5):556-571. doi: 10.1038/s41422-018-0016-8. Epub 2018 Mar 21.
• [324] Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.Oncogene. 2019 Apr;38(17):3201-3215. doi: 10.1038/s41388-018-0658-5. Epub 2019 Jan 9.
• [325] Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.
• [326] miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.Arch Biochem Biophys. 2019 Jan;661:1-9. doi: 10.1016/j.abb.2018.10.014. Epub 2018 Oct 23.
• [327] Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.Am J Transl Res. 2019 Feb 15;11(2):1145-1153. eCollection 2019.
• [328] Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.Virchows Arch. 2019 Feb;474(2):177-185. doi: 10.1007/s00428-018-2487-x. Epub 2018 Nov 22.
• [329] Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.Genomics. 1994 Sep 1;23(1):163-7. doi: 10.1006/geno.1994.1473.
• [330] The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.
• [331] E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer.Front Oncol. 2019 Mar 22;9:161. doi: 10.3389/fonc.2019.00161. eCollection 2019.
• [332] Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.Biochem Biophys Res Commun. 2019 Mar 19;510(4):580-586. doi: 10.1016/j.bbrc.2019.01.117. Epub 2019 Feb 7.
• [333] Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.Cancer Res. 2001 May 1;61(9):3806-9.
• [334] Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.Gynecol Oncol. 2009 Feb;112(2):314-8. doi: 10.1016/j.ygyno.2008.10.024. Epub 2008 Dec 2.
• [335] Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.Oncol Lett. 2019 Jun;17(6):5351-5360. doi: 10.3892/ol.2019.10221. Epub 2019 Apr 5.
• [336] Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.Cancer Res. 2018 Apr 1;78(7):1779-1791. doi: 10.1158/0008-5472.CAN-17-2460. Epub 2018 Jan 26.
• [337] Decreased Eph receptorA1 expression is related to grade in ovarian serous carcinoma.Mol Med Rep. 2018 Apr;17(4):5409-5415. doi: 10.3892/mmr.2018.8528. Epub 2018 Jan 31.
• [338] The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.Gynecol Oncol. 2014 Mar;132(3):730-8. doi: 10.1016/j.ygyno.2014.01.047. Epub 2014 Feb 4.
• [339] Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6847-58. eCollection 2015.
• [340] Epiregulin as a marker for the initial steps of ovarian cancer development.Int J Oncol. 2011 Nov;39(5):1165-72. doi: 10.3892/ijo.2011.1123. Epub 2011 Jul 14.
• [341] IRE1-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.
• [342] ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. Epub 2017 Nov 22.
• [343] The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.Clin Exp Metastasis. 2004;21(3):191-9. doi: 10.1023/b:clin.0000037703.37275.35.
• [344] Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.PLoS One. 2016 Sep 13;11(9):e0162502. doi: 10.1371/journal.pone.0162502. eCollection 2016.
• [345] Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.BMC Cancer. 2016 Nov 17;16(1):897. doi: 10.1186/s12885-016-2929-2.
• [346] Role of PAR-4 in ovarian cancer.Oncotarget. 2015 Sep 8;6(26):22641-52. doi: 10.18632/oncotarget.4010.
• [347] IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.Cancer Immunol Immunother. 2020 Jan;69(1):115-126. doi: 10.1007/s00262-019-02445-2. Epub 2019 Dec 4.
• [348] FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):509-516. doi: 10.1093/abbs/gmz028.
• [349] The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.Int J Cancer. 2018 Aug 15;143(4):992-1002. doi: 10.1002/ijc.31392. Epub 2018 Apr 1.
• [350] Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.
• [351] Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.Tumour Biol. 2017 Jul;39(7):1010428317712592. doi: 10.1177/1010428317712592.
• [352] Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.J Cancer Res Ther. 2018 Jun;14(Supplement):S347-S353. doi: 10.4103/0973-1482.235353.
• [353] VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.
• [354] Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous... Hum Pathol. 2009 Oct;40(10):1453-60.
• [355] C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.Br J Cancer. 2008 Oct 21;99(8):1269-75. doi: 10.1038/sj.bjc.6604650.
• [356] lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer.Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101. doi: 10.1016/j.omtn.2019.05.007. Epub 2019 May 24.
• [357] MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Exp Ther Med. 2018 Feb;15(2):1672-1679. doi: 10.3892/etm.2017.5529. Epub 2017 Nov 17.
• [358] MiR-342-3p inhibits cell migration and invasion through suppressing forkhead box protein Q1 in ovarian carcinoma.Anticancer Drugs. 2019 Oct;30(9):917-924. doi: 10.1097/CAD.0000000000000801.
• [359] Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20.
• [360] Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.Mol Ther. 2019 Feb 6;27(2):314-325. doi: 10.1016/j.ymthe.2018.11.014. Epub 2018 Dec 13.
• [361] BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.PLoS One. 2012;7(6):e37697. doi: 10.1371/journal.pone.0037697. Epub 2012 Jun 1.
• [362] The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.Mol Oncol. 2019 Apr;13(4):757-780. doi: 10.1002/1878-0261.12425. Epub 2019 Jan 19.
• [363] Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.Sci Rep. 2017 Oct 16;7(1):13244. doi: 10.1038/s41598-017-13802-5.
• [364] The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
• [365] Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.Cancer Res. 1995 Oct 1;55(19):4367-74.
• [366] Epithelialmesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.Mol Med Rep. 2019 Mar;19(3):1501-1508. doi: 10.3892/mmr.2019.9814. Epub 2019 Jan 3.
• [367] Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFRAkt pathway.Mol Med Rep. 2019 Mar;19(3):2287-2296. doi: 10.3892/mmr.2019.9876. Epub 2019 Jan 17.
• [368] Regulation of Survivin Isoform Expression by GLI Proteins in Ovarian Cancer.Cells. 2019 Feb 6;8(2):128. doi: 10.3390/cells8020128.
• [369] Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.Mol Pharm. 2015 Sep 8;12(9):3137-45. doi: 10.1021/mp500835z. Epub 2015 Aug 3.
• [370] Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.Mol Ther. 2013 Jan;21(1):78-90. doi: 10.1038/mt.2012.187. Epub 2012 Nov 20.
• [371] Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model.J Pharmacol Sci. 2019 Mar;139(3):231-239. doi: 10.1016/j.jphs.2019.01.009. Epub 2019 Feb 10.
• [372] Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.J Int Med Res. 2018 Feb;46(2):723-731. doi: 10.1177/0300060517717625. Epub 2017 Sep 12.
• [373] GRP137 promotes cell proliferation and metastasis through regulation of the PI3K/AKT pathway in human ovarian cancer.Tumori. 2018 Oct;104(5):330-337. doi: 10.5301/tj.5000703. Epub 2018 May 9.
• [374] Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.Oncogene. 2016 Apr 28;35(17):2186-96. doi: 10.1038/onc.2015.279. Epub 2015 Jul 27.
• [375] GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.Oncogene. 2016 Aug 25;35(34):4471-80. doi: 10.1038/onc.2015.505. Epub 2016 Jan 25.
• [376] The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.Oncogene. 2020 Feb;39(7):1600-1616. doi: 10.1038/s41388-019-1087-9. Epub 2019 Nov 7.
• [377] Selection of suitable reference genes for gene expression studies in normal human ovarian tissues, borderline ovarian tumours and ovarian cancer.Mol Med Rep. 2016 Dec;14(6):5725-5731. doi: 10.3892/mmr.2016.5933. Epub 2016 Nov 8.
• [378] EGFR and CD44 Dual-Targeted Multifunctional Hyaluronic Acid Nanogels Boost Protein Delivery to Ovarian and Breast Cancers In Vitro and In Vivo.ACS Appl Mater Interfaces. 2017 Jul 19;9(28):24140-24147. doi: 10.1021/acsami.7b06879. Epub 2017 Jul 10.
• [379] Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24.
• [380] HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.Cell Physiol Biochem. 2018;48(4):1505-1518. doi: 10.1159/000492260. Epub 2018 Aug 2.
• [381] HDAC10 as a potential therapeutic target in ovarian cancer.Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
• [382] Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1-mediated regulation of apoptosis and autophagy.Theranostics. 2019 Jan 30;9(4):1096-1114. doi: 10.7150/thno.29673. eCollection 2019.
• [383] HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.
• [384] Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.
• [385] Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.Gynecol Oncol. 2008 Jun;109(3):403-10. doi: 10.1016/j.ygyno.2008.02.018. Epub 2008 Apr 18.
• [386] MicroRNA let?d?p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.Int J Oncol. 2019 May;54(5):1771-1784. doi: 10.3892/ijo.2019.4731. Epub 2019 Feb 27.
• [387] Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.Gynecol Oncol. 2018 Nov;151(2):345-355. doi: 10.1016/j.ygyno.2018.08.032. Epub 2018 Sep 7.
• [388] The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7.Biol Chem. 2018 Apr 25;399(5):485-497. doi: 10.1515/hsz-2017-0274.
• [389] HOXB13 promotes ovarian cancer progression.Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17093-8. doi: 10.1073/pnas.0707938104. Epub 2007 Oct 17.
• [390] Expression levels of MRP1, GST-, and GSK3 in ovarian cancer and the relationship with drug resistance and prognosis of patients.Oncol Lett. 2019 Jul;18(1):22-28. doi: 10.3892/ol.2019.10315. Epub 2019 May 6.
• [391] Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am J Cancer Res. 2019 May 1;9(5):887-905. eCollection 2019.
• [392] A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
• [393] Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):115-28. doi: 10.1016/j.jsbmb.2007.10.004. Epub 2007 Nov 17.
• [394] Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.Int J Cancer. 1993 May 8;54(2):220-5. doi: 10.1002/ijc.2910540210.
• [395] The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.PLoS One. 2016 Dec 20;11(12):e0168389. doi: 10.1371/journal.pone.0168389. eCollection 2016.
• [396] Correction to: HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.Diagn Pathol. 2018 Sep 17;13(1):75. doi: 10.1186/s13000-018-0748-2.
• [397] Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.Clin Cancer Res. 2003 Feb;9(2):779-85.
• [398] IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma.Histopathology. 2011 Apr;58(5):729-38. doi: 10.1111/j.1365-2559.2011.03817.x. Epub 2011 Apr 4.
• [399] The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.Sci Rep. 2016 Dec 23;6:39334. doi: 10.1038/srep39334.
• [400] Interleukin-11 receptor expression in primary ovarian carcinomas.Gynecol Oncol. 2001 Feb;80(2):121-7. doi: 10.1006/gyno.2000.6064.
• [401] Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.Oncotarget. 2018 Oct 5;9(78):34810-34820. doi: 10.18632/oncotarget.26199. eCollection 2018 Oct 5.
• [402] Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.Mol Ther. 2018 Oct 3;26(10):2476-2486. doi: 10.1016/j.ymthe.2018.07.013. Epub 2018 Jul 17.
• [403] Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Med Sci Monit. 2016 Mar 7;22:766-75. doi: 10.12659/msm.895558.
• [404] Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.J Ovarian Res. 2014 Jan 20;7:8. doi: 10.1186/1757-2215-7-8.
• [405] Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.J Ovarian Res. 2016 Jun 27;9(1):38. doi: 10.1186/s13048-016-0248-5.
• [406] Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
• [407] Effect of integrinlinked kinase gene silencing on microRNA expression in ovarian cancer.Mol Med Rep. 2017 Nov;16(5):7267-7276. doi: 10.3892/mmr.2017.7523. Epub 2017 Sep 19.
• [408] Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.Dis Markers. 2019 Nov 11;2019:7275289. doi: 10.1155/2019/7275289. eCollection 2019.
• [409] miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin 5 expression.Am J Pathol. 2013 May;182(5):1876-89. doi: 10.1016/j.ajpath.2013.01.039. Epub 2013 Mar 15.
• [410] Expression of integrin -6 is associated with multi drug resistance and prognosis in ovarian cancer.Oncol Lett. 2019 Apr;17(4):3974-3980. doi: 10.3892/ol.2019.10056. Epub 2019 Feb 20.
• [411] Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer.Int J Biol Markers. 2018 Jan;33(1):124-131. doi: 10.5301/ijbm.5000264.
• [412] Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.Med Sci Monit. 2018 Dec 10;24:8933-8940. doi: 10.12659/MSM.911518.
• [413] Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.Mol Cancer. 2017 Oct 17;16(1):163. doi: 10.1186/s12943-017-0732-6.
• [414] Calcium-activated potassium channels as potential early markers of human cervical cancer.Oncol Lett. 2018 May;15(5):7249-7254. doi: 10.3892/ol.2018.8187. Epub 2018 Mar 7.
• [415] Low expression of KCNN3 may affect drug resistance in ovarian cancer.Mol Med Rep. 2018 Aug;18(2):1377-1386. doi: 10.3892/mmr.2018.9107. Epub 2018 May 31.
• [416] Lysine demethylase2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
• [417] Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.Oncogene. 2017 Mar;36(11):1537-1545. doi: 10.1038/onc.2016.320. Epub 2016 Oct 3.
• [418] KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.Mol Med Rep. 2017 Sep;16(3):3573-3580. doi: 10.3892/mmr.2017.6960. Epub 2017 Jul 12.
• [419] Targeting estrogen receptor beta (ER) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ER expression and functionality.Oncogenesis. 2018 Feb 9;7(2):15. doi: 10.1038/s41389-018-0027-9.
• [420] Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.
• [421] A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association.Sci Rep. 2019 Jul 31;9(1):11083. doi: 10.1038/s41598-019-47558-x.
• [422] Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis.Med Sci Monit. 2018 Jun 8;24:3863-3872. doi: 10.12659/MSM.907889.
• [423] Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.
• [424] Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.Twin Res Hum Genet. 2011 Aug;14(4):323-7. doi: 10.1375/twin.14.4.323.
• [425] Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.
• [426] Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.
• [427] Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.J Ovarian Res. 2014 Dec 5;7:109. doi: 10.1186/s13048-014-0109-z.
• [428] Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14.
• [429] Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.
• [430] The sL1CAM in sera of patients with endometrial and ovarian cancers.Arch Gynecol Obstet. 2017 Jan;295(1):225-232. doi: 10.1007/s00404-016-4226-3. Epub 2016 Nov 10.
• [431] Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.
• [432] Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.Int J Gynecol Pathol. 2020 Nov;39(6):558-566. doi: 10.1097/PGP.0000000000000657.
• [433] Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.Chem Biol Drug Des. 2016 Jan;87(1):121-30. doi: 10.1111/cbdd.12632. Epub 2015 Aug 31.
• [434] The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Nucleic Acids Res. 2016 Feb 18;44(3):1227-46. doi: 10.1093/nar/gkv1515. Epub 2015 Dec 29.
• [435] Outcome in serous ovarian cancer is not associated with LATS expression.J Cancer Res Clin Oncol. 2019 Nov;145(11):2737-2749. doi: 10.1007/s00432-019-03037-4. Epub 2019 Oct 4.
• [436] A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.
• [437] Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12.
• [438] Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.Am J Transl Res. 2019 Jun 15;11(6):3862-3878. eCollection 2019.
• [439] Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer.J Cell Biochem. 2012 Aug;113(8):2679-86. doi: 10.1002/jcb.24143.
• [440] LGR5 and LGR6 in stem cell biology and ovarian cancer.Oncotarget. 2017 Aug 11;9(1):1346-1355. doi: 10.18632/oncotarget.20178. eCollection 2018 Jan 2.
• [441] Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. Epub 2018 Oct 10.
• [442] Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling.Oncol Rep. 2014 Nov;32(5):2070-6. doi: 10.3892/or.2014.3461. Epub 2014 Sep 2.
• [443] The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.Oncogene. 2019 Feb;38(9):1381-1397. doi: 10.1038/s41388-018-0512-9. Epub 2018 Sep 28.
• [444] Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.Gynecol Oncol. 2017 Jul;146(1):170-178. doi: 10.1016/j.ygyno.2017.05.001. Epub 2017 May 9.
• [445] LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.BMC Cancer. 2016 Nov 4;16(1):846. doi: 10.1186/s12885-016-2865-1.
• [446] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
• [447] Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.Biochim Biophys Acta. 2016 Feb;1863(2):236-43. doi: 10.1016/j.bbamcr.2015.11.011. Epub 2015 Nov 17.
• [448] Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.Clin Exp Metastasis. 2011 Dec;28(8):887-97. doi: 10.1007/s10585-011-9420-x. Epub 2011 Sep 2.
• [449] Androgen receptor gene mutations do not occur in ovarian cancer.Anticancer Res. 2000 Mar-Apr;20(2A):815-9.
• [450] MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.
• [451] Overexpression of MAP3K3 promotes tumour growth through activation of the NF-B signalling pathway in ovarian carcinoma.Sci Rep. 2019 Jun 10;9(1):8401. doi: 10.1038/s41598-019-44835-7.
• [452] ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.JCI Insight. 2017 Sep 21;2(18):e91828. doi: 10.1172/jci.insight.91828. eCollection 2017 Sep 21.
• [453] Expression of Syk and MAP4 proteins in ovarian cancer.J Cancer Res Clin Oncol. 2019 Apr;145(4):909-919. doi: 10.1007/s00432-019-02856-9. Epub 2019 Feb 8.
• [454] Combined MEK and BCL-2/X(L) Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.
• [455] Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.Int J Mol Sci. 2017 Dec 23;19(1):41. doi: 10.3390/ijms19010041.
• [456] Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Oncotarget. 2017 Aug 24;8(43):74947-74961. doi: 10.18632/oncotarget.20471. eCollection 2017 Sep 26.
• [457] METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells.Int J Mol Sci. 2018 Sep 29;19(10):2976. doi: 10.3390/ijms19102976.
• [458] Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.
• [459] Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.Onco Targets Ther. 2019 Nov 21;12:10057-10075. doi: 10.2147/OTT.S228678. eCollection 2019.
• [460] The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.Hum Pathol. 2017 Jun;64:98-105. doi: 10.1016/j.humpath.2017.04.002. Epub 2017 Apr 17.
• [461] The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.Transl Res. 2019 Apr;206:71-90. doi: 10.1016/j.trsl.2018.11.001. Epub 2018 Nov 20.
• [462] Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.Clin Transl Oncol. 2018 Mar;20(3):374-381. doi: 10.1007/s12094-017-1724-0. Epub 2017 Aug 1.
• [463] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [464] Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.Nat Commun. 2017 Mar 6;8:14470. doi: 10.1038/ncomms14470.
• [465] Aberrant Activation Of Hedgehog Signalling Promotes Cell Migration And Invasion Via Matrix Metalloproteinase-7 In Ovarian Cancer Cells.J Cancer. 2019 Jan 29;10(4):990-1003. doi: 10.7150/jca.26478. eCollection 2019.
• [466] Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.J Cancer. 2019 Feb 26;10(6):1580-1592. doi: 10.7150/jca.27352. eCollection 2019.
• [467] Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.Int J Oncol. 2016 Nov;49(5):1945-1952. doi: 10.3892/ijo.2016.3683. Epub 2016 Sep 6.
• [468] PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.Cell Death Dis. 2014 Sep 4;5(9):e1407. doi: 10.1038/cddis.2014.374.
• [469] Elevated RON protein expression in endometriosis and disease-associated ovarian cancers.Arch Gynecol Obstet. 2017 Mar;295(3):631-639. doi: 10.1007/s00404-016-4248-x. Epub 2016 Nov 26.
• [470] Mucin gene expression in ovarian cancers.Cancer Res. 1998 Dec 1;58(23):5546-50.
• [471] MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18.
• [472] P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.J Ovarian Res. 2018 Jan 17;11(1):8. doi: 10.1186/s13048-018-0380-5.
• [473] Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer.Oncol Lett. 2017 Jun;13(6):4713-4719. doi: 10.3892/ol.2017.6099. Epub 2017 Apr 26.
• [474] Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
• [475] NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.Biochem Biophys Res Commun. 2020 Feb 5;522(2):292-299. doi: 10.1016/j.bbrc.2019.11.014. Epub 2019 Nov 21.
• [476] AIB1 regulates the ovarian cancer cell cycle through TUG1.Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5610-5617. doi: 10.26355/eurrev_201712_14002.
• [477] Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.
• [478] NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.Oncogene. 2018 Aug;37(35):4854-4870. doi: 10.1038/s41388-018-0296-y. Epub 2018 May 18.
• [479] PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8239-8248. doi: 10.26355/eurrev_201910_19133.
• [480] TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway.Cell Death Dis. 2018 Sep 5;9(9):908. doi: 10.1038/s41419-018-0881-6.
• [481] Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.Mol Cancer Ther. 2015 May;14(5):1202-12. doi: 10.1158/1535-7163.MCT-14-0911. Epub 2015 Feb 27.
• [482] Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019.
• [483] Natriuretic peptide receptor A as a novel target for cancer.World J Surg Oncol. 2014 Jun 3;12:174. doi: 10.1186/1477-7819-12-174.
• [484] THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.Am J Hum Genet. 1993 Apr;52(4):718-22.
• [485] Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.Mol Cancer. 2011 Mar 8;10:24. doi: 10.1186/1476-4598-10-24.
• [486] The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.Tumour Biol. 2017 May;39(5):1010428317705508. doi: 10.1177/1010428317705508.
• [487] Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.Medicine (Baltimore). 2017 Jul;96(30):e7621. doi: 10.1097/MD.0000000000007621.
• [488] Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.
• [489] Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. doi: 10.1152/ajpregu.00075.2009. Epub 2009 Mar 18.
• [490] Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.Oncotarget. 2016 May 3;7(18):25815-25. doi: 10.18632/oncotarget.8272.
• [491] Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget. 2016 Mar 1;7(9):10594-605. doi: 10.18632/oncotarget.7236.
• [492] Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
• [493] The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.Tumour Biol. 2016 Apr;37(4):5375-83. doi: 10.1007/s13277-015-4363-5. Epub 2015 Nov 12.
• [494] Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.
• [495] PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.Cell Death Dis. 2019 Feb 18;10(3):166. doi: 10.1038/s41419-019-1415-6.
• [496] Analysis of epigenetic alterations to proprotein convertase genes in disease.Methods Mol Biol. 2011;768:231-45. doi: 10.1007/978-1-61779-204-5_12.
• [497] Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.
• [498] Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines.J Clin Invest. 1988 Oct;82(4):1157-64. doi: 10.1172/JCI113712.
• [499] Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9.Asian Pac J Cancer Prev. 2011;12(12):3367-70.
• [500] Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.J Cell Physiol. 2019 May;234(5):6361-6370. doi: 10.1002/jcp.27369. Epub 2018 Sep 19.
• [501] Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.Cancer Biol Ther. 2012 Jun;13(8):671-80. doi: 10.4161/cbt.20084. Epub 2012 Jun 1.
• [502] Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.Tohoku J Exp Med. 2018 Apr;244(4):291-296. doi: 10.1620/tjem.244.291.
• [503] Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects.J Cell Physiol. 2019 Sep;234(9):15708-15716. doi: 10.1002/jcp.28224. Epub 2019 Jan 29.
• [504] Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(6):2548-2559. doi: 10.1159/000488273. Epub 2018 Mar 16.
• [505] p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.Int J Oncol. 2017 May;50(5):1721-1728. doi: 10.3892/ijo.2017.3931. Epub 2017 Mar 23.
• [506] Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer.EPMA J. 2019 Jul 19;10(3):273-290. doi: 10.1007/s13167-019-00175-0. eCollection 2019 Sep.
• [507] Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.Adv Exp Med Biol. 2019;1153:47-54. doi: 10.1007/5584_2019_353.
• [508] Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332.
• [509] PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers.Cell Metab. 2019 Jan 8;29(1):156-173.e10. doi: 10.1016/j.cmet.2018.09.002. Epub 2018 Sep 20.
• [510] Association between newly identified variant form of DNA polymerase beta ( 208-304) and ovarian cancer.Cancer Biomark. 2012;11(4):155-60. doi: 10.3233/CBM-2012-00275.
• [511] Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms.Sci Rep. 2019 Mar 25;9(1):5101. doi: 10.1038/s41598-019-41567-6.
• [512] PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
• [513] Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment.Int J Cancer. 2005 Jul 1;115(4):539-44. doi: 10.1002/ijc.20810.
• [514] The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.J Ovarian Res. 2016 Mar 31;9:20. doi: 10.1186/s13048-016-0228-9.
• [515] Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.Acta Biochim Pol. 2000;47(1):157-64.
• [516] Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.Cancer Res. 2009 Dec 15;69(24):9306-14. doi: 10.1158/0008-5472.CAN-09-1213.
• [517] Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.BMC Cancer. 2018 Oct 19;18(1):999. doi: 10.1186/s12885-018-4918-0.
• [518] Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.Cancer Res. 2019 Nov 1;79(21):5536-5549. doi: 10.1158/0008-5472.CAN-18-3029. Epub 2019 Sep 17.
• [519] Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.
• [520] FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327.
• [521] High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.Oncotarget. 2017 Sep 21;8(56):95662-95673. doi: 10.18632/oncotarget.21175. eCollection 2017 Nov 10.
• [522] Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer.Oncotarget. 2018 Jan 4;9(7):7522-7533. doi: 10.18632/oncotarget.23943. eCollection 2018 Jan 26.
• [523] PTN signaling: Components and mechanistic insights in human ovarian cancer.Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.
• [524] LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.Mol Med Rep. 2016 Sep;14(3):2465-72. doi: 10.3892/mmr.2016.5572. Epub 2016 Jul 28.
• [525] Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.Oncol Rep. 2016 Dec;36(6):3605-3610. doi: 10.3892/or.2016.5148. Epub 2016 Oct 4.
• [526] Adipokine RBP4 drives ovarian cancer cell migration.J Ovarian Res. 2018 Apr 11;11(1):29. doi: 10.1186/s13048-018-0397-9.
• [527] Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.
• [528] Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.PLoS One. 2013 Nov 1;8(11):e78417. doi: 10.1371/journal.pone.0078417. eCollection 2013.
• [529] RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.
• [530] Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.
• [531] Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.
• [532] Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.
• [533] Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.Med Oncol. 2016 Feb;33(2):11. doi: 10.1007/s12032-015-0724-6. Epub 2016 Jan 5.
• [534] MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700. doi: 10.1016/j.bbrc.2013.10.053. Epub 2013 Oct 21.
• [535] Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.J Ovarian Res. 2019 Nov 15;12(1):110. doi: 10.1186/s13048-019-0578-1.
• [536] RSF1 is a positive regulator of NF-B-induced gene expression required for ovarian cancer chemoresistance.Cancer Res. 2014 Apr 15;74(8):2258-69. doi: 10.1158/0008-5472.CAN-13-2459. Epub 2014 Feb 24.
• [537] The role of R-spondin 1 through activating Wnt/-catenin in the growth, survival and migration of ovarian cancer cells.Gene. 2019 Mar 20;689:124-130. doi: 10.1016/j.gene.2018.11.098. Epub 2018 Dec 17.
• [538] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.J Histochem Cytochem. 2010 Nov;58(11):1015-23. doi: 10.1369/jhc.2010.956821. Epub 2010 Aug 16.
• [539] Mammaglobin B expression in human endometrial cancer.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. doi: 10.1111/j.1525-1438.2007.01137.x. Epub 2007 Nov 16.
• [540] Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.Int J Mol Med. 2015 May;35(5):1374-80. doi: 10.3892/ijmm.2015.2142. Epub 2015 Mar 17.
• [541] VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer.Cell Mol Biol Lett. 2018 Jan 3;23:2. doi: 10.1186/s11658-017-0058-9. eCollection 2018.
• [542] Levels of corticosteroid-binding globulin mRNA in human ovarian cancers.Tumour Biol. 1999 Sep-Oct;20(5):263-9. doi: 10.1159/000030073.
• [543] Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):96-103. doi: 10.1016/j.ejogrb.2012.06.031. Epub 2012 Jul 18.
• [544] SERPIND1 Affects the Malignant Biological Behavior of Epithelial Ovarian Cancer via the PI3K/AKT Pathway: A Mechanistic Study.Front Oncol. 2019 Oct 4;9:954. doi: 10.3389/fonc.2019.00954. eCollection 2019.
• [545] Malignant ascites: a source of therapeutic protein against ovarian cancer?.Oncotarget. 2019 Oct 15;10(57):5894-5905. doi: 10.18632/oncotarget.27185. eCollection 2019 Oct 15.
• [546] The core genes involved in the promotion of depression in patients with ovarian cancer.Oncol Lett. 2019 Dec;18(6):5995-6007. doi: 10.3892/ol.2019.10934. Epub 2019 Sep 30.
• [547] Finding Novel Anti-carcinomas Compounds by Targeting SFRP4 Through Molecular Modeling, Docking and Dynamic Simulation Studies.Curr Comput Aided Drug Des. 2018;14(2):160-173. doi: 10.2174/1573409914666180112100122.
• [548] Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Front Oncol. 2019 Jul 9;9:542. doi: 10.3389/fonc.2019.00542. eCollection 2019.
• [549] SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer.Cancer Lett. 2020 Jan 28;469:89-101. doi: 10.1016/j.canlet.2019.10.029. Epub 2019 Oct 19.
• [550] Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.J Cancer. 2019 Oct 15;10(24):6025-6036. doi: 10.7150/jca.34886. eCollection 2019.
• [551] Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.Mol Med Rep. 2017 Apr;15(4):1638-1646. doi: 10.3892/mmr.2017.6183. Epub 2017 Feb 8.
• [552] Human Ovarian Cancer Tissue Exhibits Increase of Mitochondrial Biogenesis and Cristae Remodeling.Cancers (Basel). 2019 Sep 12;11(9):1350. doi: 10.3390/cancers11091350.
• [553] Comprehensive Analysis of Expression and Prognostic Value of Sirtuins in Ovarian Cancer.Front Genet. 2019 Sep 13;10:879. doi: 10.3389/fgene.2019.00879. eCollection 2019.
• [554] The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.J Trace Elem Med Biol. 2019 Dec;56:131-138. doi: 10.1016/j.jtemb.2019.07.008. Epub 2019 Aug 19.
• [555] Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma.Int J Gynecol Cancer. 2019 Oct;29(8):1280-1284. doi: 10.1136/ijgc-2019-000229.
• [556] The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.Oncotarget. 2017 Dec 27;9(9):8614-8628. doi: 10.18632/oncotarget.23808. eCollection 2018 Feb 2.
• [557] Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):963-75. doi: 10.1111/j.1525-1438.2007.01134.x. Epub 2007 Nov 20.
• [558] GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.J Cell Physiol. 2018 Feb;233(2):1396-1401. doi: 10.1002/jcp.26023. Epub 2017 Jul 14.
• [559] The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.
• [560] SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion.Oncol Lett. 2018 Oct;16(4):4977-4983. doi: 10.3892/ol.2018.9273. Epub 2018 Aug 7.
• [561] Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer. Yonsei Med J. 2017 Jan;58(1):27-34.
• [562] Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.Mol Cancer Ther. 2013 Aug;12(8):1537-44. doi: 10.1158/1535-7163.MCT-12-0926. Epub 2013 Jun 11.
• [563] Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers.Int J Oncol. 2000 Dec;17(6):1087-91. doi: 10.3892/ijo.17.6.1087.
• [564] Circular RNA circ-SMAD7 promoted ovarian cancer cell proliferation and metastasis by suppressing KLF6.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5603-5610. doi: 10.26355/eurrev_201907_18294.
• [565] SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.Int J Cancer. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30.
• [566] Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.Mol Cancer Ther. 2018 Sep;17(9):1941-1950. doi: 10.1158/1535-7163.MCT-17-0822. Epub 2018 Jun 11.
• [567] Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.Oncogene. 2019 May;38(22):4366-4383. doi: 10.1038/s41388-019-0728-3. Epub 2019 Feb 14.
• [568] Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer. 2008 Sep 15;123(6):1376-84. doi: 10.1002/ijc.23667.
• [569] SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881.
• [570] Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.
• [571] Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.Sci Rep. 2019 Sep 26;9(1):13924. doi: 10.1038/s41598-019-50436-1.
• [572] Decreasing the ratio of matriptase/HAI? by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.Mol Med Rep. 2016 Aug;14(2):1465-74. doi: 10.3892/mmr.2016.5435. Epub 2016 Jun 23.
• [573] Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer.Onco Targets Ther. 2019 Apr 11;12:2789-2798. doi: 10.2147/OTT.S196150. eCollection 2019.
• [574] STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.Oncol Rep. 2015 Sep;34(3):1494-502. doi: 10.3892/or.2015.4120. Epub 2015 Jul 9.
• [575] Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.EMBO Mol Med. 2013 May;5(5):707-22. doi: 10.1002/emmm.201201504. Epub 2013 Apr 22.
• [576] Expression and clinical significance of SLP-2 in ovarian tumors.Oncol Lett. 2019 May;17(5):4626-4632. doi: 10.3892/ol.2019.10116. Epub 2019 Mar 5.
• [577] Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12.
• [578] Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells.Exp Ther Med. 2017 Sep;14(3):1947-1952. doi: 10.3892/etm.2017.4788. Epub 2017 Jul 12.
• [579] Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.
• [580] Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.J Cell Mol Med. 2017 Mar;21(3):510-518. doi: 10.1111/jcmm.12995. Epub 2016 Nov 7.
• [581] Screening the molecular targets of ovarian cancer based on bioinformatics analysis.Tumori. 2015 Jul-Aug;101(4):384-9. doi: 10.5301/tj.5000319. Epub 2015 Jul 2.
• [582] Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.Int J Oncol. 2002 Nov;21(5):941-8.
• [583] Transforming growth factor-beta isoform expression in human ovarian tumours.Eur J Cancer. 1997 Dec;33(14):2397-403. doi: 10.1016/s0959-8049(97)00304-3.
• [584] Extracellular tissue transglutaminase activates noncanonical NF-B signaling and promotes metastasis in ovarian cancer.Neoplasia. 2013 Jun;15(6):609-19. doi: 10.1593/neo.121878.
• [585] Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.
• [586] GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
• [587] Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
• [588] Prognostic values of transketolase family genes in ovarian cancer.Oncol Lett. 2019 Nov;18(5):4845-4857. doi: 10.3892/ol.2019.10818. Epub 2019 Sep 6.
• [589] Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.
• [590] Expression patterns of Thymosin 4 and cancer stem cell marker CD133 in ovarian cancers.Pathol Oncol Res. 2013 Apr;19(2):237-45. doi: 10.1007/s12253-012-9574-0. Epub 2012 Oct 10.
• [591] Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers.Int J Cancer. 2012 Mar 15;130(6):1314-8. doi: 10.1002/ijc.26134. Epub 2011 May 30.
• [592] Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. doi: 10.1186/s13046-019-1171-6.
• [593] Molecular characterization of a novel human brain tumor-associated gene BR-3.Anticancer Res. 2002 May-Jun;22(3):1467-74.
• [594] Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.Oncol Res. 2016;24(3):189-96. doi: 10.3727/096504016X14641336229602.
• [595] High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.BMC Cancer. 2018 Apr 16;18(1):425. doi: 10.1186/s12885-018-4339-0.
• [596] Pro-survival effects by NF-B, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.Biomed Pharmacother. 2016 Dec;84:1078-1087. doi: 10.1016/j.biopha.2016.10.028. Epub 2016 Oct 22.
• [597] Interferon- produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.Angiogenesis. 2014 Jul;17(3):529-40. doi: 10.1007/s10456-013-9397-y. Epub 2013 Oct 20.
• [598] Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling.Biomed Res Int. 2019 Feb 20;2019:2686340. doi: 10.1155/2019/2686340. eCollection 2019.
• [599] Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.Mol Pathol. 1997 Oct;50(5):247-53. doi: 10.1136/mp.50.5.247.
• [600] TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.J Cell Biochem. 2018 Sep;119(9):7540-7555. doi: 10.1002/jcb.27065. Epub 2018 Jun 15.
• [601] Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.Biomed Pharmacother. 2019 Jan;109:595-601. doi: 10.1016/j.biopha.2018.10.148. Epub 2018 Nov 3.
• [602] Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial-mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/-catenin signaling pathway.Neoplasma. 2017;64(6):893-900. doi: 10.4149/neo_2017_611.
• [603] TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.Int J Biol Sci. 2018 Nov 3;14(14):2073-2082. doi: 10.7150/ijbs.28757. eCollection 2018.
• [604] Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.Int J Oncol. 2016 Jan;48(1):243-52. doi: 10.3892/ijo.2015.3254. Epub 2015 Nov 19.
• [605] FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.Endocr Relat Cancer. 2013 May 30;20(3):415-29. doi: 10.1530/ERC-12-0005. Print 2013 Jun.
• [606] TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.J Exp Clin Cancer Res. 2019 Feb 28;38(1):106. doi: 10.1186/s13046-019-1061-y.
• [607] Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
• [608] Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses.Mol Cell Proteomics. 2007 Feb;6(2):294-304. doi: 10.1074/mcp.M600305-MCP200. Epub 2006 Nov 16.
• [609] MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2.Biol Res. 2019 Apr 3;52(1):18. doi: 10.1186/s40659-019-0219-6.
• [610] Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis from rare etiologies.Am J Surg. 2019 May;217(5):923-927. doi: 10.1016/j.amjsurg.2019.01.011. Epub 2019 Jan 25.
• [611] 4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.J Ovarian Res. 2014 Oct 11;7:94. doi: 10.1186/s13048-014-0094-2.
• [612] Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.Mol Nutr Food Res. 2014 Oct;58(10):2023-35. doi: 10.1002/mnfr.201400068. Epub 2014 Jul 28.
• [613] Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.J Clin Invest. 2017 Dec 1;127(12):4554-4568. doi: 10.1172/JCI92914. Epub 2017 Nov 13.
• [614] UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-B pathway.Oncogene. 2020 Jan;39(2):322-333. doi: 10.1038/s41388-019-0987-z. Epub 2019 Sep 2.
• [615] The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
• [616] Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.Genet Mol Res. 2015 Jun 29;14(2):7241-7. doi: 10.4238/2015.June.29.17.
• [617] Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
• [618] USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.Sci Adv. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235. eCollection 2019 May.
• [619] Amplification of USP13 drives ovarian cancer metabolism.Nat Commun. 2016 Nov 28;7:13525. doi: 10.1038/ncomms13525.
• [620] Inhibition of ubiquitinspecific protease14 promotes connexin32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.Oncol Rep. 2019 Sep;42(3):1237-1247. doi: 10.3892/or.2019.7232. Epub 2019 Jul 15.
• [621] The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.Cell Physiol Biochem. 2017;43(5):1755-1766. doi: 10.1159/000484062. Epub 2017 Oct 19.
• [622] Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.Lab Invest. 1997 Dec;77(6):607-14.
• [623] VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother. 2020 Jan;69(1):33-42. doi: 10.1007/s00262-019-02434-5. Epub 2019 Nov 28.
• [624] B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):515-522. doi: 10.1097/PAI.0000000000000608.
• [625] Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
• [626] An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.Oncogene. 2017 Jun 15;36(24):3384-3396. doi: 10.1038/onc.2016.487. Epub 2017 Jan 23.
• [627] Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.Cancer Lett. 1996 Nov 29;108(2):233-7. doi: 10.1016/s0304-3835(96)04428-x.
• [628] FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.Biochem Pharmacol. 2018 Jan;147:93-103. doi: 10.1016/j.bcp.2017.11.009. Epub 2017 Nov 16.
• [629] Expression of Yes-associated protein1 and its clinical significance in ovarian serous cystadenocarcinoma.Oncol Rep. 2017 May;37(5):2620-2632. doi: 10.3892/or.2017.5517. Epub 2017 Mar 21.
• [630] ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.Int J Clin Exp Pathol. 2014 May 15;7(6):3038-47. eCollection 2014.
• [631] A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition.Cancer Res. 2006 Dec 15;66(24):11718-25. doi: 10.1158/0008-5472.CAN-06-1968.
• [632] Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.Cancer Sci. 2012 Feb;103(2):239-444. doi: 10.1111/j.1349-7006.2011.02156.x. Epub 2011 Dec 23.
• [633] Calpain system protein expression and activity in ovarian cancer.J Cancer Res Clin Oncol. 2019 Feb;145(2):345-361. doi: 10.1007/s00432-018-2794-2. Epub 2018 Nov 17.
• [634] Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.Br J Cancer. 2001 Sep 14;85(6):891-7. doi: 10.1054/bjoc.2001.2020.
• [635] Constitutive expression of TGF-bta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma.Eur Cytokine Netw. 2003 Oct-Dec;14(4):246-55.
• [636] Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.Oncotarget. 2015 May 10;6(13):11216-30. doi: 10.18632/oncotarget.3589.
• [637] MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.J Cell Biochem. 2019 Mar;120(3):2940-2953. doi: 10.1002/jcb.26865. Epub 2018 Dec 9.
• [638] Overexpression of Growth-Related Oncogene- Is Associated with Tumorigenesis, Metastasis, and Poor Prognosis in Ovarian Cancer.Dis Markers. 2015;2015:387382. doi: 10.1155/2015/387382. Epub 2015 Apr 30.
• [639] Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. doi: 10.1073/pnas.1317242111. Epub 2014 Mar 24.
• [640] Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.
• [641] E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.
• [642] Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.Cancer Res. 2019 May 15;79(10):2564-2579. doi: 10.1158/0008-5472.CAN-18-2674. Epub 2019 Mar 21.
• [643] miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.Oncogene. 2019 Jan;38(4):564-580. doi: 10.1038/s41388-018-0459-x. Epub 2018 Aug 30.
• [644] Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.Gynecol Oncol. 2017 Apr;145(1):167-175. doi: 10.1016/j.ygyno.2017.01.022. Epub 2017 Jan 29.
• [645] A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer.BMC Cancer. 2005 Apr 29;5:43. doi: 10.1186/1471-2407-5-43.
• [646] Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer.Tumour Biol. 2015 Sep;36(10):7649-58. doi: 10.1007/s13277-015-3463-6. Epub 2015 Apr 30.
• [647] The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.Regul Pept. 2000 Jun 30;90(1-3):77-84. doi: 10.1016/s0167-0115(00)00114-2.
• [648] Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.
• [649] PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
• [650] Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.Mol Oncol. 2011 Feb;5(1):48-60. doi: 10.1016/j.molonc.2010.08.002. Epub 2010 Aug 11.
• [651] Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.Thromb Haemost. 2009 Mar;101(3):541-6.
• [652] Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017.
• [653] Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.BMC Cancer. 2018 Jun 5;18(1):636. doi: 10.1186/s12885-018-4521-4.
• [654] Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.Int J Mol Sci. 2017 Jun 8;18(6):1230. doi: 10.3390/ijms18061230.
• [655] Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF- pathways.J Ovarian Res. 2017 Apr 20;10(1):28. doi: 10.1186/s13048-017-0325-4.
• [656] Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.Hum Pathol. 2014 Jun;45(6):1285-93. doi: 10.1016/j.humpath.2014.02.008. Epub 2014 Feb 28.
• [657] Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.Med Oncol. 2014 Aug;31(8):132. doi: 10.1007/s12032-014-0132-3. Epub 2014 Jul 18.
• [658] MicroRNA-30c inhibits metastasis of ovarian cancer by targeting metastasis-associated gene 1.J Cancer Res Ther. 2017;13(4):676-682. doi: 10.4103/jcrt.JCRT_132_17.
• [659] Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.Transl Oncol. 2020 Jan;13(1):86-91. doi: 10.1016/j.tranon.2019.09.007. Epub 2019 Dec 2.
• [660] Efficient Near-Infrared Photosensitizer with Aggregation-Induced Emission for Imaging-Guided Photodynamic Therapy in Multiple Xenograft Tumor Models.ACS Nano. 2020 Jan 28;14(1):854-866. doi: 10.1021/acsnano.9b07972. Epub 2019 Dec 16.
• [661] Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells.Oncotarget. 2017 Dec 28;9(4):5344-5367. doi: 10.18632/oncotarget.23747. eCollection 2018 Jan 12.
• [662] Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.BMC Cancer. 2018 Mar 7;18(1):267. doi: 10.1186/s12885-018-4073-7.
• [663] Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.Oncol Rep. 2015 Sep;34(3):1193-202. doi: 10.3892/or.2015.4113. Epub 2015 Jul 7.
• [664] Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA(1-/2-) carriers.Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
• [665] Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.Am J Cancer Res. 2019 Jan 1;9(1):145-159. eCollection 2019.
• [666] Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.Asian Pac J Cancer Prev. 2015;16(8):3325-31. doi: 10.7314/apjcp.2015.16.8.3325.
• [667] Autoantibody to thioredoxin reductase in an ovarian cancer patient.Biochem Biophys Res Commun. 1998 Jan 14;242(2):267-71. doi: 10.1006/bbrc.1997.7914.
• [668] PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.
• [669] The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.BMC Cancer. 2015 Jun 16;15:471. doi: 10.1186/s12885-015-1435-2.
• [670] MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.Oncol Rep. 2015 Jul;34(1):111-20. doi: 10.3892/or.2015.3952. Epub 2015 May 5.
• [671] Effects of shRNA-mediated knockdown of SPOCK1 on ovarian cancer growth and metastasis.Cell Mol Biol (Noisy-le-grand). 2015 Nov 30;61(7):102-9.
• [672] Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.Dev Cell. 2014 May 27;29(4):421-36. doi: 10.1016/j.devcel.2014.03.024. Epub 2014 May 8.
• [673] MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.Am J Cancer Res. 2017 May 1;7(5):1096-1106. eCollection 2017.
• [674] Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer.PLoS Genet. 2014 Oct 30;10(10):e1004751. doi: 10.1371/journal.pgen.1004751. eCollection 2014 Oct.
• [675] The impact of microRNA expression on cellular proliferation.Hum Genet. 2014 Jul;133(7):931-8. doi: 10.1007/s00439-014-1434-4. Epub 2014 Mar 8.
• [676] GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.Oncology. 2004;66(5):404-10. doi: 10.1159/000079489.
• [677] Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.Gynecol Oncol. 2011 Aug;122(2):361-5. doi: 10.1016/j.ygyno.2011.04.025. Epub 2011 May 13.
• [678] Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. doi: 10.1593/neo.09286.
• [679] ATP-binding cassette transporter A7 accelerates epithelial-to-mesenchymal transition in ovarian cancer cells by upregulating the transforming growth factor- signaling pathway.Oncol Lett. 2018 Nov;16(5):5868-5874. doi: 10.3892/ol.2018.9366. Epub 2018 Aug 24.
• [680] ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.Medicine (Baltimore). 2019 May;98(19):e15698. doi: 10.1097/MD.0000000000015698.
• [681] Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
• [682] miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A.Onco Targets Ther. 2019 Dec 6;12:10727-10737. doi: 10.2147/OTT.S221236. eCollection 2019.
• [683] A water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo.Int J Biol Macromol. 2018 Feb;107(Pt A):713-718. doi: 10.1016/j.ijbiomac.2017.09.043. Epub 2017 Sep 15.
• [684] A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Sci Rep. 2016 Mar 10;6:22811. doi: 10.1038/srep22811.
• [685] SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.Neoplasma. 2018 Nov 15;65(6):915-924. doi: 10.4149/neo_2018_180122N48. Epub 2018 Sep 4.
• [686] GLUT5 increases fructose utilization in ovarian cancer.Onco Targets Ther. 2019 Jul 8;12:5425-5436. doi: 10.2147/OTT.S205522. eCollection 2019.
• [687] MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6062-6069. doi: 10.26355/eurrev_201907_18419.
• [688] Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.Int J Mol Sci. 2018 Jan 2;19(1):117. doi: 10.3390/ijms19010117.
• [689] Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
• [690] The novel ZIP4 regulation and its role in ovarian cancer.Oncotarget. 2017 Sep 30;8(52):90090-90107. doi: 10.18632/oncotarget.21435. eCollection 2017 Oct 27.
• [691] High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer. PLoS One. 2017 Nov 1;12(11):e0187385.
• [692] Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.Gynecol Oncol. 2005 Apr;97(1):110-7. doi: 10.1016/j.ygyno.2004.12.031.
• [693] Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas.Oncol Rep. 2015 Feb;33(2):599-606. doi: 10.3892/or.2014.3666. Epub 2014 Dec 11.
• [694] The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.J Cancer. 2019 Oct 22;10(26):6754-6760. doi: 10.7150/jca.36236. eCollection 2019.
• [695] Avian prostatic acid phosphatase: estrogen regulation in the oviduct and epithelial cell-derived ovarian carcinomas.Biol Reprod. 2014 Jul;91(1):3. doi: 10.1095/biolreprod.114.118893. Epub 2014 May 14.
• [696] ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer.Cancers (Basel). 2019 Oct 14;11(10):1553. doi: 10.3390/cancers11101553.
• [697] Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer.Front Oncol. 2019 Oct 18;9:1072. doi: 10.3389/fonc.2019.01072. eCollection 2019.
• [698] Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2338-2342. doi: 10.1080/21691401.2019.1622551.
• [699] Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of -catenin.Pathol Res Pract. 2019 Dec;215(12):152681. doi: 10.1016/j.prp.2019.152681. Epub 2019 Oct 3.
• [700] -Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.Gynecol Oncol. 2018 Apr;149(1):163-172. doi: 10.1016/j.ygyno.2018.01.023. Epub 2018 Feb 9.
• [701] FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.Cancer Res. 2018 Mar 1;78(5):1184-1199. doi: 10.1158/0008-5472.CAN-17-2506. Epub 2017 Dec 19.
• [702] Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas.Gynecol Oncol. 1993 Jan;48(1):5-10. doi: 10.1006/gyno.1993.1002.
• [703] The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.
• [704] Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2009 Sep;116(3-5):134-53. doi: 10.1016/j.jsbmb.2009.05.005. Epub 2009 May 19.
• [705] MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.Oncol Lett. 2017 Jun;13(6):4039-4046. doi: 10.3892/ol.2017.5961. Epub 2017 Mar 31.
• [706] Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.Medicine (Baltimore). 2018 Apr;97(17):e0098. doi: 10.1097/MD.0000000000010098.
• [707] Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.Cell Death Dis. 2018 Mar 12;9(3):392. doi: 10.1038/s41419-018-0395-2.
• [708] Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3/-catenin signaling pathway.J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1.
• [709] Expression of prostaglandin D synthase in ovarian cancer.Clin Chem Lab Med. 2001 Dec;39(12):1198-203. doi: 10.1515/CCLM.2001.190.
• [710] A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression.Oncotarget. 2016 Jun 21;7(25):38064-38077. doi: 10.18632/oncotarget.9345.
• [711] ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3.
• [712] Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25.
• [713] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [714] Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
• [715] Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer.Genes Chromosomes Cancer. 2014 Jun;53(6):447-53. doi: 10.1002/gcc.22152. Epub 2014 Feb 24.
• [716] Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.Hum Pathol. 2012 Nov;43(11):2062-9. doi: 10.1016/j.humpath.2012.02.016. Epub 2012 May 29.
• [717] Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19.
• [718] Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.J Cell Mol Med. 2012 Feb;16(2):337-48. doi: 10.1111/j.1582-4934.2011.01316.x.
• [719] ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.Br J Cancer. 2011 May 10;104(10):1602-10. doi: 10.1038/bjc.2011.117. Epub 2011 Apr 19.
• [720] ATP11B mediates platinum resistance in ovarian cancer.J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.
• [721] An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y.
• [722] BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.Gynecol Oncol. 2010 May;117(2):189-97. doi: 10.1016/j.ygyno.2009.12.034. Epub 2010 Feb 26.
• [723] Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
• [724] Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.Int J Oncol. 2013 Dec;43(6):1925-34. doi: 10.3892/ijo.2013.2124. Epub 2013 Oct 3.
• [725] BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels.PLoS One. 2013 Dec 5;8(12):e80630. doi: 10.1371/journal.pone.0080630. eCollection 2013.
• [726] BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.Cell Death Dis. 2016 Sep 22;7(9):e2374. doi: 10.1038/cddis.2016.278.
• [727] Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016.
• [728] CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Oncotarget. 2010 Sep;1(5):329-38. doi: 10.18632/oncotarget.165.
• [729] Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2422-8. doi: 10.1111/j.1582-4934.2012.01559.x.
• [730] CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1/CXCR4 axis.Mol Cancer. 2013 Oct 5;12(1):115. doi: 10.1186/1476-4598-12-115.
• [731] Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.
• [732] CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour Biol. 2012 Dec;33(6):2299-306. doi: 10.1007/s13277-012-0492-2. Epub 2012 Aug 25.
• [733] MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.FEBS Lett. 2013 May 2;587(9):1434-9. doi: 10.1016/j.febslet.2013.03.023. Epub 2013 Mar 20.
• [734] CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.Eur J Pharmacol. 2011 Nov 16;670(1):96-104. doi: 10.1016/j.ejphar.2011.08.006. Epub 2011 Sep 3.
• [735] EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo.Cancer Sci. 2011 Mar;102(3):530-9. doi: 10.1111/j.1349-7006.2010.01836.x. Epub 2011 Jan 18.
• [736] Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries.Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):179-87. doi: 10.1016/j.plefa.2013.08.001. Epub 2013 Aug 14.
• [737] Expression and biological role of -catenin in human ovarian cancer.J Cancer Res Clin Oncol. 2012 Oct;138(10):1769-76. doi: 10.1007/s00432-012-1257-4. Epub 2012 Jun 15.
• [738] Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Cancer Res. 2010 Nov 15;70(22):9197-206. doi: 10.1158/0008-5472.CAN-10-1568. Epub 2010 Nov 2.
• [739] Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
• [740] Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.Gynecol Oncol. 2013 Aug;130(2):369-76. doi: 10.1016/j.ygyno.2013.05.002. Epub 2013 May 14.
• [741] OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.Oncol Lett. 2017 May;13(5):2929-2936. doi: 10.3892/ol.2017.5848. Epub 2017 Mar 13.
• [742] Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.
• [743] Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.Neoplasia. 2010 Jul;12(7):579-89. doi: 10.1593/neo.10340.
• [744] Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.Cancer Res. 2010 Dec 1;70(23):9979-90. doi: 10.1158/0008-5472.CAN-10-2394. Epub 2010 Nov 30.
• [745] Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.Cancer Immunol Immunother. 2013 Aug;62(8):1411-9. doi: 10.1007/s00262-013-1445-3. Epub 2013 Jun 7.
• [746] C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion.Oncol Rep. 2010 Oct;24(4):933-9.
• [747] Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.Virchows Arch. 2011 Sep;459(3):255-63. doi: 10.1007/s00428-011-1135-5. Epub 2011 Aug 5.
• [748] Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.Folia Biol (Praha). 2012;58(6):246-50.
• [749] Suppression of GNAI2 message in ovarian cancer.J Ovarian Res. 2014 Jan 14;7:6. doi: 10.1186/1757-2215-7-6.
• [750] Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).Curr Pharm Des. 2014;20(11):1904-16. doi: 10.2174/13816128113199990530.
• [751] Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.Differentiation. 2009 Feb;77(2):162-71. doi: 10.1016/j.diff.2008.09.018. Epub 2008 Oct 25.
• [752] Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
• [753] Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7.
• [754] Mutations in BRIP1 confer high risk of ovarian cancer.Nat Genet. 2011 Oct 2;43(11):1104-7. doi: 10.1038/ng.955.
• [755] Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.
• [756] Transformation of human ovarian surface epithelial cells by Krppel-like factor 8.Oncogene. 2014 Jan 2;33(1):10-8. doi: 10.1038/onc.2012.545. Epub 2012 Dec 10.
• [757] Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.Clin Biochem. 2013 Oct;46(15):1453-61. doi: 10.1016/j.clinbiochem.2013.03.002. Epub 2013 Mar 13.
• [758] Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.Arch Gynecol Obstet. 2014 Jul;290(1):149-54. doi: 10.1007/s00404-014-3177-9. Epub 2014 Feb 21.
• [759] Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27.
• [760] Identification of LMX1B as a novel oncogene in human ovarian cancer.Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.
• [761] Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.Mol Cancer Ther. 2013 Jun;12(6):937-49. doi: 10.1158/1535-7163.MCT-12-1082. Epub 2013 Mar 27.
• [762] Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.Int J Cancer. 2010 Mar 15;126(6):1378-89. doi: 10.1002/ijc.24797.
• [763] SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.Biochim Biophys Acta. 2013 Oct;1833(10):2357-68. doi: 10.1016/j.bbamcr.2013.06.003. Epub 2013 Jun 13.
• [764] Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.Mol Med Rep. 2012 Nov;6(5):1050-6. doi: 10.3892/mmr.2012.1065. Epub 2012 Sep 5.
• [765] Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.
• [766] Common variation in Nemo-like kinase is associated with risk of ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):523-8. doi: 10.1158/1055-9965.EPI-11-0797. Epub 2012 Jan 17.
• [767] MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.Oncotarget. 2017 Sep 30;8(60):101649-101658. doi: 10.18632/oncotarget.21417. eCollection 2017 Nov 24.
• [768] miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.Mol Cancer Res. 2013 Nov;11(11):1314-25. doi: 10.1158/1541-7786.MCR-13-0131. Epub 2013 Sep 17.
• [769] Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.J Clin Endocrinol Metab. 2013 Jul;98(7):E1152-62. doi: 10.1210/jc.2013-1081. Epub 2013 May 20.
• [770] Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16348-53. doi: 10.1073/pnas.1205226109. Epub 2012 Sep 17.
• [771] PES1 differentially regulates the expression of ER and ER in ovarian cancer.IUBMB Life. 2013 Dec;65(12):1017-25. doi: 10.1002/iub.1228. Epub 2013 Nov 24.
• [772] PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage.Cell Signal. 2013 Jan;25(1):74-84. doi: 10.1016/j.cellsig.2012.09.009. Epub 2012 Sep 11.
• [773] HOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3.Med Sci Monit. 2016 Jan 31;22:325-31. doi: 10.12659/msm.894913.
• [774] Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.BMC Cancer. 2010 Nov 8;10:611. doi: 10.1186/1471-2407-10-611.
• [775] Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.BMC Cancer. 2011 Jun 25;11:270. doi: 10.1186/1471-2407-11-270.
• [776] iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.
• [777] A novel serine protease highly expressed in the pancreas is expressed in various kinds of cancer cells.FEBS J. 2005 Oct;272(19):4911-23. doi: 10.1111/j.1742-4658.2005.04901.x.
• [778] Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.
• [779] Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway.Cancer Sci. 2010 Jun;101(6):1454-62. doi: 10.1111/j.1349-7006.2010.01558.x. Epub 2010 Mar 10.
• [780] RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.Mol Cancer Res. 2012 Sep;10(9):1169-77. doi: 10.1158/1541-7786.MCR-12-0331. Epub 2012 Jul 13.
• [781] Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways.PLoS One. 2013 Nov 11;8(11):e79117. doi: 10.1371/journal.pone.0079117. eCollection 2013.
• [782] Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.
• [783] Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.Horm Cancer. 2013 Jun;4(3):154-64. doi: 10.1007/s12672-013-0135-0. Epub 2013 Feb 27.
• [784] Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis.Int J Oncol. 2017 May;50(5):1693-1700. doi: 10.3892/ijo.2017.3957. Epub 2017 Apr 7.
• [785] Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.Biochem Biophys Res Commun. 2013 Sep 20;439(2):187-90. doi: 10.1016/j.bbrc.2013.08.065. Epub 2013 Aug 29.
• [786] NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma.Tumour Biol. 2011 Apr;32(2):359-66. doi: 10.1007/s13277-010-0128-3. Epub 2010 Nov 12.
• [787] TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.Diagn Pathol. 2017 Feb 2;12(1):16. doi: 10.1186/s13000-017-0605-8.
• [788] Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer.Cancer Sci. 2010 May;101(5):1255-60. doi: 10.1111/j.1349-7006.2010.01497.x. Epub 2010 Jan 18.
• [789] Transcriptional regulation of hTREX84 in human cancer cells.PLoS One. 2012;7(8):e43610. doi: 10.1371/journal.pone.0043610. Epub 2012 Aug 27.
• [790] Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target.Int J Oncol. 2013 Aug;43(2):416-24. doi: 10.3892/ijo.2013.1957. Epub 2013 May 24.
• [791] DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.BMC Cancer. 2012 May 14;12:176. doi: 10.1186/1471-2407-12-176.
• [792] Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.Cancer Immunol Immunother. 2012 May;61(5):615-28. doi: 10.1007/s00262-011-1122-3. Epub 2011 Oct 22.
• [793] STAMP alters the growth of transformed and ovarian cancer cells.BMC Cancer. 2010 Apr 7;10:128. doi: 10.1186/1471-2407-10-128.
• [794] RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.
• [795] Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.Tumour Biol. 2014 Apr;35(4):3385-9. doi: 10.1007/s13277-013-1446-z. Epub 2013 Nov 28.
• [796] The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.Mol Cancer. 2014 Aug 12;13:189. doi: 10.1186/1476-4598-13-189.
• [797] Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3001-3005. doi: 10.31557/APJCP.2019.20.10.3001.
• [798] Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.Mol Oncol. 2019 Jul;13(7):1467-1489. doi: 10.1002/1878-0261.12480. Epub 2019 Jun 10.
• [799] Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.BMC Cancer. 2014 Aug 27;14:620. doi: 10.1186/1471-2407-14-620.
• [800] ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.Cancer Sci. 2018 Feb;109(2):471-482. doi: 10.1111/cas.13469.
• [801] Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90.FEBS Lett. 2006 Jan 9;580(1):245-50. doi: 10.1016/j.febslet.2005.12.005. Epub 2005 Dec 12.
• [802] Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.Clin Cancer Res. 2007 Dec 15;13(24):7370-9. doi: 10.1158/1078-0432.CCR-07-0747.
• [803] Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.Cancer Res. 2008 Jul 1;68(13):5067-75. doi: 10.1158/0008-5472.CAN-08-0062.
• [804] p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.Cancer Res. 2006 Dec 1;66(23):11432-40. doi: 10.1158/0008-5472.CAN-06-1867.
• [805] Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer. 2009 Sep 15;125(6):1454-63. doi: 10.1002/ijc.24546.
• [806] Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.Cancer Res. 2007 Jul 1;67(13):6100-5. doi: 10.1158/0008-5472.CAN-07-0369.
• [807] BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.
• [808] Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.Cancer. 2005 Dec 1;104(11):2417-29. doi: 10.1002/cncr.21538.
• [809] Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.Oncogene. 2005 Jul 28;24(32):5089-100. doi: 10.1038/sj.onc.1208700.
• [810] Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88. doi: 10.4161/cbt.7.2.5253. Epub 2007 Nov 15.
• [811] Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients.Oncol Res. 2008;17(1):43-9. doi: 10.3727/096504008784046090.
• [812] Tumor-associated alterations in caspase-14 expression in epithelial malignancies.Clin Cancer Res. 2005 Aug 1;11(15):5462-71. doi: 10.1158/1078-0432.CCR-04-2527.
• [813] The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.Cancer Lett. 2015 Feb 28;357(2):535-41. doi: 10.1016/j.canlet.2014.12.010. Epub 2014 Dec 9.
• [814] Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.Cancer Cell. 2007 Jun;11(6):498-512. doi: 10.1016/j.ccr.2007.04.011.
• [815] Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.In Vivo. 2007 Jul-Aug;21(4):593-8.
• [816] Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.
• [817] Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers.Cancer Biol Ther. 2005 Dec;4(12):1409-14. doi: 10.4161/cbt.4.12.2378. Epub 2005 Dec 5.
• [818] Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.Clin Cancer Res. 2007 Oct 1;13(19):5889-96. doi: 10.1158/1078-0432.CCR-07-0703.
• [819] ERCC5 is a novel biomarker of ovarian cancer prognosis.J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806.
• [820] Molecular pathogenesis of Fanconi anemia: recent progress.Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21.
• [821] Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.Br J Cancer. 2009 Oct 20;101(8):1433-43. doi: 10.1038/sj.bjc.6605316. Epub 2009 Sep 15.
• [822] Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression.Med Mol Morphol. 2009 Jun;42(2):82-91. doi: 10.1007/s00795-008-0436-5. Epub 2009 Jun 18.
• [823] Functional proteomics, human genetics and cancer biology of GIPC family members.Exp Mol Med. 2013 Jun 7;45(6):e26. doi: 10.1038/emm.2013.49.
• [824] Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.
• [825] Genetic risk factors for ovarian cancer and their role for endometriosis risk.Gynecol Oncol. 2017 Apr;145(1):142-147. doi: 10.1016/j.ygyno.2017.02.022. Epub 2017 Feb 14.
• [826] Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.Clin Biochem. 2008 May;41(7-8):561-9. doi: 10.1016/j.clinbiochem.2008.01.004. Epub 2008 Jan 16.
• [827] Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro.J Exp Clin Cancer Res. 2008 Nov 27;27(1):77. doi: 10.1186/1756-9966-27-77.
• [828] Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.Int J Cancer. 2009 May 15;124(10):2353-60. doi: 10.1002/ijc.24214.
• [829] LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication.Biochimie. 2012 May;94(5):1151-7. doi: 10.1016/j.biochi.2012.01.019. Epub 2012 Feb 2.
• [830] Mutation and expression analysis of LZTS1 in ovarian cancer.Cancer Lett. 2006 Feb 20;233(1):151-7. doi: 10.1016/j.canlet.2005.03.008.
• [831] A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.
• [832] Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.Hum Mol Genet. 2009 Jun 15;18(12):2297-304. doi: 10.1093/hmg/ddp138. Epub 2009 Mar 20.
• [833] The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.Cancer Biol Ther. 2008 Sep;7(9):1460-7. doi: 10.4161/cbt.7.9.6427. Epub 2008 Sep 11.
• [834] Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer. 2009 Jun 6;9:170. doi: 10.1186/1471-2407-9-170.
• [835] Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.Br J Cancer. 2009 Mar 24;100(6):993-1001. doi: 10.1038/sj.bjc.6604947. Epub 2009 Feb 24.
• [836] Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.Br J Cancer. 2005 Apr 25;92(8):1561-73. doi: 10.1038/sj.bjc.6602480.
• [837] PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.Cancer Res. 2008 Nov 15;68(22):9302-10. doi: 10.1158/0008-5472.CAN-08-2592.
• [838] SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.Int J Cancer. 2005 Sep 10;116(4):547-54. doi: 10.1002/ijc.20912.
• [839] Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.Br J Cancer. 2009 Oct 20;101(8):1461-8. doi: 10.1038/sj.bjc.6605284. Epub 2009 Sep 8.
• [840] L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells.Gynecol Oncol. 2007 Feb;104(2):461-9. doi: 10.1016/j.ygyno.2006.08.038. Epub 2006 Oct 9.
• [841] Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.Pathol Int. 2007 Nov;57(11):725-33. doi: 10.1111/j.1440-1827.2007.02169.x.
• [842] Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.Clin Cancer Res. 2004 Jul 15;10(14):4652-60. doi: 10.1158/1078-0432.CCR-03-0439.
• [843] Histone modifications silence the GATA transcription factor genes in ovarian cancer.Oncogene. 2006 Aug 31;25(39):5446-61. doi: 10.1038/sj.onc.1209533. Epub 2006 Apr 10.
• [844] RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.Cancer Lett. 2005 Feb 10;218(2):191-7. doi: 10.1016/j.canlet.2004.09.023.
• [845] SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8.Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1495-1501.
• [846] Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of MMP9.Mol Carcinog. 2016 Jul;55(7):1127-37. doi: 10.1002/mc.22355. Epub 2015 Jul 8.
• [847] -Estradiol-dependent activation of the JAK/STAT pathway requires p/CIP and CARM1.Biochim Biophys Acta. 2013 Jun;1833(6):1463-75. doi: 10.1016/j.bbamcr.2013.02.009. Epub 2013 Feb 20.
• [848] Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I.Int J Gynecol Cancer. 2008 Jul-Aug;18(4):677-91. doi: 10.1111/j.1525-1438.2007.01090.x. Epub 2007 Oct 18.
• [849] Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.J Physiol Pharmacol. 2008 Sep;59 Suppl 4:53-65.
• [850] Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.Eur J Cancer. 2006 Oct;42(15):2647-52. doi: 10.1016/j.ejca.2006.05.030. Epub 2006 Aug 23.
• [851] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250.
• [852] The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. doi: 10.1073/pnas.0605752103. Epub 2006 Oct 23.
• [853] Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.Oncotarget. 2016 Jul 26;7(30):47620-47636. doi: 10.18632/oncotarget.9951.
• [854] Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.BMC Cancer. 2019 Sep 5;19(1):878. doi: 10.1186/s12885-019-6087-1.
• [855] Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.
• [856] ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1.Cell Death Dis. 2019 Oct 24;10(11):811. doi: 10.1038/s41419-019-2050-y.
• [857] Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.Mod Pathol. 2009 Apr;22(4):499-507. doi: 10.1038/modpathol.2008.234. Epub 2009 Jan 16.
• [858] MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
• [859] Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11.
• [860] MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.Neoplasia. 2019 Feb;21(2):206-215. doi: 10.1016/j.neo.2018.12.005. Epub 2019 Jan 9.
• [861] Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.EBioMedicine. 2019 Dec;50:191-202. doi: 10.1016/j.ebiom.2019.11.009. Epub 2019 Nov 22.
• [862] Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
• [863] Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27.Cancer Res. 1996 Dec 15;56(24):5586-9.
• [864] High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.Oncol Lett. 2019 Nov;18(5):4900-4906. doi: 10.3892/ol.2019.10829. Epub 2019 Sep 9.
• [865] Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.Autophagy. 2018;14(12):2065-2082. doi: 10.1080/15548627.2018.1501135. Epub 2018 Aug 17.
• [866] Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.
• [867] Expression of brx proto-oncogene in normal ovary and in epithelial ovarian neoplasms.Am J Obstet Gynecol. 2000 Feb;182(2):286-95. doi: 10.1016/s0002-9378(00)70213-4.
• [868] Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
• [869] Clinical and biological significance of an isozyme tumor marker--PLAP.Clin Biochem. 1987 Dec;20(6):387-92. doi: 10.1016/0009-9120(87)90003-8.
• [870] Ovarian cancer detection by DNA methylation in cervical scrapings.Clin Epigenetics. 2019 Nov 27;11(1):166. doi: 10.1186/s13148-019-0773-3.
• [871] Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.Gynecol Oncol. 1994 Feb;52(2):247-52. doi: 10.1006/gyno.1994.1040.
• [872] Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16.
• [873] The role of annexin A4 in cancer.Front Biosci (Landmark Ed). 2016 Jun 1;21(5):949-57. doi: 10.2741/4432.
• [874] Upregulated Expression of Calcium-Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma.Proteomics Clin Appl. 2020 Mar;14(2):e1900078. doi: 10.1002/prca.201900078. Epub 2020 Jan 9.
• [875] Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.Int J Oncol. 2017 Apr;50(4):1087-1096. doi: 10.3892/ijo.2017.3898. Epub 2017 Mar 7.
• [876] Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy.Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):17-22.
• [877] LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.Am J Transl Res. 2019 Oct 15;11(10):6561-6568. eCollection 2019.
• [878] APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.
• [879] APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.
• [880] Different Prognostic Implications of Aquaporin-1 and Aquaporin-5 Expression among Different Histological Types of Ovarian Carcinoma.Pathol Oncol Res. 2020 Jan;26(1):263-271. doi: 10.1007/s12253-018-0456-y. Epub 2018 Jul 19.
• [881] CXCL12 promotes human ovarian cancer cell invasion through suppressing ARHGAP10 expression.Biochem Biophys Res Commun. 2019 Oct 20;518(3):416-422. doi: 10.1016/j.bbrc.2019.07.098. Epub 2019 Aug 22.
• [882] Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.
• [883] Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26.
• [884] ARID3B Directly Regulates Ovarian Cancer Promoting Genes.PLoS One. 2015 Jun 29;10(6):e0131961. doi: 10.1371/journal.pone.0131961. eCollection 2015.
• [885] RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis.J Natl Cancer Inst. 2001 Aug 1;93(15):1159-65. doi: 10.1093/jnci/93.15.1159.
• [886] Association of the ARLTS1 variants with familial ovarian cancer risk in China.Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.
• [887] ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas.Biochem Biophys Res Commun. 2001 Jan 12;280(1):340-7. doi: 10.1006/bbrc.2000.4125.
• [888] Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
• [889] Rare ATAD5 missense variants in breast and ovarian cancer patients.Cancer Lett. 2016 Jun 28;376(1):173-7. doi: 10.1016/j.canlet.2016.03.048. Epub 2016 Apr 1.
• [890] The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.
• [891] Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.Oncol Rep. 2017 Jul;38(1):309-316. doi: 10.3892/or.2017.5706. Epub 2017 Jun 6.
• [892] Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787.
• [893] LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p.J Cell Physiol. 2019 Dec;234(12):23421-23436. doi: 10.1002/jcp.28911. Epub 2019 Jun 21.
• [894] The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.J Biol Chem. 2018 Oct 5;293(40):15483-15496. doi: 10.1074/jbc.RA118.004084. Epub 2018 Aug 22.
• [895] Low BCL7A expression predicts poor prognosis in ovarian cancer.J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
• [896] Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.
• [897] MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3270-3276. doi: 10.26355/eurrev_201904_17688.
• [898] Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.Br J Cancer. 2003 Jan 27;88(2):270-6. doi: 10.1038/sj.bjc.6600674.
• [899] Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma.Oncogene. 2007 Nov 29;26(54):7584-9. doi: 10.1038/sj.onc.1210563. Epub 2007 Jun 4.
• [900] Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer.J Ovarian Res. 2019 Apr 30;12(1):38. doi: 10.1186/s13048-019-0514-4.
• [901] Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5595-5602. doi: 10.26355/eurrev_201907_18293.
• [902] ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma.Sci Rep. 2013;3:1305. doi: 10.1038/srep01305.
• [903] BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
• [904] Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.Cancer Res. 1999 Oct 15;59(20):5370-5.
• [905] The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.Oncogene. 2012 Apr 26;31(17):2175-86. doi: 10.1038/onc.2011.399. Epub 2011 Sep 19.
• [906] URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011 Mar 8;19(3):317-32. doi: 10.1016/j.ccr.2011.01.019.
• [907] C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer.Int J Gynecol Cancer. 2017 Jun;27(5):863-871. doi: 10.1097/IGC.0000000000000965.
• [908] Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.J Cell Mol Med. 2020 Jan;24(1):202-213. doi: 10.1111/jcmm.14701. Epub 2019 Oct 30.
• [909] It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
• [910] CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.Mol Med Rep. 2019 Jun;19(6):5097-5104. doi: 10.3892/mmr.2019.10212. Epub 2019 Apr 30.
• [911] L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.
• [912] Capn4 overexpression indicates poor prognosis of ovarian cancer patients.J Cancer. 2018 Jan 1;9(2):304-309. doi: 10.7150/jca.22004. eCollection 2018.
• [913] Small molecule inhibition of the CBF/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.
• [914] CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.
• [915] Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Front Oncol. 2019 Oct 1;9:986. doi: 10.3389/fonc.2019.00986. eCollection 2019.
• [916] Development of a M cell-targeted microparticulate platform, BSK02? for oral immunization against the ovarian cancer antigen, sperm protein 17.J Biomed Mater Res B Appl Biomater. 2019 Jan;107(1):29-36. doi: 10.1002/jbm.b.34092. Epub 2018 Mar 4.
• [917] Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.Cancer Biomark. 2017 Dec 12;21(1):97-104. doi: 10.3233/CBM-170305.
• [918] Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector.Biol Pharm Bull. 2005 Jun;28(6):1066-70. doi: 10.1248/bpb.28.1066.
• [919] Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Eur J Cancer. 2016 Nov;67:152-163. doi: 10.1016/j.ejca.2016.08.007. Epub 2016 Sep 24.
• [920] LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer.Cell Physiol Biochem. 2018;49(4):1289-1303. doi: 10.1159/000493408. Epub 2018 Sep 11.
• [921] CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.Cancer Med. 2019 Jan;8(1):351-362. doi: 10.1002/cam4.1812. Epub 2018 Dec 18.
• [922] APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study.Cancer Cell Int. 2018 May 29;18:78. doi: 10.1186/s12935-018-0572-5. eCollection 2018.
• [923] Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028.
• [924] Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin v3-mediated ovarian cancer biology.Cell Signal. 2015 Mar;27(3):652-62. doi: 10.1016/j.cellsig.2014.11.028. Epub 2014 Nov 27.
• [925] Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.Biochem Biophys Res Commun. 2019 Oct 22;518(4):698-705. doi: 10.1016/j.bbrc.2019.08.113. Epub 2019 Aug 28.
• [926] lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer.Mol Ther Oncolytics. 2019 Mar 26;13:35-48. doi: 10.1016/j.omto.2019.03.003. eCollection 2019 Jun 28.
• [927] Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.Oncol Rep. 2016 Jun;35(6):3548-58. doi: 10.3892/or.2016.4697. Epub 2016 Mar 23.
• [928] The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.Tumour Biol. 2016 Mar;37(3):2909-24. doi: 10.1007/s13277-015-4103-x. Epub 2015 Sep 26.
• [929] MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
• [930] Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.Pathol Oncol Res. 2019 Oct;25(4):1457-1465. doi: 10.1007/s12253-018-0500-y. Epub 2018 Oct 27.
• [931] MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer.Biomed Pharmacother. 2019 Feb;110:850-856. doi: 10.1016/j.biopha.2018.11.104. Epub 2018 Dec 14.
• [932] CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4535-44. eCollection 2015.
• [933] Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.
• [934] CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.Biomed Pharmacother. 2019 Jun;114:108787. doi: 10.1016/j.biopha.2019.108787. Epub 2019 Mar 27.
• [935] CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7283-7294. doi: 10.26355/eurrev_201909_18833.
• [936] CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.Gynecol Obstet Invest. 2011;72(3):203-7. doi: 10.1159/000323883. Epub 2011 Aug 23.
• [937] The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Jan 24;9(2):93. doi: 10.1038/s41419-017-0137-x.
• [938] A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.Nat Genet. 2019 May;51(5):815-823. doi: 10.1038/s41588-019-0395-x. Epub 2019 May 1.
• [939] The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.Cancer Gene Ther. 2012 Aug;19(8):588-91. doi: 10.1038/cgt.2012.33. Epub 2012 Jun 8.
• [940] Chordin is underexpressed in ovarian tumors and reduces tumor cell motility.FASEB J. 2006 Feb;20(2):240-50. doi: 10.1096/fj.05-4126com.
• [941] CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.
• [942] MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.Pathol Res Pract. 2019 Oct;215(10):152606. doi: 10.1016/j.prp.2019.152606. Epub 2019 Aug 19.
• [943] Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.Oncol Rep. 2017 May;37(5):3084-3092. doi: 10.3892/or.2017.5534. Epub 2017 Mar 27.
• [944] Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis.Int J Biochem Cell Biol. 2013 May;45(5):979-86. doi: 10.1016/j.biocel.2013.02.003. Epub 2013 Feb 14.
• [945] Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.Cancer Res. 2001 Feb 15;61(4):1291-5.
• [946] Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts.J Control Release. 2013 Dec 28;172(3):679-89. doi: 10.1016/j.jconrel.2013.10.015. Epub 2013 Oct 18.
• [947] An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.J Immunother Cancer. 2018 Apr 17;6(1):28. doi: 10.1186/s40425-018-0339-5.
• [948] Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer.Biol Reprod. 2000 Jun;62(6):1600-9. doi: 10.1095/biolreprod62.6.1600.
• [949] Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models.Mol Cancer. 2009 Sep 27;8:78. doi: 10.1186/1476-4598-8-78.
• [950] CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874773. doi: 10.1177/1533033819874773.
• [951] Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.Oncogene. 2018 Aug;37(35):4809-4820. doi: 10.1038/s41388-018-0297-x. Epub 2018 May 17.
• [952] Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.Oncol Rep. 2019 Jul;42(1):151-175. doi: 10.3892/or.2019.7147. Epub 2019 May 3.
• [953] Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.
• [954] Investigating key genes associated with ovarian cancer by integrating affinity propagation clustering and mutual information network analysis.Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2532-40.
• [955] Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics.EPMA J. 2019 Jun 8;10(2):153-172. doi: 10.1007/s13167-019-00170-5. eCollection 2019 Jun.
• [956] High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019.
• [957] The role of CT10 regulation of kinase-like in cancer.Future Oncol. 2014 Dec;10(16):2687-97. doi: 10.2217/fon.14.199.
• [958] circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.Biomed Pharmacother. 2019 Jun;114:108832. doi: 10.1016/j.biopha.2019.108832. Epub 2019 Apr 11.
• [959] Expression of high molecular weight cysteine proteinase inhibitor in ovarian cancer tissues: regulation of cathepsin B expression by placental CPI.Biol Chem. 2003 Jul;384(7):1103-7. doi: 10.1515/BC.2003.123.
• [960] Transforming growth factor?miR?43?p/cystatin B axis is a therapeutic target in human ovarian cancer.Int J Oncol. 2019 Jul;55(1):267-276. doi: 10.3892/ijo.2019.4815. Epub 2019 May 28.
• [961] Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
• [962] Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
• [963] BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.Neoplasia. 2013 Jun;15(6):600-8. doi: 10.1593/neo.121674.
• [964] CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.Oncotarget. 2017 Jul 10;8(37):62217-62230. doi: 10.18632/oncotarget.19216. eCollection 2017 Sep 22.
• [965] Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer.Int J Gynecol Cancer. 2017 Jan;27(1):22-27. doi: 10.1097/IGC.0000000000000850.
• [966] Amazon Fruits Inhibit Growth and Promote Pro-apoptotic Effects on Human Ovarian Carcinoma Cell Lines.Biomolecules. 2019 Nov 6;9(11):707. doi: 10.3390/biom9110707.
• [967] Mllerian inhibiting substance inhibits an ovarian cancer cell line via -catenin interacting protein deregulation of the Wnt signal pathway.Int J Oncol. 2017 Mar;50(3):1022-1028. doi: 10.3892/ijo.2017.3874. Epub 2017 Feb 13.
• [968] Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.Exp Cell Res. 2017 Aug 1;357(1):124-134. doi: 10.1016/j.yexcr.2017.05.008. Epub 2017 May 10.
• [969] MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research.BMC Cancer. 2019 Feb 22;19(1):171. doi: 10.1186/s12885-019-5371-4.
• [970] Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.Mol Oncol. 2013 Jun;7(3):419-27. doi: 10.1016/j.molonc.2012.11.005. Epub 2012 Dec 12.
• [971] miR?77 targets CUL4A and regulates metastatic capability in ovarian cancer.Int J Mol Med. 2018 Jun;41(6):3147-3156. doi: 10.3892/ijmm.2018.3540. Epub 2018 Mar 7.
• [972] Expression and biological role of cytoglobin in human ovarian cancer.Tumour Biol. 2014 Jul;35(7):6933-9. doi: 10.1007/s13277-014-1941-x. Epub 2014 Apr 17.
• [973] Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.
• [974] DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.Pathol Res Pract. 2019 Jul;215(7):152452. doi: 10.1016/j.prp.2019.152452. Epub 2019 May 14.
• [975] DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.Sci Rep. 2017 Aug 24;7(1):9285. doi: 10.1038/s41598-017-08249-7.
• [976] DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.J Ovarian Res. 2018 Oct 18;11(1):90. doi: 10.1186/s13048-018-0462-4.
• [977] Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.Eur J Immunol. 2003 Apr;33(4):1030-40. doi: 10.1002/eji.200323185.
• [978] Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):443-450. doi: 10.21873/cgp.20148.
• [979] DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1206-1213.
• [980] DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.Cell Death Dis. 2018 May 1;9(5):561. doi: 10.1038/s41419-018-0585-y.
• [981] Epigenetic down-regulated DDX10 promotes cell proliferation through Akt/NF-B pathway in ovarian cancer.Biochem Biophys Res Commun. 2016 Jan 22;469(4):1000-5. doi: 10.1016/j.bbrc.2015.12.069. Epub 2015 Dec 20.
• [982] Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells.Oncol Lett. 2018 Jul;16(1):905-909. doi: 10.3892/ol.2018.8718. Epub 2018 May 16.
• [983] Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.Oncol Rep. 2011 Sep;26(3):703-10. doi: 10.3892/or.2011.1337. Epub 2011 Jun 6.
• [984] Long noncoding RNA SNHG14 enhances migration and invasion of ovarian cancer by upregulating DGCR8.Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10226-10233. doi: 10.26355/eurrev_201912_19659.
• [985] Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.Epigenetics. 2020 Jan-Feb;15(1-2):122-133. doi: 10.1080/15592294.2019.1656155. Epub 2019 Sep 3.
• [986] Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.J Exp Clin Cancer Res. 2013 Aug 30;32(1):60. doi: 10.1186/1756-9966-32-60.
• [987] MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.Cancer Biol Ther. 2019;20(6):897-911. doi: 10.1080/15384047.2019.1579960. Epub 2019 Mar 12.
• [988] DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-/SMAD4 signaling.Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.
• [989] Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
• [990] The DNA2 nuclease/helicase is an estrogen-dependent gene mutated in breast and ovarian cancers.Oncotarget. 2014 Oct 15;5(19):9396-409. doi: 10.18632/oncotarget.2414.
• [991] Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.Mol Oncol. 2016 Jun;10(6):789-805. doi: 10.1016/j.molonc.2016.01.003. Epub 2016 Jan 29.
• [992] Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.Carcinogenesis. 2004 May;25(5):693-701. doi: 10.1093/carcin/bgh066. Epub 2004 Jan 16.
• [993] Erratum: Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum].Onco Targets Ther. 2019 Nov 15;12:9793. doi: 10.2147/OTT.S236659. eCollection 2019.
• [994] Elmo1 helps dock180 to regulate Rac1 activity and cell migration of ovarian cancer.Int J Gynecol Cancer. 2014 Jun;24(5):844-50. doi: 10.1097/IGC.0000000000000137.
• [995] DOCK4, a GTPase activator, is disrupted during tumorigenesis.Cell. 2003 Mar 7;112(5):673-84. doi: 10.1016/s0092-8674(03)00155-7.
• [996] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [997] Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6716-23. eCollection 2015.
• [998] Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer.Cancer Manag Res. 2019 Jul 1;11:5925-5938. doi: 10.2147/CMAR.S205158. eCollection 2019.
• [999] E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.Cancer Sci. 2019 Mar;110(3):1085-1095. doi: 10.1111/cas.13920. Epub 2019 Jan 25.
• [1000] The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.Fam Cancer. 2009;8(4):399-402. doi: 10.1007/s10689-009-9255-7. Epub 2009 Jun 11.
• [1001] Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.Anticancer Res. 2017 Aug;37(8):4415-4424. doi: 10.21873/anticanres.11836.
• [1002] Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.Mol Carcinog. 2016 Jun;55(6):1048-59. doi: 10.1002/mc.22349. Epub 2015 Aug 10.
• [1003] eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.Oncotarget. 2015 Sep 22;6(28):25441-51. doi: 10.18632/oncotarget.4555.
• [1004] Identifying Gene Network Rewiring by Integrating Gene Expression and Gene Network Data.IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):2079-2085. doi: 10.1109/TCBB.2018.2809603. Epub 2018 Feb 26.
• [1005] ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.
• [1006] ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.Oncol Rep. 2017 Mar;37(3):1412-1418. doi: 10.3892/or.2017.5418. Epub 2017 Feb 2.
• [1007] NF-B1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Oncotarget. 2017 Apr 11;8(15):24853-24868. doi: 10.18632/oncotarget.15267.
• [1008] TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.Oncol Rep. 2016 Jan;35(1):359-65. doi: 10.3892/or.2015.4388. Epub 2015 Nov 3.
• [1009] Neutrophil elastase-dependent cleavage compromises the tumor suppressor role of EMILIN1.Matrix Biol. 2014 Feb;34:22-32. doi: 10.1016/j.matbio.2014.01.018. Epub 2014 Feb 7.
• [1010] Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5.
• [1011] rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.Int J Mol Sci. 2018 Aug 21;19(9):2473. doi: 10.3390/ijms19092473.
• [1012] circEPSTI1 regulates ovarian cancer progression via decoying miR-942.J Cell Mol Med. 2019 May;23(5):3597-3602. doi: 10.1111/jcmm.14260. Epub 2019 Mar 19.
• [1013] Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial.Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: 10.1097/IGC.0000000000000982.
• [1014] Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.Int J Cancer. 2007 Jan 1;120(1):81-90. doi: 10.1002/ijc.22256.
• [1015] ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Oncogenesis. 2017 Oct 9;6(10):e389. doi: 10.1038/oncsis.2017.87.
• [1016] Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
• [1017] PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.Mol Cancer Res. 2007 May;5(5):413-21. doi: 10.1158/1541-7786.MCR-07-0019. Epub 2007 May 2.
• [1018] Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.Mol Cancer Res. 2012 Jul;10(7):914-24. doi: 10.1158/1541-7786.MCR-11-0449. Epub 2012 May 15.
• [1019] LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway.Exp Ther Med. 2017 Jun;13(6):2819-2827. doi: 10.3892/etm.2017.4343. Epub 2017 Apr 18.
• [1020] TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.
• [1021] Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming.Cell Death Dis. 2017 Jun 8;8(6):e2870. doi: 10.1038/cddis.2017.273.
• [1022] Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR?46/VAMP2 and miR?47/MDM2 signaling pathways.Oncol Rep. 2019 Dec;42(6):2728-2737. doi: 10.3892/or.2019.7366. Epub 2019 Oct 10.
• [1023] The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.
• [1024] FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.BMC Med Genet. 2018 Jan 19;19(1):12. doi: 10.1186/s12881-018-0524-x.
• [1025] Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer.J Clin Pathol. 2016 Feb;69(2):109-16. doi: 10.1136/jclinpath-2015-203129. Epub 2015 Aug 6.
• [1026] Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.Oncol Rep. 2019 Apr;41(4):2321-2328. doi: 10.3892/or.2019.6986. Epub 2019 Jan 28.
• [1027] Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.Int J Oncol. 2000 Jul;17(1):103-6. doi: 10.3892/ijo.17.1.103.
• [1028] FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming.J Cell Biochem. 2018 Nov;119(10):8174-8189. doi: 10.1002/jcb.26820. Epub 2018 Jun 15.
• [1029] POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.PLoS One. 2010 Nov 4;5(11):e13837. doi: 10.1371/journal.pone.0013837.
• [1030] FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling.J Immunol Res. 2018 Feb 20;2018:7438608. doi: 10.1155/2018/7438608. eCollection 2018.
• [1031] miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer.Cell Death Dis. 2019 May 8;10(5):372. doi: 10.1038/s41419-019-1604-3.
• [1032] Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1LC103 gene combined with low-dose cisplatin on ovarian cancer.Oncotarget. 2017 Jul 22;8(44):76432-76442. doi: 10.18632/oncotarget.19464. eCollection 2017 Sep 29.
• [1033] Flotillin 1 is differentially expressed in human epithelial ovarian tumors.Neoplasma. 2018;65(4):561-571. doi: 10.4149/neo_2018_170714N483.
• [1034] MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.Cell Cycle. 2018;17(21-22):2474-2483. doi: 10.1080/15384101.2018.1542898. Epub 2018 Nov 18.
• [1035] miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.Cancer Res. 2018 Aug 1;78(15):4175-4190. doi: 10.1158/0008-5472.CAN-17-3014. Epub 2018 May 10.
• [1036] FOXK1 facilitates cell proliferation through regulating the expression of p21, and promotes metastasis in ovarian cancer.Oncotarget. 2017 Jul 31;8(41):70441-70451. doi: 10.18632/oncotarget.19713. eCollection 2017 Sep 19.
• [1037] Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.Int J Biochem Cell Biol. 2016 Mar;72:51-54. doi: 10.1016/j.biocel.2016.01.003. Epub 2016 Jan 11.
• [1038] The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.Mol Cancer Res. 2015 Mar;13(3):502-9. doi: 10.1158/1541-7786.MCR-14-0407. Epub 2014 Nov 3.
• [1039] MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway.Clin Chim Acta. 2017 Oct;473:237-244. doi: 10.1016/j.cca.2017.07.008. Epub 2017 Jul 8.
• [1040] c-Fos mediates 1, 2-fucosyltransferase 1 and Lewisy expression in response to TGF-1 in ovarian cancer.Oncol Rep. 2017 Dec;38(6):3355-3366. doi: 10.3892/or.2017.6052. Epub 2017 Oct 23.
• [1041] A FXYD5/TGF?SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.Int J Oncol. 2020 Jan;56(1):301-314. doi: 10.3892/ijo.2019.4911. Epub 2019 Nov 13.
• [1042] Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.
• [1043] The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.PLoS One. 2015 Sep 30;10(9):e0138692. doi: 10.1371/journal.pone.0138692. eCollection 2015.
• [1044] MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.Biomed Pharmacother. 2016 May;80:381-387. doi: 10.1016/j.biopha.2015.12.027. Epub 2016 Apr 8.
• [1045] GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.Oncotarget. 2017 Jun 27;8(26):42588-42601. doi: 10.18632/oncotarget.16585.
• [1046] Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers.Clin Genet. 2020 Jan;97(1):64-72. doi: 10.1111/cge.13630. Epub 2019 Aug 28.
• [1047] The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.
• [1048] MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/-catenin signaling pathway in ovarian cancer.Oncol Lett. 2019 Mar;17(3):2631-2638. doi: 10.3892/ol.2019.9923. Epub 2019 Jan 14.
• [1049] GEN-1 immunotherapy for the treatment of ovarian cancer.Future Oncol. 2019 Feb;15(4):421-438. doi: 10.2217/fon-2018-0423. Epub 2018 Oct 16.
• [1050] ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.Gynecol Oncol. 2017 Nov;147(2):418-425. doi: 10.1016/j.ygyno.2017.08.025. Epub 2017 Aug 31.
• [1051] Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.Horm Metab Res. 2011 Oct;43(11):816-20. doi: 10.1055/s-0031-1287766. Epub 2011 Oct 18.
• [1052] Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.J Ovarian Res. 2019 Nov 8;12(1):106. doi: 10.1186/s13048-019-0580-7.
• [1053] Therapeutic implications of GIPC1 silencing in cancer.PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.
• [1054] The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4039-4044.
• [1055] The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-B signaling pathway.J Exp Clin Cancer Res. 2017 Oct 4;36(1):137. doi: 10.1186/s13046-017-0607-0.
• [1056] Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways.Theranostics. 2018 Jan 1;8(2):423-436. doi: 10.7150/thno.22377. eCollection 2018.
• [1057] GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.Oncogene. 2018 Nov;37(44):5873-5886. doi: 10.1038/s41388-018-0377-y. Epub 2018 Jul 4.
• [1058] Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10403-10407. doi: 10.1073/pnas.0602971103. Epub 2006 Jun 26.
• [1059] The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.
• [1060] Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.
• [1061] A natural entkaurane diterpenoid induces antiproliferation in ovarian cancer cells via ERK1/2 regulation and inhibition of cellular migration and invasion.Mol Med Rep. 2018 Oct;18(4):3898-3906. doi: 10.3892/mmr.2018.9377. Epub 2018 Aug 9.
• [1062] HPIP Silencing Prevents Epithelial-Mesenchymal Transition Induced by TGF-1 in Human Ovarian Cancer Cells.Oncol Res. 2016;24(1):33-9. doi: 10.3727/096504016X14575597858654.
• [1063] Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.Cancer Lett. 2017 Dec 28;411:65-73. doi: 10.1016/j.canlet.2017.09.048. Epub 2017 Oct 6.
• [1064] Screening of HELQ in breast and ovarian cancer families.Fam Cancer. 2016 Jan;15(1):19-23. doi: 10.1007/s10689-015-9838-4.
• [1065] LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A.J Cell Physiol. 2020 Apr;235(4):3939-3949. doi: 10.1002/jcp.29289. Epub 2019 Oct 9.
• [1066] T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.
• [1067] Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.Hum Immunol. 2018 Jun;79(6):463-470. doi: 10.1016/j.humimm.2018.02.012. Epub 2018 Mar 2.
• [1068] Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.J Immunol Res. 2014;2014:326593. doi: 10.1155/2014/326593. Epub 2014 Apr 27.
• [1069] Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.Biochem Biophys Res Commun. 2018 Jun 22;501(2):380-386. doi: 10.1016/j.bbrc.2018.04.203. Epub 2018 May 10.
• [1070] SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.Oncol Rep. 2019 Dec;42(6):2706-2715. doi: 10.3892/or.2019.7379. Epub 2019 Oct 17.
• [1071] Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.Cancer Res. 2019 Jul 1;79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. Epub 2019 May 6.
• [1072] Increased RHAMM expression relates to ovarian cancer progression.J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.
• [1073] MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4663-4672. doi: 10.26355/eurrev_201906_18046.
• [1074] HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.
• [1075] Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
• [1076] Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression.Oncotarget. 2017 Oct 13;8(61):103410-103414. doi: 10.18632/oncotarget.21902. eCollection 2017 Nov 28.
• [1077] Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.
• [1078] Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer.Med Sci Monit. 2018 Jun 12;24:3997-4008. doi: 10.12659/MSM.909418.
• [1079] HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer.Sci Rep. 2019 Sep 2;9(1):12628. doi: 10.1038/s41598-019-48992-7.
• [1080] Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease.Cytokine. 2017 Jan;89:136-142. doi: 10.1016/j.cyto.2016.01.017. Epub 2016 Feb 8.
• [1081] Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.Am J Cancer Res. 2017 Jun 1;7(6):1252-1269. eCollection 2017.
• [1082] High-temperature requirement factor A3 (Htra3): a novel serine protease and its potential role in ovarian function and ovarian cancers.Mol Cell Endocrinol. 2010 Oct 7;327(1-2):13-8. doi: 10.1016/j.mce.2010.06.001. Epub 2010 Jun 9.
• [1083] Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade.Cancer Res. 2017 Sep 15;77(18):4773-4784. doi: 10.1158/0008-5472.CAN-16-2597. Epub 2017 Jul 7.
• [1084] Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.Biochem Biophys Res Commun. 2018 Jun 22;501(2):556-562. doi: 10.1016/j.bbrc.2018.05.038. Epub 2018 May 11.
• [1085] Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.
• [1086] Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
• [1087] Epigenetic and genetic alterations of p33ING1b in ovarian cancer.Carcinogenesis. 2005 Apr;26(4):855-63. doi: 10.1093/carcin/bgi011. Epub 2005 Jan 27.
• [1088] MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.J Ovarian Res. 2017 Jan 11;10(1):1. doi: 10.1186/s13048-016-0301-4.
• [1089] Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer.Int J Gynecol Cancer. 2002 Sep-Oct;12(5):443-7. doi: 10.1046/j.1525-1438.2002.01143.x.
• [1090] Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.Oncotarget. 2015 Apr 30;6(12):10548-62. doi: 10.18632/oncotarget.3307.
• [1091] Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics.Oncogene. 2002 Mar 14;21(12):1882-9. doi: 10.1038/sj.onc.1205265.
• [1092] Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/-catenin signaling.Int J Oncol. 2016 Jan;48(1):153-60. doi: 10.3892/ijo.2015.3228. Epub 2015 Nov 4.
• [1093] Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.Cancer Biomark. 2020;27(1):51-61. doi: 10.3233/CBM-190460.
• [1094] Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.Gynecol Oncol. 2016 Mar;140(3):545-53. doi: 10.1016/j.ygyno.2015.12.006. Epub 2015 Dec 12.
• [1095] Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.J Cell Mol Med. 2019 Jun;23(6):4005-4018. doi: 10.1111/jcmm.14286. Epub 2019 Apr 16.
• [1096] Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.Mol Med Rep. 2017 Sep;16(3):3600-3605. doi: 10.3892/mmr.2017.7024. Epub 2017 Jul 17.
• [1097] Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.Signal Transduct Target Ther. 2019 Jul 26;4:24. doi: 10.1038/s41392-019-0055-8. eCollection 2019.
• [1098] Intestinal stem cell overproliferation resulting from inactivation of the APC tumor suppressor requires the transcription cofactors Earthbound and Erect wing.PLoS Genet. 2017 Jul 14;13(7):e1006870. doi: 10.1371/journal.pgen.1006870. eCollection 2017 Jul.
• [1099] GCN-5/PGC-1 signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.Aging (Albany NY). 2019 Jul 17;11(14):4890-4899. doi: 10.18632/aging.102082.
• [1100] HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells.Nanomedicine. 2019 Apr;17:254-265. doi: 10.1016/j.nano.2019.01.017. Epub 2019 Feb 10.
• [1101] Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis.Oncol Rep. 2015 Feb;33(2):685-92. doi: 10.3892/or.2014.3649. Epub 2014 Dec 5.
• [1102] Clinical relevance of cytoskeleton associated proteins for ovarian cancer.J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.
• [1103] The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.Oncogene. 2019 Feb;38(7):1080-1092. doi: 10.1038/s41388-018-0490-y. Epub 2018 Sep 11.
• [1104] miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.
• [1105] The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Oncogene. 2017 May 4;36(18):2565-2576. doi: 10.1038/onc.2016.412. Epub 2016 Nov 21.
• [1106] Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell Cycle. 2019 Jul;18(14):1601-1618. doi: 10.1080/15384101.2019.1624112. Epub 2019 Jun 9.
• [1107] Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer.Cell Physiol Biochem. 2018;50(3):810-822. doi: 10.1159/000494467. Epub 2018 Oct 23.
• [1108] KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries.J Ovarian Res. 2014 May 12;7:53. doi: 10.1186/1757-2215-7-53. eCollection 2014.
• [1109] LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):201-208. doi: 10.26355/eurrev_201908_18648.
• [1110] Long non-coding RNA OR3A4 promotes metastasis of ovarian cancer via inhibiting KLF6.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2360-2365. doi: 10.26355/eurrev_201903_17380.
• [1111] Lentivirus-mediated knockdown of Krppel-like factor 9 inhibits the growth of ovarian cancer.Arch Gynecol Obstet. 2015 Feb;291(2):377-82. doi: 10.1007/s00404-014-3405-3. Epub 2014 Sep 13.
• [1112] Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer.Clin Cancer Res. 2004 Apr 15;10(8):2766-70. doi: 10.1158/1078-0432.ccr-03-0269.
• [1113] A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.BMC Cancer. 2011 Apr 1;11:119. doi: 10.1186/1471-2407-11-119.
• [1114] Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.
• [1115] Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.
• [1116] Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer.Nat Genet. 1994 Jan;6(1):106-10. doi: 10.1038/ng0194-106.
• [1117] Correlation of LAMA3 with onset and prognosis of ovarian cancer.Oncol Lett. 2019 Sep;18(3):2813-2818. doi: 10.3892/ol.2019.10600. Epub 2019 Jul 10.
• [1118] LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.Tumour Biol. 2017 Mar;39(3):1010428317695014. doi: 10.1177/1010428317695014.
• [1119] La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells.Tohoku J Exp Med. 2019 Jan;247(1):59-67. doi: 10.1620/tjem.247.59.
• [1120] Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.Arch Pharm Res. 2004 Jun;27(6):633-9. doi: 10.1007/BF02980163.
• [1121] Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/-Catenin Signaling in Ovarian Cancer.Mol Ther Oncolytics. 2019 Apr 19;14:94-106. doi: 10.1016/j.omto.2019.04.002. eCollection 2019 Sep 27.
• [1122] Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.Oncotarget. 2016 Jan 12;7(2):1408-20. doi: 10.18632/oncotarget.6368.
• [1123] Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.Br J Cancer. 2015 Jul 28;113(3):414-24. doi: 10.1038/bjc.2015.254. Epub 2015 Jul 9.
• [1124] Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer.J Cell Physiol. 2019 Jul;234(7):10800-10808. doi: 10.1002/jcp.27903. Epub 2018 Dec 7.
• [1125] LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24.
• [1126] Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.J Clin Invest. 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18.
• [1127] LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.Cancer Res. 2012 Aug 15;72(16):4060-73. doi: 10.1158/0008-5472.CAN-12-0203.
• [1128] Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.Arch Pathol Lab Med. 1988 Feb;112(2):151-4.
• [1129] A multiple mixed TiO(2) mesocrystal junction based PEC-colorimetric immunoassay for specific recognition of lipolysis stimulated lipoprotein receptor.Biosens Bioelectron. 2020 Jan 15;148:111809. doi: 10.1016/j.bios.2019.111809. Epub 2019 Oct 26.
• [1130] Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis.Arch Gynecol Obstet. 2016 Feb;293(2):421-7. doi: 10.1007/s00404-015-3833-8. Epub 2015 Aug 12.
• [1131] The significance of lumican expression in ovarian cancer drug-resistant cell lines.Oncotarget. 2017 Aug 10;8(43):74466-74478. doi: 10.18632/oncotarget.20169. eCollection 2017 Sep 26.
• [1132] Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys.Int J Cancer. 1996 Jan 26;65(3):284-94. doi: 10.1002/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W.
• [1133] Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.J Exp Clin Cancer Res. 2011 Sep 16;30(1):83. doi: 10.1186/1756-9966-30-83.
• [1134] The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
• [1135] Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.Br J Cancer. 2019 Nov;121(11):944-953. doi: 10.1038/s41416-019-0607-2. Epub 2019 Oct 29.
• [1136] Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.Sci Rep. 2017 Feb 7;7:41977. doi: 10.1038/srep41977.
• [1137] MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.Int J Gynecol Cancer. 2017 Jul;27(6):1082-1087. doi: 10.1097/IGC.0000000000001003.
• [1138] MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells.Autophagy. 2017 Feb;13(2):333-344. doi: 10.1080/15548627.2016.1256520. Epub 2016 Nov 22.
• [1139] Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.Cell Physiol Biochem. 2018;47(2):654-666. doi: 10.1159/000490020. Epub 2018 May 22.
• [1140] Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma.PLoS One. 2013;8(3):e54643. doi: 10.1371/journal.pone.0054643. Epub 2013 Mar 5.
• [1141] MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.Tumour Biol. 2015 Jun;36(6):4261-9. doi: 10.1007/s13277-015-3063-5. Epub 2015 Jan 16.
• [1142] Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Reproduction. 2017 Mar;153(3):277-284. doi: 10.1530/REP-16-0265. Epub 2016 Dec 13.
• [1143] Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.PLoS One. 2012;7(5):e36054. doi: 10.1371/journal.pone.0036054. Epub 2012 May 2.
• [1144] METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
• [1145] The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.J Biol Chem. 2017 Sep 29;292(39):16351-16359. doi: 10.1074/jbc.M117.783936. Epub 2017 Aug 23.
• [1146] Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition.Cancer Lett. 2015 Jul 10;363(1):71-82. doi: 10.1016/j.canlet.2015.04.002. Epub 2015 Apr 9.
• [1147] MICU1 drives glycolysis and chemoresistance in ovarian cancer.Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.
• [1148] Involvement of AF1q/MLLT11 in the progression of ovarian cancer.Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.
• [1149] Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.Sci Rep. 2019 Aug 12;9(1):11677. doi: 10.1038/s41598-019-47871-5.
• [1150] Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.Oncogene. 2017 Mar 23;36(12):1698-1706. doi: 10.1038/onc.2016.336. Epub 2016 Oct 10.
• [1151] MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.Oncol Rep. 2019 Aug;42(2):679-687. doi: 10.3892/or.2019.7199. Epub 2019 Jun 12.
• [1152] Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
• [1153] Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Clin Cancer Res. 2016 Jun 15;22(12):3097-3104. doi: 10.1158/1078-0432.CCR-15-1669. Epub 2016 Jan 13.
• [1154] A low cost PS based microfluidic platform to investigate cell cycle towards developing a therapeutic strategy for cancer.Biomed Microdevices. 2018 Jul 5;20(3):57. doi: 10.1007/s10544-018-0302-8.
• [1155] Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.Yonsei Med J. 2014 Sep;55(5):1206-13. doi: 10.3349/ymj.2014.55.5.1206.
• [1156] MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells.Br J Cancer. 2008 Aug 5;99(3):520-6. doi: 10.1038/sj.bjc.6604517.
• [1157] MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.Biochem Biophys Res Commun. 2016 Aug 5;476(4):493-500. doi: 10.1016/j.bbrc.2016.05.152. Epub 2016 May 30.
• [1158] Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.Am J Pathol. 2003 May;162(5):1603-10. doi: 10.1016/S0002-9440(10)64294-0.
• [1159] Diverse functions of myosin VI elucidated by an isoform-specific -helix domain.Nat Struct Mol Biol. 2016 Apr;23(4):300-308. doi: 10.1038/nsmb.3187. Epub 2016 Mar 7.
• [1160] Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.
• [1161] Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.Int J Cancer. 2004 Oct 20;112(1):150-4. doi: 10.1002/ijc.20339.
• [1162] Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis.Br J Cancer. 1997;75(3):396-402. doi: 10.1038/bjc.1997.64.
• [1163] Cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4.Tumori. 1994 Dec 31;80(6):473-9. doi: 10.1177/030089169408000613.
• [1164] [Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.Int J Oncol. 2017 Jun;50(6):2236. doi: 10.3892/ijo.2017.3977. Epub 2017 Apr 27.
• [1165] New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).Eur J Pharmacol. 2019 Jun 5;852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2.
• [1166] Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas.Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):605-610. doi: 10.1097/PAI.0000000000000510.
• [1167] Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.Hum Mutat. 2003 Jun;21(6):654. doi: 10.1002/humu.9148.
• [1168] High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
• [1169] Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.Acta Pharmacol Sin. 2013 Apr;34(4):541-8. doi: 10.1038/aps.2012.197. Epub 2013 Mar 11.
• [1170] NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.Oncotarget. 2016 Jan 19;7(3):3018-32. doi: 10.18632/oncotarget.6576.
• [1171] Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?.Cancer Sci. 2019 Jun;110(6):1872-1882. doi: 10.1111/cas.13992. Epub 2019 May 2.
• [1172] Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
• [1173] Deregulation of sialidases in human normal and tumor tissues.Cancer Biomark. 2018 Feb 14;21(3):591-601. doi: 10.3233/CBM-170548.
• [1174] NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.Tumour Biol. 2016 Apr;37(4):4493-500. doi: 10.1007/s13277-015-4245-x. Epub 2015 Oct 26.
• [1175] Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells.Oncotarget. 2017 Jul 25;8(55):93502-93515. doi: 10.18632/oncotarget.19548. eCollection 2017 Nov 7.
• [1176] NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.Oncotarget. 2017 May 16;8(20):33110-33121. doi: 10.18632/oncotarget.16145.
• [1177] Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer.Gynecol Obstet Invest. 2018;83(5):461-465. doi: 10.1159/000481798. Epub 2017 Nov 7.
• [1178] Diagnostic Utility of Thyroid Transcription Factor-1 in Ovarian Carcinoma and Its Relationship With Clinicopathologic Prognostic Parameters.Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):237-243. doi: 10.1097/PAI.0000000000000301.
• [1179] Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFB Activation.Mol Cancer Res. 2018 Jun;16(6):986-999. doi: 10.1158/1541-7786.MCR-17-0603. Epub 2018 Mar 9.
• [1180] Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor.Tumour Biol. 2015 Mar;36(3):1429-35. doi: 10.1007/s13277-014-2187-3. Epub 2015 Jan 22.
• [1181] Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.Biomed Pharmacother. 2017 Jan;85:248-255. doi: 10.1016/j.biopha.2016.11.012. Epub 2016 Nov 28.
• [1182] E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156.
• [1183] NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.Tumour Biol. 2017 Sep;39(9):1010428317714631. doi: 10.1177/1010428317714631.
• [1184] Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer.Pharmacogenet Genomics. 2017 Jul;27(7):264-269. doi: 10.1097/FPC.0000000000000288.
• [1185] Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
• [1186] Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.J Biol Chem. 2016 Sep 2;291(36):18897-914. doi: 10.1074/jbc.M116.734533. Epub 2016 Jul 11.
• [1187] Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.Clin Chem Lab Med. 2014 May;52(5):735-42. doi: 10.1515/cclm-2013-0736.
• [1188] The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001 Apr;7(4):806-11.
• [1189] The non-coding RNA OTUB1-isoform2 promotes ovarian tumour progression and predicts poor prognosis.J Cell Mol Med. 2018 Oct;22(10):4794-4806. doi: 10.1111/jcmm.13733. Epub 2018 Jul 25.
• [1190] Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.Drug Deliv. 2018 Nov;25(1):995-1003. doi: 10.1080/10717544.2018.1461956.
• [1191] hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells.Oncotarget. 2017 Feb 28;8(9):14806-14820. doi: 10.18632/oncotarget.14775.
• [1192] miR-193b-3p possesses anti-tumor activity in ovarian carcinoma cells by targeting p21-activated kinase 3.Biomed Pharmacother. 2017 Dec;96:1275-1282. doi: 10.1016/j.biopha.2017.11.086. Epub 2017 Nov 21.
• [1193] PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.Anal Cell Pathol (Amst). 2018 Sep 2;2018:8073124. doi: 10.1155/2018/8073124. eCollection 2018.
• [1194] AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.Mol Med Rep. 2017 Oct;16(4):5151-5156. doi: 10.3892/mmr.2017.7286. Epub 2017 Aug 18.
• [1195] Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.PLoS One. 2019 Nov 21;14(11):e0224564. doi: 10.1371/journal.pone.0224564. eCollection 2019.
• [1196] An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.Int J Cancer. 2009 Jan 15;124(2):387-93. doi: 10.1002/ijc.23957.
• [1197] UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Aug 8;10(8):262. doi: 10.3390/cancers10080262.
• [1198] PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.Oncol Rep. 2016 Jan;35(1):488-96. doi: 10.3892/or.2015.4396. Epub 2015 Nov 4.
• [1199] Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1.Cancer Res. 2016 Nov 1;76(21):6351-6361. doi: 10.1158/0008-5472.CAN-16-0980. Epub 2016 Sep 2.
• [1200] Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.Cancer Biomark. 2018;23(1):125-133. doi: 10.3233/CBM-181493.
• [1201] Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer.Int J Gynecol Cancer. 2018 Feb;28(2):346-354. doi: 10.1097/IGC.0000000000001169.
• [1202] MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.Onco Targets Ther. 2019 Oct 8;12:8329-8338. doi: 10.2147/OTT.S220339. eCollection 2019.
• [1203] PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.Int J Cancer. 2018 Dec 1;143(11):2973-2984. doi: 10.1002/ijc.31800. Epub 2018 Oct 4.
• [1204] Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.
• [1205] Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.Nanoscale. 2017 Sep 14;9(35):13142-13152. doi: 10.1039/c7nr04473a.
• [1206] ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.Int J Oncol. 2019 Jan;54(1):249-260. doi: 10.3892/ijo.2018.4628. Epub 2018 Nov 7.
• [1207] Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.J Cell Biochem. 2019 Apr;120(4):6057-6070. doi: 10.1002/jcb.27892. Epub 2018 Oct 18.
• [1208] Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer.Cancer Manag Res. 2018 Dec 24;11:251-262. doi: 10.2147/CMAR.S185015. eCollection 2019.
• [1209] PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.Life Sci. 2019 Sep 15;233:116715. doi: 10.1016/j.lfs.2019.116715. Epub 2019 Jul 31.
• [1210] Immunohistochemical investigation of the correlation between LIM kinase 1 expression and development and progression of human ovarian carcinoma.J Int Med Res. 2012;40(3):1067-73. doi: 10.1177/147323001204000325.
• [1211] MAP17 overexpression is a common characteristic of carcinomas.Carcinogenesis. 2007 Aug;28(8):1646-52. doi: 10.1093/carcin/bgm083. Epub 2007 Apr 9.
• [1212] Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.Cancer. 2008 Apr 1;112(7):1489-502. doi: 10.1002/cncr.23323.
• [1213] Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18.
• [1214] miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma.FASEB J. 2018 Jun 6:fj201800495RR. doi: 10.1096/fj.201800495RR. Online ahead of print.
• [1215] PHLDA1, another PHLDA family protein that inhibits Akt.Cancer Sci. 2018 Nov;109(11):3532-3542. doi: 10.1111/cas.13796. Epub 2018 Oct 13.
• [1216] Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Oncogene. 2015 Jan 15;34(3):373-83. doi: 10.1038/onc.2013.562. Epub 2014 Jan 27.
• [1217] PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7.
• [1218] Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF- and Activin-A.Mol Cancer. 2015 Aug 23;14:162. doi: 10.1186/s12943-015-0433-y.
• [1219] PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer.Biochem Biophys Res Commun. 2019 Jan 8;508(2):646-653. doi: 10.1016/j.bbrc.2018.11.163. Epub 2018 Dec 4.
• [1220] Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells.J Cell Sci. 2007 Apr 15;120(Pt 8):1393-404. doi: 10.1242/jcs.000018. Epub 2007 Mar 20.
• [1221] Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.Gynecol Oncol. 2004 Dec;95(3):449-55. doi: 10.1016/j.ygyno.2004.08.051.
• [1222] MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2.Reprod Biol. 2018 Sep;18(3):218-224. doi: 10.1016/j.repbio.2018.07.005. Epub 2018 Jul 24.
• [1223] EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.Mol Carcinog. 2003 Dec;38(4):188-200. doi: 10.1002/mc.10162.
• [1224] The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841.
• [1225] Identification of potential prognostic TF-associated lncRNAs for predicting survival in ovarian cancer.J Cell Mol Med. 2019 Mar;23(3):1840-1851. doi: 10.1111/jcmm.14084. Epub 2018 Dec 13.
• [1226] Epigenetic activation of POTE genes in ovarian cancer.Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
• [1227] Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Feb;241(2):165-173. doi: 10.1620/tjem.241.165.
• [1228] The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.Cell Tissue Res. 2018 Dec;374(3):577-585. doi: 10.1007/s00441-018-2906-y. Epub 2018 Sep 4.
• [1229] Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression.Mol Med Rep. 2018 May;17(5):6285-6292. doi: 10.3892/mmr.2018.8714. Epub 2018 Mar 9.
• [1230] MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016 Feb;77:92-7.
• [1231] Age is associated with prognosis in serous ovarian carcinoma.J Ovarian Res. 2017 Jun 12;10(1):36. doi: 10.1186/s13048-017-0331-6.
• [1232] Frequent loss of pRb2/p130 in human ovarian carcinoma.Clin Cancer Res. 2004 May 1;10(9):3098-103. doi: 10.1158/1078-0432.ccr-03-0524.
• [1233] Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
• [1234] Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.Biochem Biophys Res Commun. 2019 Feb 5;509(2):373-378. doi: 10.1016/j.bbrc.2018.12.127. Epub 2018 Dec 25.
• [1235] PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.
• [1236] Long non-coding RNA RP11-552M11.4 favors tumorigenesis and development of cervical cancer via modulating miR-3941/ATF1 signaling.Int J Biol Macromol. 2019 Jun 1;130:24-33. doi: 10.1016/j.ijbiomac.2019.02.083. Epub 2019 Feb 18.
• [1237] PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/-Catenin Pathway.Cell Physiol Biochem. 2018;49(2):696-705. doi: 10.1159/000493034. Epub 2018 Aug 30.
• [1238] PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.J Mol Med (Berl). 2019 May;97(5):691-709. doi: 10.1007/s00109-019-01763-3. Epub 2019 Mar 25.
• [1239] PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.Gynecol Oncol. 2015 Jun;137(3):546-52. doi: 10.1016/j.ygyno.2015.02.022. Epub 2015 Feb 28.
• [1240] PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis.Arch Gynecol Obstet. 2016 Jun;293(6):1297-307. doi: 10.1007/s00404-015-3904-x. Epub 2015 Oct 6.
• [1241] The Effect of PTCH1 on Ovarian Cancer Cell Proliferation and Apoptosis.Cancer Biother Radiopharm. 2019 Mar;34(2):103-109. doi: 10.1089/cbr.2018.2626. Epub 2018 Dec 6.
• [1242] PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.Stem Cell Rev Rep. 2019 Dec;15(6):866-879. doi: 10.1007/s12015-019-09911-5.
• [1243] circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p.Mol Ther Nucleic Acids. 2019 Dec 6;18:882-892. doi: 10.1016/j.omtn.2019.09.032. Epub 2019 Oct 23.
• [1244] High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.Ann Diagn Pathol. 2018 Jun;34:161-165. doi: 10.1016/j.anndiagpath.2018.03.002. Epub 2018 Mar 14.
• [1245] Epigenetic inactivation of TMS1/ASC in ovarian cancer.Clin Cancer Res. 2004 Mar 15;10(6):2000-6. doi: 10.1158/1078-0432.ccr-0932-03.
• [1246] Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway.Oncol Lett. 2018 Apr;15(4):5155-5160. doi: 10.3892/ol.2018.7949. Epub 2018 Feb 5.
• [1247] Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer.Clin Cancer Res. 2009 Mar 15;15(6):2192-203. doi: 10.1158/1078-0432.CCR-08-1417. Epub 2009 Mar 10.
• [1248] Upregulation of Circular RNA VPS13C-has-circ-001567 Promotes Ovarian Cancer Cell Proliferation and Invasion.Cancer Biother Radiopharm. 2019 Mar;34(2):110-118. doi: 10.1089/cbr.2018.2641. Epub 2018 Oct 30.
• [1249] Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B.Nat Commun. 2015 Jan 8;6:5917. doi: 10.1038/ncomms6917.
• [1250] Frequent somatic demethylation of RAPGEF1/C3G intronic sequences in gastrointestinal and gynecological cancer.Int J Oncol. 2011 Jun;38(6):1575-7. doi: 10.3892/ijo.2011.972. Epub 2011 Mar 11.
• [1251] The HRAS1 minisatellite locus and risk of ovarian cancer.Cancer Res. 2000 Jan 15;60(2):259-61.
• [1252] Suppression of FIP200 and autophagy by tumor-derived lactate promotes nave T cell apoptosis and affects tumor immunity.Sci Immunol. 2017 Nov 17;2(17):eaan4631. doi: 10.1126/sciimmunol.aan4631.
• [1253] The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.Mol Carcinog. 2019 Feb;58(2):196-205. doi: 10.1002/mc.22919. Epub 2018 Oct 28.
• [1254] High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
• [1255] CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
• [1256] RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.FASEB J. 2019 Apr;33(4):5350-5365. doi: 10.1096/fj.201801529RR. Epub 2019 Feb 15.
• [1257] Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating Hippo pathway.Life Sci. 2018 Dec 15;215:73-79. doi: 10.1016/j.lfs.2018.10.070. Epub 2018 Nov 2.
• [1258] Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.PLoS One. 2014 Jan 27;9(1):e87455. doi: 10.1371/journal.pone.0087455. eCollection 2014.
• [1259] RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.Oncol Rep. 2019 Jan;41(1):165-177. doi: 10.3892/or.2018.6811. Epub 2018 Oct 22.
• [1260] The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.Gynecol Oncol. 2013 Sep;130(3):570-8. doi: 10.1016/j.ygyno.2013.06.004. Epub 2013 Jun 10.
• [1261] RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.J Exp Clin Cancer Res. 2018 Aug 3;37(1):182. doi: 10.1186/s13046-018-0854-8.
• [1262] Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.Gynecol Obstet Invest. 2019;84(6):591-598. doi: 10.1159/000501681. Epub 2019 Jul 16.
• [1263] Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.Int J Cancer. 2006 Mar 15;118(6):1565-71. doi: 10.1002/ijc.21520.
• [1264] Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.Oncol Rep. 2014 Jul;32(1):362-72. doi: 10.3892/or.2014.3175. Epub 2014 May 13.
• [1265] Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. doi: 10.1152/ajpcell.00283.2017. Epub 2018 May 2.
• [1266] Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.Cancer Res. 2019 Feb 15;79(4):760-772. doi: 10.1158/0008-5472.CAN-18-2297. Epub 2018 Dec 18.
• [1267] miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells.Cell Cycle. 2014;13(22):3519-28. doi: 10.4161/15384101.2014.958413.
• [1268] Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus.Genomics. 1999 Jul 1;59(1):97-101. doi: 10.1006/geno.1999.5864.
• [1269] Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.PLoS One. 2015 Nov 30;10(11):e0143659. doi: 10.1371/journal.pone.0143659. eCollection 2015.
• [1270] Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers.PLoS One. 2009;4(3):e5064. doi: 10.1371/journal.pone.0005064. Epub 2009 Mar 31.
• [1271] A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.
• [1272] MicroRNA-181 Functions as an Antioncogene and Mediates NF-B Pathway by Targeting RTKN2 in Ovarian Cancers.Reprod Sci. 2019 Aug;26(8):1071-1081. doi: 10.1177/1933719118805865. Epub 2018 Oct 11.
• [1273] Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.Exp Physiol. 2020 Jan;105(1):75-87. doi: 10.1113/EP087847. Epub 2019 Dec 9.
• [1274] Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.Int J Cancer. 2011 May 1;128(9):2063-74. doi: 10.1002/ijc.25554.
• [1275] H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.Mol Med. 1996 Mar;2(2):189-203.
• [1276] Prognostic values of S100 family mRNA expression in ovarian cancer.Cancer Biomark. 2019;25(1):67-78. doi: 10.3233/CBM-182276.
• [1277] S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.J Ovarian Res. 2019 Nov 18;12(1):113. doi: 10.1186/s13048-019-0592-3.
• [1278] Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):110-116. doi: 10.1097/PAI.0000000000000275.
• [1279] S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
• [1280] SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes.Mol Oncol. 2018 Jun;12(7):1026-1046. doi: 10.1002/1878-0261.12308. Epub 2018 May 21.
• [1281] SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.Oncol Rep. 2016 Mar;35(3):1796-806. doi: 10.3892/or.2016.4545. Epub 2016 Jan 5.
• [1282] SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression.Biol Chem. 2004 Sep;385(9):785-90. doi: 10.1515/BC.2004.102.
• [1283] Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33. doi: 10.1016/j.omtn.2019.07.012. Epub 2019 Jul 29.
• [1284] Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.J Biomed Inform. 2019 Dec;100:103313. doi: 10.1016/j.jbi.2019.103313. Epub 2019 Oct 23.
• [1285] Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.Gynecol Oncol. 2008 Apr;109(1):115-21. doi: 10.1016/j.ygyno.2007.12.030. Epub 2008 Feb 13.
• [1286] The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Clin Cancer Res. 2014 Dec 15;20(24):6504-16. doi: 10.1158/1078-0432.CCR-14-1553. Epub 2014 Oct 14.
• [1287] Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Gynecol Obstet Invest. 2018;83(5):508-514. doi: 10.1159/000479027. Epub 2017 Jul 22.
• [1288] Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry.Int J Hyperthermia. 2018;35(1):361-369. doi: 10.1080/02656736.2018.1503345. Epub 2018 Oct 9.
• [1289] Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.Int J Cancer. 2007 May 1;120(9):1863-73. doi: 10.1002/ijc.22300.
• [1290] SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.Cancer Lett. 2017 Jan 28;385:271-279. doi: 10.1016/j.canlet.2016.09.032. Epub 2016 Oct 3.
• [1291] AEG-1 Contributes to Metastasis in Hypoxia-Related Ovarian Cancer by Modulating the HIF-1alpha/NF-kappaB/VEGF Pathway.Biomed Res Int. 2018 Mar 25;2018:3145689. doi: 10.1155/2018/3145689. eCollection 2018.
• [1292] Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.Onco Targets Ther. 2019 Sep 11;12:7451-7457. doi: 10.2147/OTT.S220700. eCollection 2019.
• [1293] MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.J Zhejiang Univ Sci B. 2019 Mar.;20(3):219-237. doi: 10.1631/jzus.B1800190.
• [1294] Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.Int J Cancer. 2010 Aug 1;127(3):555-67. doi: 10.1002/ijc.25083.
• [1295] Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
• [1296] Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug.
• [1297] Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4760-5. doi: 10.1073/pnas.0831000100. Epub 2003 Apr 3.
• [1298] Bioinformatics analysis to screen the key prognostic genes in ovarian cancer.J Ovarian Res. 2017 Apr 13;10(1):27. doi: 10.1186/s13048-017-0323-6.
• [1299] Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.J Cell Biochem. 2019 Jun;120(6):10643-10651. doi: 10.1002/jcb.28354. Epub 2019 Jan 22.
• [1300] SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.Sci Rep. 2019 Jun 5;9(1):8295. doi: 10.1038/s41598-019-44826-8.
• [1301] SNAP23 promotes the malignant process of ovarian cancer.J Ovarian Res. 2016 Nov 17;9(1):80. doi: 10.1186/s13048-016-0289-9.
• [1302] Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018.
• [1303] The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.
• [1304] MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression.Int J Mol Sci. 2017 Jun 6;18(6):1208. doi: 10.3390/ijms18061208.
• [1305] SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).Med Sci Monit. 2019 Aug 20;25:6244-6254. doi: 10.12659/MSM.915729.
• [1306] Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.Tumour Biol. 2016 Sep;37(9):12263-12271. doi: 10.1007/s13277-016-5095-x. Epub 2016 Jun 1.
• [1307] Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.Tumour Biol. 2018 May;40(5):1010428318773652. doi: 10.1177/1010428318773652.
• [1308] Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.
• [1309] Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer.J Mol Histol. 2016 Feb;47(1):47-57. doi: 10.1007/s10735-015-9646-z. Epub 2015 Dec 7.
• [1310] Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(3):1061-1071. doi: 10.1159/000487348. Epub 2018 Feb 7.
• [1311] Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer.Aging (Albany NY). 2019 Dec 3;11(23):11416-11439. doi: 10.18632/aging.102538. Epub 2019 Dec 3.
• [1312] SPOP Regulates The Biological Mechanism Of Ovarian Cancer Cells Through The Hh Signaling Pathway.Onco Targets Ther. 2019 Nov 6;12:9239-9248. doi: 10.2147/OTT.S215940. eCollection 2019.
• [1313] Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.Sci Rep. 2018 Feb 6;8(1):2462. doi: 10.1038/s41598-018-20846-8.
• [1314] SPSB1 enhances ovarian cancer cell survival by destabilizing p21.Biochem Biophys Res Commun. 2019 Mar 12;510(3):364-369. doi: 10.1016/j.bbrc.2019.01.088. Epub 2019 Jan 31.
• [1315] Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.Mol Cancer. 2015 Aug 19;14:158. doi: 10.1186/s12943-015-0422-1.
• [1316] Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.
• [1317] Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-1-induced EMT and confers paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Oct 30;9(11):1102. doi: 10.1038/s41419-018-1101-0.
• [1318] Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer.Glycobiology. 2018 Nov 1;28(11):898-903. doi: 10.1093/glycob/cwy065.
• [1319] Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.Cancer Cell Int. 2019 Apr 5;19:86. doi: 10.1186/s12935-019-0780-7. eCollection 2019.
• [1320] Sequencing of a 'mouse azoospermia' gene panel in azoospermic men: identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest.Hum Reprod. 2019 Jun 4;34(6):978-988. doi: 10.1093/humrep/dez042.
• [1321] Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.Oncotarget. 2017 Apr 18;8(16):27380-27392. doi: 10.18632/oncotarget.16068.
• [1322] PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
• [1323] Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment.Anal Chem. 2014 May 6;86(9):4521-7. doi: 10.1021/ac500466x. Epub 2014 Apr 9.
• [1324] Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.Oncol Rep. 2015 Feb;33(2):774-82. doi: 10.3892/or.2014.3623. Epub 2014 Nov 25.
• [1325] Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.PLoS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860. eCollection 2019.
• [1326] CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.Oncogene. 2017 Jul 20;36(29):4191-4200. doi: 10.1038/onc.2017.31. Epub 2017 Mar 27.
• [1327] Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.Platelets. 2018 Dec;29(8):834-837. doi: 10.1080/09537104.2018.1530345. Epub 2018 Oct 18.
• [1328] SWAP-70: a new type of oncogene.PLoS One. 2013;8(3):e59245. doi: 10.1371/journal.pone.0059245. Epub 2013 Mar 12.
• [1329] RAD-ical New Insights into RAD51 Regulation.Genes (Basel). 2018 Dec 13;9(12):629. doi: 10.3390/genes9120629.
• [1330] Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
• [1331] Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-B pathway.Cell Prolif. 2016 Dec;49(6):657-668. doi: 10.1111/cpr.12293. Epub 2016 Sep 21.
• [1332] TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.Theranostics. 2019 Jan 24;9(3):676-690. doi: 10.7150/thno.30224. eCollection 2019.
• [1333] Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5251-5256. doi: 10.1007/s11033-019-04982-6. Epub 2019 Jul 18.
• [1334] TCF12 overexpression as a poor prognostic factor in ovarian cancer.Pathol Res Pract. 2019 Sep;215(9):152527. doi: 10.1016/j.prp.2019.152527. Epub 2019 Jul 7.
• [1335] Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.J Clin Med. 2019 Mar 8;8(3):330. doi: 10.3390/jcm8030330.
• [1336] TCTN2: a novel tumor marker with oncogenic properties.Oncotarget. 2017 Aug 24;8(56):95256-95269. doi: 10.18632/oncotarget.20438. eCollection 2017 Nov 10.
• [1337] Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.Int J Oncol. 2009 Nov;35(5):1069-79.
• [1338] Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.
• [1339] TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.Cell Biol Int. 2017 Apr;41(4):405-414. doi: 10.1002/cbin.10734. Epub 2017 Feb 16.
• [1340] TET3 inhibits TGF-1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.J Exp Clin Cancer Res. 2016 May 4;35:72. doi: 10.1186/s13046-016-0350-y.
• [1341] TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.Life Sci. 2020 Jan 15;241:117171. doi: 10.1016/j.lfs.2019.117171. Epub 2019 Dec 13.
• [1342] ERRATUM.Oncol Res. 2017 Jan 2;25(1):155. doi: 10.3727/096504017X14811155525280.
• [1343] Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.Jpn J Cancer Res. 2002 Oct;93(10):1114-22. doi: 10.1111/j.1349-7006.2002.tb01213.x.
• [1344] Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer.J Ovarian Res. 2014 Apr 23;7:42. doi: 10.1186/1757-2215-7-42. eCollection 2014.
• [1345] Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.J Ovarian Res. 2019 Nov 17;12(1):112. doi: 10.1186/s13048-019-0590-5.
• [1346] Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.
• [1347] TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.
• [1348] TMED2 promotes epithelial ovarian cancer growth.Oncotarget. 2017 Oct 6;8(55):94151-94165. doi: 10.18632/oncotarget.21593. eCollection 2017 Nov 7.
• [1349] Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.Biosci Rep. 2016 Feb 19;36(1):e00298. doi: 10.1042/BSR20150258. Print 2016.
• [1350] Overexpression of TMEM158 contributes to ovarian carcinogenesis.J Exp Clin Cancer Res. 2015 Aug 4;34(1):75. doi: 10.1186/s13046-015-0193-y.
• [1351] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.Oncol Rep. 2015 Jun;33(6):3124-30. doi: 10.3892/or.2015.3902. Epub 2015 Apr 7.
• [1352] A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.Gynecol Oncol. 2012 Jun;125(3):720-6. doi: 10.1016/j.ygyno.2012.03.026. Epub 2012 Mar 21.
• [1353] Thymosin 10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.PLoS One. 2012;7(5):e35399. doi: 10.1371/journal.pone.0035399. Epub 2012 May 18.
• [1354] Tumor necrosis factor -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.Hum Pathol. 2018 Dec;82:239-248. doi: 10.1016/j.humpath.2018.02.031. Epub 2018 Aug 11.
• [1355] Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.
• [1356] Tenascin-X is a novel diagnostic marker of malignant mesothelioma.Am J Surg Pathol. 2009 Nov;33(11):1673-82. doi: 10.1097/PAS.0b013e3181b6bde3.
• [1357] Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.J Ovarian Res. 2019 Mar 27;12(1):30. doi: 10.1186/s13048-019-0498-0.
• [1358] Overexpression of salusin- is associated with poor prognosis in ovarian cancer.Oncol Rep. 2017 Mar;37(3):1826-1832. doi: 10.3892/or.2017.5429. Epub 2017 Feb 7.
• [1359] TPM4 promotes cell migration by modulating F-actin formation in lung cancer.Onco Targets Ther. 2019 May 31;12:4055-4063. doi: 10.2147/OTT.S198542. eCollection 2019.
• [1360] Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells.Oncol Res. 2017 Apr 14;25(4):551-558. doi: 10.3727/096504016X14758370595285. Epub 2016 Oct 12.
• [1361] TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.J Neurooncol. 2019 Nov;145(2):211-222. doi: 10.1007/s11060-019-03301-0. Epub 2019 Oct 11.
• [1362] TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1412-1420. doi: 10.1016/j.bbamcr.2019.06.002. Epub 2019 Jun 6.
• [1363] Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.IUBMB Life. 2019 Feb;71(2):177-182. doi: 10.1002/iub.1948. Epub 2018 Oct 3.
• [1364] Ovarian cancer proliferation and apoptosis are regulated by human transfer RNA methyltransferase 9-likevia LIN9.Oncol Lett. 2017 Oct;14(4):4461-4466. doi: 10.3892/ol.2017.6750. Epub 2017 Aug 14.
• [1365] TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells.BMB Rep. 2018 Oct;51(10):514-519. doi: 10.5483/BMBRep.2018.51.10.042.
• [1366] Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
• [1367] TSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer.Mol Cells. 2019 Jul 31;42(7):557-567. doi: 10.14348/molcells.2019.0015.
• [1368] Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.DNA Cell Biol. 2017 Dec;36(12):1108-1116. doi: 10.1089/dna.2017.3904. Epub 2017 Oct 3.
• [1369] Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.J BUON. 2017 Sep-Oct;22(5):1314-1321.
• [1370] Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma.Mol Oncol. 2017 Nov;11(11):1595-1615. doi: 10.1002/1878-0261.12134. Epub 2017 Sep 29.
• [1371] Sox9 and Hif-2 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.
• [1372] Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma.Biomed Res Int. 2014;2014:379847. doi: 10.1155/2014/379847. Epub 2014 Apr 2.
• [1373] Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.PLoS Biol. 2014 Feb 4;12(2):e1001784. doi: 10.1371/journal.pbio.1001784. eCollection 2014 Feb.
• [1374] Overexpression of WDFY2 inhibits prostate cancer cell growth and migration via inactivation of Akt pathway.Tumour Biol. 2017 Jun;39(6):1010428317704821. doi: 10.1177/1010428317704821.
• [1375] An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.Nucleic Acids Res. 2012 Jan;40(2):499-510. doi: 10.1093/nar/gkr731. Epub 2011 Sep 14.
• [1376] Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties.Anticancer Res. 2015 Nov;35(11):5993-9.
• [1377] Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.
• [1378] NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6.
• [1379] Cytotoxicity of Nubein6.8 peptide isolated from the snake venom of Naja nubiae on melanoma and ovarian carcinoma cell lines.Toxicon. 2019 Oct;168:22-31. doi: 10.1016/j.toxicon.2019.06.220. Epub 2019 Jun 21.
• [1380] The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.Cancer. 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8.
• [1381] The homeoprotein DLX4 stimulates NF-B activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer.Am J Pathol. 2015 Aug;185(8):2298-308. doi: 10.1016/j.ajpath.2015.04.004. Epub 2015 Jun 9.
• [1382] The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.Int J Cancer. 2008 Oct 15;123(8):1761-9. doi: 10.1002/ijc.23708.
• [1383] Promoter Hypermethylation and Decreased Expression of Syncytin-1 in Pancreatic Adenocarcinomas.PLoS One. 2015 Jul 31;10(7):e0134412. doi: 10.1371/journal.pone.0134412. eCollection 2015.
• [1384] Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors.Am J Pathol. 1998 Nov;153(5):1579-88. doi: 10.1016/S0002-9440(10)65746-X.
• [1385] Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.
• [1386] Absence of BRCA/FMR1 correlations in women with ovarian cancers.PLoS One. 2014 Jul 18;9(7):e102370. doi: 10.1371/journal.pone.0102370. eCollection 2014.
• [1387] Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.
• [1388] Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour Biol. 2013 Dec;34(6):4059-63. doi: 10.1007/s13277-013-0995-5. Epub 2013 Jul 25.
• [1389] Methylation profile in benign, borderline and malignant ovarian tumors.J Cancer Res Clin Oncol. 2007 May;133(5):331-41. doi: 10.1007/s00432-006-0178-5. Epub 2006 Dec 20.
• [1390] HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.Mol Cancer. 2014 Jul 14;13:170. doi: 10.1186/1476-4598-13-170.
• [1391] Downregulation of HOXC6 in Serous Ovarian Cancer.Cancer Invest. 2015;33(7):303-11. doi: 10.3109/07357907.2015.1041641. Epub 2015 Jun 5.
• [1392] Genome-wide significant risk associations for mucinous ovarian carcinoma.Nat Genet. 2015 Aug;47(8):888-97. doi: 10.1038/ng.3336. Epub 2015 Jun 15.
• [1393] Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.Oncol Rep. 2014 May;31(5):2139-46. doi: 10.3892/or.2014.3110. Epub 2014 Mar 24.
• [1394] Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo.Genet Mol Res. 2015 Jun 18;14(2):6591-7. doi: 10.4238/2015.June.18.1.
• [1395] MKK4 acts as a potential tumor suppressor in ovarian cancer.Tumour Biol. 2011 Aug;32(4):661-70. doi: 10.1007/s13277-011-0166-5. Epub 2011 Apr 14.
• [1396] Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.Br J Cancer. 2016 Apr 12;114(8):945-52. doi: 10.1038/bjc.2016.50.
• [1397] Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.Gynecol Oncol. 2005 Jul;98(1):68-76. doi: 10.1016/j.ygyno.2005.04.002.
• [1398] Downregulation of NEK11 is associated with drug resistance in ovarian cancer.Int J Oncol. 2014 Sep;45(3):1266-74. doi: 10.3892/ijo.2014.2503. Epub 2014 Jun 18.
• [1399] OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.Carcinogenesis. 2014 Jul;35(7):1573-81. doi: 10.1093/carcin/bgu070. Epub 2014 Mar 25.
• [1400] Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):756-62. doi: 10.1093/abbs/gmt075. Epub 2013 Jul 3.
• [1401] Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Mol Cell Proteomics. 2014 Nov;13(11):3138-51. doi: 10.1074/mcp.M113.033217. Epub 2014 Aug 5.
• [1402] Nac1 interacts with the POZ-domain transcription factor, Miz1.Biosci Rep. 2014 Jun 5;34(3):e00110. doi: 10.1042/BSR20140049.
• [1403] Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.Mol Med Rep. 2013 Jun;7(6):1826-30. doi: 10.3892/mmr.2013.1416. Epub 2013 Apr 9.
• [1404] Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.Cell Cycle. 2012 Feb 1;11(3):451-9. doi: 10.4161/cc.11.3.19057. Epub 2012 Feb 1.
• [1405] Rab25 is responsible for phosphoinositide 3-kinase/AKTmediated cisplatin resistance in human epithelial ovarian cancer cells.Mol Med Rep. 2015 Mar;11(3):2173-8. doi: 10.3892/mmr.2014.2963. Epub 2014 Nov 17.
• [1406] RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.Oncotarget. 2014 Aug 30;5(16):6734-45. doi: 10.18632/oncotarget.2244.
• [1407] ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation.Int J Clin Exp Pathol. 2015 Aug 1;8(8):8968-75. eCollection 2015.
• [1408] The role of S100A14 in epithelial ovarian tumors.Oncotarget. 2014 Jun 15;5(11):3482-96. doi: 10.18632/oncotarget.1947.
• [1409] Expression profile and prognostic value of SFN in human ovarian cancer.Biosci Rep. 2019 May 2;39(5):BSR20190100. doi: 10.1042/BSR20190100. Print 2019 May 31.
• [1410] Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/-catenin signaling pathway.J Ovarian Res. 2014 Sep 5;7:87. doi: 10.1186/s13048-014-0087-1.
• [1411] Emerging Roles of SPINK1 in Cancer.Clin Chem. 2016 Mar;62(3):449-57. doi: 10.1373/clinchem.2015.241513. Epub 2015 Dec 11.